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ABSTRACT
Human cerebral gliomas are the most commonly occurring 
form of brain tumour, yet treatment has only a marginal 
effect on the outcome, with poorly differentiated gliomas 
having a mean survival time of between six months and one 
year. In view of the large kinetic difference in cell 
division-rates of the tumour and normal brain tissue, 
chemotherapy might be expected to be effective in the 
treatment of this condition, yet the blood-brain barrier 
prevents the delivery of most chemotherapeutic agents.at 
therapeutic concentrations to the tumour following systemic
t
administration.
■Local injection of drug into the tumour has been 
attempted, but the vascularity of the glioma tissue bed is 
such that sufficiently high concentrations of drug cannot 
be sustained for an adequate period of time. An inert 
depot preparation of the drug injected locally, giving 
sustained release of drug at therapeutic concentrations, 
might be more effective and therefore an investigation has 
been made of the use of liposomes containing high concen­
trations of bleomycin as a means of achieving this goal.
By careful study of the factors affecting incorporation 
of drugs within liposomes, high entrapment efficiencies of 
bleomycin have been achieved and these preparations have been 
shown to have similar dose-response curves' against a glioma
(ii)
^ell line as free preparations of^the drug. Following^ 
intracerebral injection of bleomycin entrapped within 
liposomes in rats, no detectable, cerebral toxicity, could 
be demonstrated, and a delayed clearance of the drug from 
the injection site occurred as compared with local in­
jection of similar concentrations of free bleomycin.
Liposome-bleomycin preparations, when injected through 
Ommaya reservoirs into the residual tumour bed of patients 
with grade IV cerebral gliomas following surgery, were well 
tolerated with only minimal side effects being observed. 
Only very low concentrations of bleomycin appeared in the 
blood, and urinary clearance of the drug was considerably 
reduced as compared to when free drug was injected via 
the reservoir. These preliminary observations suggest a 
role for the local delivery of drugs entrapped within lipo­
somes in the treatment of human cerebral gliomas.
(iii)
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CHAPTER 1 
GENERAL INTRODUCTION
11.1 GLIOMAS ----------------------- ---------------- --------
Human cerebral gliomas are the most common form of
i
brain tumour occurring at an average age of only 45 years 
yet having a depressingly poor prognosis. Surgery, radio­
therapy and more recently chemotherapy and immunotherapy 
have improved the outcome to some limited extent, but 
nevertheless the condition is still uniformly fatal with
poorly differentiated gliomas having a reported median
2
survival time of 5-13 months .
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Figure 1 - i  Survival curves o f  patients (adults only) with differentiated (grades I  and I I) , and  
malignant (grades I I I  and IV )  astrocytomas (histologically verified) treated at the Regional 
Radiotherapy Centre, Guildford, 1961-1976
21.1.1 Classification -of—brain—tumours----------------------
Primary intracranial tumours may arise from the 
brain and its soft tissue or bony covering or from the 
cranial nerves or the pituitary, while metastases may 
spread from virtually any other body tumour to the brain.
In adults the most common neoplasms are gliomas which are 
infiltrative tumours, meningiomas, which are essentially 
benign, or from metastases, whereas in children the most • 
common are medullo-blastomas or astrocytomas, frequently 
arising in the posterior fossa. In view of the confusing 
terminology that has arisen, a number of attempts have 
been made to produce a logical classification of intra­
cranial tumours, the most recent of which by an inter-
3
national panel of the World Health Organisation .
Most of the central nervous system (CNS) tissues are
thought to derive from primitive neural epithelium, known
as neuroectoderm, which subsequently differentiates through
a number of stages to produce two main cell types, nerve
cells and glial cells. Two main forms of glial cell can
be identified - the macroglia of ectodermal origin, and
the smaller microglia of mesodermal origin. Macroglia
develop from a common stem cell, the spongioblast, to
produce three main cell types, the astrocyte, the oligo-
4
dendrocyte and the ependymal cell .
The astrocyte
The processes and cell bodies of the astrocyte form
3..a....complex_packing_thr.oughout_the_CNS_parenchyma.. JThere_____
is a considerable variation within this cell type, with
the two ends of the spectrum being typified by the so-
called protoplasmic and fibrous astrocytes. The difference
between these cell types is quantitative rather than 
4structural . Protoplasmic astrocytes range from 1 0—4 0i_l 
in size and are most commonly seen in grey matter. The 
nucleus is ovoid with a largely homogeneous nucleochroma- 
tin. Fibrous astrocytes occur in white matter and contain 
twig-like processes consisting of tight bundles of glial 
filaments. In addition to these two forms there is some 
regional specialisation, such as specialised thickening 
on the outer membrane of astrocytes located in subpial 
zones and adjacent to blood vessels.
The functions of the astrocytes have not been fully 
elucidated, although one of the major functions appears 
to be structural since they appear to sustain and provide 
a packing for other components. They also serve to iso­
late certain structures, e.g. Purkinje cells, by ensheath- 
ment. Astrocytes also appear to play an important role 
in repair processes, and following any form or trauma will 
proliferate, swell, accumulate glycogen and undergo fibrosis 
by accumulation of filaments, these phenomena occurring in 
both grey and white matter.
It has also been suggested that the astrocyte may be 
involved in transport mechanisms, although the evidence
4-io2^ -this^Ls_mainly_patholog±cal-,— being—based—on—-the focal-
swelling of astrocytes, presumed to arise as a result of
a disturbance in fluid transport which occurs in response
to local inflammation or vasculature damage. It is known,
however, that transfer of large molecules across the CNS
occurs without the involvement of astrocytes. Although
there is some evidence to suggest a role for the astrocyte
4 5 6in the blood-brain barrier, various workers ' ' have 
demonstrated that the astrocytic end feet provide minimal 
resistance to the movement of molecules, and that the 
barrier to the movement of molecules into the brain occurs 
at the endothelial cell lining blood vessels.
The oligodendrocyte
Oligodendrocytes are again highly variable cells
differing in location, morphology and function but are
4definable by certain morphological criteria . The 
globular cell soma which ranges in size from 10-20^ is 
denser than that of the astrocyte. The margin of the 
cell is irregular and few cell processes are seen. Many 
organelles are found within the cytoplasm, although unlike 
the astrocyte no glial filaments can be demonstrated.
The nucleus is generally ovoid with densely-staining 
nucleochromatin, containing clumps of denser heterochrom­
atin .
Three different classes of oligodendrocyte have been 
identified - the satellite, intermediate, and interfasci­
cular (myelating) oligodendrocyte. The small (1 0m>)
5sate11ite ..cells,which are foundonlyin grey matter_____ ___
closely applied to the surface of neurons, are thought 
to be involved in the maintenance of the neuron. Inter­
fascicular cells are large (20jj.) during myelination but 
range from 10 — 15ju in the adult with the nucleus occupying 
a large percentage of the cell body. Intermediate cells 
are regarded as potential satellite or myelinating forms.
The interfascicular oligodendrocyte is capable of producing 
many internodes of myelin simultaneously (3 0-50 in the 
case of optic nerve oligodendrocytes) and it has been 
estimated that the surface area of myelin sustained by a 
single cell is greater than 600 times the area of the 
cell soma. However, the cell possesses a slow mitotic rate 
and a poor regenerative capacity, and hence damage to 
only a few cells can produce a considerable area of 
primary demyelination.
The ependymal cell
Ependymal cells are arranged in single palisade arrays
lining the ventricles and centre canal. Cilia extend from
the free surface of the cell into the ventricular cavity,
4each cilia containing an arrangement of microtubules . 
Numerous microvilli containing microfilaments also extend 
from the free surface of the cell. It is thought that 
these ciliated cells facilitate the movement of cerebro­
spinal fluid (CSF).
All three of the cell types described above are capable
6-of-undergoing-inalignant—tra nsformation—to—p r o duce—the—tumours
known collectively as gliomas. A further type of tumour,
the medulloblastoma which in fact probably arises from
residual foetal cells of the cerebellar external granular
layer which are potential nerve cells, are nevertheless
frequently classified with the gliomas. Other terms have
been used to describe poorly differentiated tumours
(glioblastomas), or tumours where embryonic cells are
predominant (spongioblastomas), but these are probably
more accurately classified with the high grade astrocytomas.
A simplified classification of CNS tumours based on the
fi 7above cell types is shown in Table 1.1 ' .
1.1.2 Description of the most commonly occurring cerebral
gliomas
Astrocytoma
Astrocytomas account for about 75% of all cerebral 
gliomas and vary considerably in appearance and malignancy, 
from well differentiated types where the predominant cell 
is very similar in appearance to normal astrocytes to 
highly anaplastic tumours. They occur mainly in adults 
but occasionally in children, generally as a single tumour 
(95% of cases) most frequently affecting the cortex or 
basal ganglia and may arise in any part of the hemisphere. 
Macroscopically these tumours are indistinctly demarcated 
or grossly infiltrative, are grey in colour, firmer than 
the surrounding tissue and may vary in size from a few 
centimetres in diameter to those that occupy virtually
7TABLE 1.1
Classification of CNS tumours
NEUROECTODERM
NEUROGLIA MEDULLOBLASTS
Medulloblastoma
NERVE CELLS MENINGES
Neurocytoma Meningioma
Neuroblastoma
Retinoblastoma
ASTROCYTES
Astrocytoma 
(Grades I-IV)
OLIGODENDROCYTES
Oligodendroglioma
EPENDYMA
Ependymoma 
(Grades I-IV)
Choroid papilloma
Colloid cyst
-a—whole—lobe-.— The—tumours-can—be-graded-on—the—basis—of
7 .
their histological appearance into grades I to IV, of 
which the higher grades are more malignant.
Grade I astrocytoma
Frequently referred to as fibrillary or protoplasmic 
astrocytomas, these tumours show an increased cellularity 
due to an excess of astrocyte bodies and fibres which form 
a mass of processes thicker than normal. Individual cells 
however, closely resemble mature astrocytes. The astro­
cytoma may occasionally contain a large cyst filled with 
either clear or yellow fluid.- Microcytes are also a 
common feature. Lymphocyte cuffing may be seen, and this 
has been interpreted as an immunological host response to 
the tumour.
Grade II astrocytoma
Sometimes referred to as astroblastomas, the cells 
are still recognisably astrocytes, although more abundant 
than grade I tumours and there is some variation in cell 
size.
Grades III and IV astrocytomas
Although nomenclature is somewhat confusing in this 
area, these high grade astrocytomas are synonymous with 
glioblastoma multiforme, which forms 50-60% of all gliomas 
Grade III tumours still show some recognisable astrocytes 
although pleomorphism is marked, mitosis present and 
occasional giant cell forms are seen. Proliferation of
9-the—endothelial-Cells of_blood_vessels__is_also_present_.__
Grade IV tumours are extremely cellular with only 
a few cells recognisable as astrocytes. Pleomorphism, 
mitosis, giant cells and endothelial cell proliferation 
are all prominent. These tumours are most frequently 
found in the white matter of the anterior of the cerebral 
hemispheres, the majority in adults aged between 45 and 
55 years. Variable amounts of haemorrhage and cyst form-’ 
ation are often seen. Most glioblastomas probably derive 
by anaplasia from a pre-existing astrocytoma, although 
other so-called primary glioblastomas may arise directly 
as anaplastic, poorly-differentiated tumours. The 
symptoms and signs of this tumour are determined by its 
highly malignant nature with rapidly developing raised 
intracranial pressure and progressive focal neurological 
deficit. Extensive oedema may occur when the tumour is 
still small, leading to early neurological disturbance 
and depression of consciousness.
All grades of astrocytoma are malignant although 
prognosis varies with the grade. Patients with grades 
I and II tumours may survive for many years (57% one-year 
survival, 23% five-year survival) , although this is 
generally only a few weeks or months in the case of grade 
IV astrocytomas (38% one-year survival, 8% five-year 
survival).
10
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These constitute approximately 5% of all gliomas, 
and are most commonly found in the deep white matter of 
the frontal, parietal and temporal lobes and have a ten­
dency to invade the corpus callosum or septum pellucidum. 
Macroscopically these tumours are usually well circum­
scribed, rather gelatinous and are frequently calcified.
20% are cystic. They are frequently seen to be the largest 
of all intracranial tumours at the time of surgery. Micro­
scopically this is a cellular tumour. The cells are small 
with regular nuclei and clear, poorly-staining cytoplasm 
and are arranged in sheets broken up by a distinctive 
network of blood vessels.
The disease takes a relatively benign course in many 
patients, generally with a long delay between the onset 
of symptoms and diagnosis, with a reported mean survival 
time ranging from 28 to 70 months. However, a small
subgroup of patients can be identified where the tumour
. , ' , . 8  takes a more malignant course with a much poorer prognosis .
Ependymoma
Ependymomas constitute approximately 6% of all gliomas 
and most commonly occur in young children under 10 years 
and in the 20-30 year-old age group. They originate from 
the ependymal and underlying glial layer lining the ven­
tricular system and can occur in all four cerebral lobes 
as well as in the third and fourth ventricles, cerebello-
-pon tin e—an g-le ,—sp -in a-1— g o  rd-andc au da—e quin a-.— They have----
a tendency to metastasis both spontaneously and after 
surgery, particularly to the cisterna magna, basal cisterns 
and spinal cord. The pattern of growth of the tumour at 
the varying sites determines the clinical presentation 
and progression of signs and symptoms. The well- 
differentiated tumours generally grow slowly over a 
number of years, and as they enlarge may become partly 
cystic, blocking the foramen of Monro, producing obstruct­
ive hydrocephalus. Occasionally the tumour becomes more 
malignant with a histological appearance similar to an 
anaplastic astrocytoma, in which case it takes a much 
shorter course. Histologically the tumour is character­
ised by rosettes, small canaliculi and perivascular pseudo­
rosettes which are composed of a central blood vessel 
surrounded by an eosinophilic fibrillary halo composed of 
the radiating processes of the tumour cells orientated 
towards it. The tumours may be graded I to IV of malig­
nancy according to the degree of pleomorphism, mitosis, 
etc., 50% of cases being in the better differentiated 
grades I and II.
Medulloblastoma
Although constituting only about 5-7% of all gliomas, 
medulloblastomas are the most common intracranial tumour 
encountered in children, accounting for up to 25% of all 
cases. Of these, 50% occur during the first decade of 
life, becoming less common in late adolescence and rare
12
-in adults.— The tumours—are—thought—to_ derive—f rom _____
primitive embryonal cells of the cerebellar external 
granular layer which normally would migrate inwards to 
augment the neurones of the cerebellum. They expand 
throughout the cerebellum and frequently seed through 
the CSF to produce numerous deposits on the surface of 
the spinal cord. At one time the prognosis was very 
poor with a 15% survival at three years and only 1-2% 
at 10 years, despite radiotherapy. However, this has 
improved significantly with early surgery followed by 
cranial and spinal cord irradiation to give reported 
survivals ranging from 32% to 75% at five years to 26% 
to 50% at 10 years.
1.1.3 Incidence and epidemiology
9
Figures provided by the World Health Organisation , 
based on mortality rates from malignant brain tumours 
from 27 countries, indicate an incidence of approximately 
five in 100,000 ranging from one in 100,000 in Mexico 
to seven in 100,000 in Israel. However, there are a 
number of difficulties in interpreting these official 
figures and more rigorous studies, based upon defined 
populations, have yielded figures ranging from approxi­
mately 12 in 100 ,000^ to as high as 46 in 100 ,000^.
The latter figures included nine pituitary tumours as 
well as 12 probably but unconfirmed cases. All included 
primary tumours of all types and metastases. A number of
13
_factors account for the high figures obtained from these 
more detailed studies, the most important being that 36% 
of all cases were diagnosed at post-mortem.
Although more recent studies have suggested that
there is no overall sex preponderance in primary cerebral 
12tumours, Zulch found evidence that there was a slight 
male preponderance although this varied considerably 
with tumour type (Table 1.2). Of these approximately 75%' 
are astrocytomas (half of these being the most malignant 
grade IV glioblastoma multiforme type), 5-10% ependymomas, 
5% oligodendrogliomas, and 5-7% medulloblastomas. In 
children, however, medulloblastomas account for up to 25% 
of all intracranial tumours and ependymomas a further 10%. 
In a survey of 653 adult cases studied at the National 
Hospitals for Nervous Diseases, well-differentiated astro­
cytomas and ependymomas presented at an earlier age than
gliobastoma multiforme, while the oligodendrogliomas
1
were intermediate in timing (Table 1.4). It is interest­
ing to note that in this series of adult patients, no 
less than 93% were classified as astrocytomas, with 31% of 
these being classified as the most malignant grade IV glio­
blastoma multiforme. The cerebral gliomas most frequently 
affected the frontal lobes of the brain followed by the 
temporal and parietal lobes, while the occipital lobes 
were rarely affected. This pattern is similar for all 
types of cerebral glioma.
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TABLE 1.2
Sex preponderance of various 
intracranial tumour
types of
Type of tumour M:F ratio
Medulloblastoma 5:2
Oligodendroglioma 9:7
Astrocytoma 3:2
Glioblastoma 2:1
Ependymoma 6:5
Metastases 6:5
Meningiomas 7:6
Neurinomas 2:1
Gliomas account for approximately 40% of all 
brain tumours (see Table 1.3)
TABLE 1 .3
Frequency of different types of brain tumour^
Type of tumour Frequency
Glioma 38%
Meningioma 16%
Pituitary adenoma 8%
Neurilemmona 6%
Craniopharyngioma 3%
Heamangioblastoma 2%
Metastasis 12%
Others 15%
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__________ TABLE 1-.-4____________
Age at first assessment of  ^
patients with cerebral gliomas
Type of tumour n Mean(years) ±S. D .
Well-differentiated astrocytomas 
(grade I)
48 37.5 15.6
Intermediate grade astrocytomas 
(grades II and III)
341 45.8 15.1
Glioblastoma multiforme 
(grade IV)
175 52.6 11 .9
Oligodendroglioma 36 47.3 11 .8
Ependymoma 4 37.0 14.9
Astrocytosis
(non-specific gliosis on biopsy)
1 49.0 0
TOTAL POPULATION 605 47.1 14.7
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------Unlike -ce-rta-i-n other— disea-ses-, these—epidemio 1-ogy----
studies have not yielded any clear understanding of the 
aetiology or pathogenesis of gliomas. An increased in­
cidence of certain types of cerebral tumour among resident
rural farm workers has been tentatively associated with an
14 15increased rate of toxoplasma infection ' . However, no
definite causal relationship has been demonstrated. This 
is also true in the case of various other aetiological 
factors such as head injury and industrial exposure to 
rubber and petrochemicals. Brain tumours have, however, 
been induced in animal models by the injection of human 
polyoma virus1
1.1.4 Clinical presentation
The signs and symptoms of gliomas may occur alone or 
in combination1:
1. as general, non-localised symptoms, e.g. epilepsy or 
mental symptoms;
2. focal symptoms, e.g. heimparesis or cranial nerve 
palsy;
3. features of raised intracranial pressure, e.g. head­
aches .
Headache and epilepsy are the most common presenting 
features in cases of cerebral glioma (Table 1.5). The 
headache associated with these tumours will normally have 
been of less than one year's duration and is due to the
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TABLE 1 .5
Frequency of occurrence of 
symptoms in cerebral gliomas^
Relative
frequency Relative
as initial frequency
symptom at diagnosis
Symptom (%) (%)
Epilepsy 38 .3 53 .9
Grand Mai 15.9 20.4
Focal 14.7 22.8
Temporal lobe 7.2 8.6
Minor absence 0.5 2.1
Headache 35.2 71 .4
Mental change 16.5 52.2
Hemiparesis 10.3 43.3
Vomiting 7.5 31 .5
Dysphasia 6 .9 27.0
Impaired consciousness 4.6 24 .8
Visual failure 4.3 17.9
Hemianaesthesia 3.4 13.6
Hemianopia 1 .8 8.1
Cranial nerve palsy 1 .8 10.9
Miscellaneous 2.3 7.0
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effect of increased intracranial pressure producing vas­
cular distension and to a local effect on pain-sensitive 
nerve fibres from pressure or infiltration by the glioma 
tissue. The headache is generally moderately severe, of 
a throbbing nature, and in the initial stages is inter­
mittent in nature, most frequently occurring in the 
morning. It is often lateralised to the affected side 
of the head. Later on during the course of the disease 
it becomes more severe and long-lasting, with severe 
exacerbations. Symptoms frequently present as a triad 
of headache, vomiting and ocular disturbance, due to the 
effects of the raised intracranial pressure. The vomit­
ing is not usually preceded by nausea or retching, often 
occurs in the early morning, and may be exacerbated by 
changes in posture or by straining. Papilloedema may be 
noted, of varying severity, from absence of venous puls­
ation through to consequitive optic atrophy. Transient 
visual obscuration due to raised intracranial pressure 
will require urgent investigation owing to the risk of 
permanent blindness developing. Focal symptoms may in­
clude various visual defects as well as deafness, ataxia, 
weakness and dysphasia, and can give useful to the presence 
and site of the tumour.
Epilepsy is often an early symptom of glioma which 
frequently predates the onset of focal symptoms or papill­
oedema. Approximately 5% of tumour patients with epilepsy 
have been shown to have more than a 10-year history of
epilepsy prior to diagnosis, and thus patients suffering 
from epilepsy may be selected out as a high risk group 
who may later go on to develop intracranial tumours.
This group can be further selected out on the basis of 
the nature of the epilepsy such as onset after the age 
of 30 years, undue drug resistance, etc. The actual 
incidence of these various symptoms vary to some extent 
with the glioma type.
1.1.5 Investigations and diagnosis
Most brain tumours present as non-specific space-
occupying lesions, so that in many cases final diagnosis
Ccin only be made following brain biopsy. Prior to surgical
procedures, however, a number of preliminary investigations
17would normally be carried out 
Blood tests
Blood tests show few changes associated with a primary 
cerebral tumour, although the ESR may be significantly 
increased in cases of cerebral secondaries arising from a 
latent systemic cancer. However, the non-specific acute 
phase proteins, in particular haptoglobin, ai-acid glyco­
protein and ai-antitrypsin, have been shown to be in­
creased in the serum in a variety of brain tumours,
18especially in the case of gliomas . Increases in serum 
levels of glycoprotein-associated carbohydrates including 
sialic acid, neutral hexose and fucose have also been 
demonstrated in cases of astrocytoma, meningioma and pituit­
ary adenomas.
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Elevated levels of prolactin or growth hormone may 
be found in cases of pituitary adenoma, together with 
possible evidence of hypopituitarism (e.g. low cortisol 
or thyroid hormone levels). Tumours of the pineal gland 
may be associated with elevation of chorionic gonado­
trophin, or occasionally of melanocyte-stimulating hormone.
Cerebrospinal fluid (CSF)
It has been suggested that the estimation of CSF
lysozyme levels may be useful in the early and rapid
detection of metastatic tumours of the CNS and more rarely
1 9in the detection of primary CNS malignancies . More
detailed studies have been unable to confirm this finding
since the assay is very non-specific, giving rise to high
20 21levels of false positive and false negative results '
Furthermore, lumbar puncture is generally contra-indicated
in the case of cerebral tumour, especially where there
is evidence of raised intracranial pressure, owing to the
high risk of fatal herniation of the medial temporal lobe
or of the cerebellar tonsils through the foramen magnum 
22(coning) . In certain rare instances this procedure may 
be performed following careful assessment of the patient, 
particularly in the diagnosis of medulloblastoma and 
pineal tumour where exfoliative cytology may be diagnostic. 
However, set against the high risk of coning, it must be 
realised that less than 15% of cases of primary cerebral 
tumour will show characteristic cells in the CSF. The 
CSF should be examined in cases of subacute meningitis
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of unknown aetiology for evidence of increased protein 
and reduced glucose in the absence of microbial infection 
that is characteristic of diffuse meningeal tumours.
It has recently been reported that the use of immuno- 
fluorimetric techniques using a panel of monoclonal anti­
bodies is useful in the early detection and character-
23isation of neoplastic meningitis
Electroencephalography (EEG)
This technique is now mainly confined to the investi­
gation of epilepsy, since the advent of computerised 
tomography scanning.
Radiology
Neuroradiology is essential for both the diagnosis 
and localisation of tumours prior to surgery and radio­
therapy. Although skull X-ray will only occasionally 
show direct evidence of a tumour (through abnormal 
vasculature or sclerosis of bone), it will frequently 
show evidence of raised intracranial pressure or hydro­
cephalus in children. Abnormal calcification such as 
occurs in the supracellular region in cases of cranio­
pharyngioma or local bone erosion as in pituitary adenomas 
may also be detected.
Computerised tomography (CT)
CT has become the single most important technique 
in the diagnosis of brain tumours over the last decade.
It is nonevasive, although the intravenous injection of
22
contrast media is still required, and the occasional 
restless patient will require sedation. In addition to 
evidence of raised intracranial pressure and hydrocephalus, 
most tumours can themselves be directly visualised with 
this technique. The instrumentation is continually 
improving, allowing not only much more sophisticated 
scanning to be achieved (e.g. the use of coronal and 
sagittal planes), but also allowing the time required 
for investigation of each patient to be reduced consider­
ably.
Angiography
Angiography of the carotid or vertebral circulation 
is generally carried out following the less invasive 
techniques such as skull X-ray and CT, and will show any 
shift or normal vessels by the tumour mass as well as any 
abnormal circulation such as occurs in cases of cerebral 
glioma.
Lumbar air encephalography and ventriculography
Techniques which use air or other contrast media to 
outline the ventricular system have largely been super­
seded by CT scanning, although they may still be used 
occasionally to delineate certain pituitary adenomas as 
well as brainstem gliomas and in certain other specific 
cases.
Isotope scanning
Scanning using radiolabelled 99t c albumin has also
23
largely been superseded by CT scanning.
Biopsy examination
Brain biopsy material may be obtained either through
a burr hole biopsy of a focal lesion or during the course
of open intracranial or spinal surgery. Ideally the
material should be processed immediately and examined
whilst the patient is still in the operating theatre.
A smear technique is frequently used rather than a frozen'
section as this shows far more detailed cytology, although
at the expense of tissue architecture. Specimens can be
processed, stained and examined within 10 minutes with a
24reported accuracy of 94% . This can then be followed
up later by the examination of standard paraffin sections 
which form the basis of the definitive histological diag­
nosis in most cases. Although the biopsy material may 
also be examined using various enzyme histochemical and 
immunological techniques, these have not so far been 
proved to be of value in the routine differential diag­
nosis of cerebral tumour.
Other techniques
Positron emission tomography (ECAT scanning) , based 
on the administration of substances such as oxygen or 
glucose labelled with short-lived positron-emitting iso­
topes, has been used to produce a tomographic image, but 
the complexity of the technique probably prevents it 
from being widely adopted.
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Noninvasive nuclear magnetic resonance (NMR) tech­
niques which measure changes in microwave transmission 
in response to changes in magnetic resonance have pro­
duced tomographic scans with a level of detail as good 
as, if not better than, those produced by conventional 
CT scanning. Although at present rather more expensive 
than CT instrumentation, it is likely that NMR techniques 
will become more widely adopted in the future.
1.1.6 Treatment
Although surgery, radiotherapy and chemotherapy have 
been used extensively in the treatment of gliomas, the 
response has generally been limited. Although low grade 
astrocytomas, oligodendrogliomas and ependymomas may 
occasionally be cured by surgery and radiotherapy, highly 
malignant tumours such as glioblastoma multiforme are 
considered incurable by present standards, and it is 
unlikely that the 50% survival time of 37 weeks can be 
further extended by these conventional techniques alone.
Whilst on theoretical grounds there is reason to 
believe that chemotherapy of primary cerebral gliomas 
should be very effective, the enormous pharmacological 
difficulties of achieving an adequate concentration of 
drug at the tumour site for an adequate period of time 
have yet to be overcome, and consequently the results 
of chemotherapy have so far been rather limited. 
Immunotherapy of cerebral tumours may well have a consider­
25
able part to play in the future, particularly with the 
increasing availability of monoclonal antisera with a 
specificity for determinants on the tumour cell membrane, 
but with no cross-reactivity for normal brain tissue.
In the meantime, at least in the more malignant 
cases, treatment is largely aimed at the relief of some 
of the more distressing symptoms of raised intracranial 
pressure such as severe headache and the possibility of 
visual failure. Although there may be some increase in 
survival, it is doubtful that the quality of life will be 
at all improved. There are .of course exceptions to this, 
as in the case of medulloblastomas in children where more 
aggressive treatment has considerably improved both the 
length and quality of survival.
Surgery
The principal objectives of surgery are initially to
confirm the pathological diagnosis and then, where possible,
to relieve some of the more distressing symptoms of the
25condition and to lengthen survival . In situations 
where the untreated course of the disease is invariably 
fatal, it is clearly essential that the pathological 
diagnosis is beyond doubt. The development of computer­
ised axial tomography has greatly reduced the risk of 
diagnostic error, particularly in the differentiation 
between benign and malignant tumours. However, biopsy 
followed by histological diagnosis is still valuable in 
certain cases, for example in the differentiation between
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cystic or necrotic gliomas and cerebral abscess. Histo­
logical examination of biopsy material may also give some 
idea of the prognosis and an indication of the subsequent 
benefits of radiotherapy and chemotherapy. The normal 
procedure used is a burrhole biopsy, which although simple, 
rapid and inexpensive does carry morbidity and mortality 
rates comparable to craniotomy. Apart from imposing 
grave limitations of access to the tumour site, it must 
always be remembered that the small amounts of material 
obtained by needle biopsy may be unrepresentative of the 
whole, and hence grading the tumour on the basis of the 
biopsy material does carry some risk of error.
The symptoms of raised intracranial pressure are head­
ache, nausea and vomiting, deterioration in intellect and 
level of consciousness, and failing visual acuity. Decline 
in intellect and level of consciousness, although dis­
tressing for the relatives, may be regarded as a form of 
natural relief for the patient, and where a diagnosis of
anaplastic astrocytoma has been made, does not alone
25justify surgical intervention . However, severe headache 
that does not respond to corticosteroids, or declining 
visual acuity in the presence of a reasonable intellect, 
are strong grounds for palliative decompression surgery. 
Decompression may take the form of short procedures to 
relieve hydrocephalus due to obstruction of CSF circulation, 
particularly in tumours of the third ventricle or pineal 
region, and surgical removal of the tumour. Surgical
27
removal of the tumour will relieve the rapidly rising 
intracranial pressure, avert the risk of herniation at the 
tentorial liatus or foramen magnum and hence should increase 
survival to some extent. This is more so in the case of 
infratentorial tumours (e.g. medulloblastoma) than in 
supratentorial tumours, since removal of a small infra­
tentorial tumour will relieve the pressure caused by CSF 
obstruction at the aqueduct or fourth ventricle. Whether 
or not removal of the tumour will by itself result in 
lengthened survival is still somewhat debatable; however, 
it may be valuable as part of a combined therapy, as usually 
practiced, involving surgery, radiotherapy and frequently 
chemotherapy.
Radiotherapy
Generally speaking radiotherapy is indicated for patients 
suffering from malignant glioma if they have come through 
surgery without severe disability, a typical course of 
treatment being 5500 rad delivered over 5-6 weeks. However, 
the benefits are modest and a judgement must be made in 
each individual case. In cases of medulloblastoma or 
ependymoma full neuraxis radiation may be necessary to 
prevent seeding of metastases through the CSF pathways.
Various techniques have been employed in an attempt 
to improve the effectiveness of radiation therapy, includ­
ing the use of hyperbaric oxygen, radiosensitisers and cell 
synchronisers. Hypoxic cells are known to be more resistant
28
to radiation than normally oxygenated cells. Although 
gliomas generally have a profuse blood supply it is abnormal 
and oxygen diffusion to some areas of the tumour may be 
deficient resulting in hypoxia. Attempts to improve oxy­
genation of the tumour by placing the patient in oxygen 
raised to several atmospheres of pressure, followed by 
irradiation, have been applied to the treatment of several
tumours; however, the evidence suggests that there is no
2 6improvement in survival when applied to brain tumours
Another approach has been the use of radiosensitisers,
such as misonidazole to enhance oxygenation. Various 
27 28workers ' have reported significant radiosensitisation
effects using this technique, although its use is limited
by toxic effects such as peripheral neuropathy and organic
psychoses. An alternative approach has been the use of
bromouridine which is preferentially incorporated into the
29DNA of tumour cells during mitosis. Although initial 
results are encouraging, significant side effects and 
difficulties in use remain.
Colchicine has been used in an attempt to synchronise
tumour growth, followed by radiation tuned to coincide with
30the point of maximum synchronisation . In practice it 
has been very difficult, however, to determine the cell 
kinetics of the tumour in sufficient time and with suf­
ficient accuracy to be of value.
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Immunotherapy
It was originally thought that the CNS was an immuno-
logically privileged site since it developed in the foetus
behind the blood-brain barrier without any subsequent
31contact with circulating blood lymphocytes . However, 
although this is certainly true to some extent, the brain 
is not such an immunologically protected system as first 
thought. It has been shown in man and in experimental 
animals that an immune reaction can certainly occur within 
the brain, although other immunological factors limit the 
effectiveness of such a reaction in rejecting cerebral 
tumours.
Although immunotherapy has not been applied routinely 
to the therapy of cerebral gliomas, a number of small-scale 
trials of various forms of immunotherapy have taken place, 
although results have been variable. These have generally 
taken two main forms: adoptive immunotherapy (i.e. attempts 
to increase the number of immunocompetent cells by lympho­
cyte transfer) and active immunotherapy (i.e. stimulation 
of the immune system either specifically or non-specifically 
against tumour antigens) . Techniques using histocompatible, 
non-tumour bearing donors to provide bone marrow trans­
plants for intravenous administration, or leukocytes for 
intratumoural administration have been claimed to yield 
one-year survivals of 85% and two-year survivals of 60% in
glioblastoma patients who have previously undergone surgery
32or radiotherapy . However, attempts at intratumoural
30
transplantation of the patient's own, previously stimulated
33lymphocytes have only met with very moderate success , 
partly, it would appear, because of the difficulties of 
achieving lymphocyte infiltration beyond the tumour edge.
Specific active immunotherapy, achieved by immunising
the patient with an homogenised extract of his own tumour
cells in the presence of an adjuvant has yielded increased
34 •survival rates m  both low and high grade astrocytomas 
Both intradermal and immunoprecipitation techniques in­
dicated that a marked antiglioma immunisation had taken 
place in these patients.
The use of monoclonal antibody techniques open up a
wide range of possibilities for the localisation and treat-
35ment of cerebral gliomas. Sikora et al have fused intra­
tumoural lymphocytes from patients undergoing craniotomy 
for malignant glioma with a human myeloma cell line to 
produce a number of stable hybridomas. Several of these 
hybridoma cell lines have been shown to produce glioma 
cell-specific immunoglobulin, one of which has subsequently 
been used labelled with 131j to localise a recurrent glioma 
in the patient from whom the cell line was originally 
derived . These workers have subsequently developed a 
technique for the continuous infusion of monoclonal anti­
bodies directly into the patient from hybridoma cells
37isolated in a subcutaneously implanted culture chamber 
No adverse reaction to the culture chamber nor spread of
31
hybridoma cells outside the chamber could be demonstrated 
in a patient who had an implant in situ for three months.
Chemotherapy
It has been estimated that the potential doubling time
38of high grade astrocytomas is 10 days , although on
clinical grounds this figure may represent an oversetimate
implying some cell loss. This is comparable with the rates
39of proliferation found in other types of tumour , except ' 
that in no other type of cancer is there such a clear 
kinetic difference between the tumour tissue and the co­
existing normal tissues. It might be reasonable to expect, 
therefore, that cell cycle-specific drugs such as metho­
trexate and cytosine arabinoside would be highly effective 
in these circumstances. In practice, however, this potential 
has not been realised and this can be ascribed to a number 
of physiological and pharmacological factors. Firstly, 
many cells within the tumour mass may, because of in­
adequate nutrition, be prevented from dividing rapidly.
It is difficult to estimate the growth fraction of brain
40tumours, although Hishino et al have produced estimates 
ranging from 14-39% for astrocytomas of various grades by 
thymidine-labelling techniques. Perhaps the major diffi­
culty, however, is the problem of drug access to the tumour 
site. Systemically-administered drugs must overcome a
41number of barriers before reaching their site of action 
Orally-administered drugs must be capable of withstanding 
the effects of pH and enzyme degradation within the stomach
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and small intestine and must then be absorbed across the 
intestinal wall and survive hepatic degradation within 
enterohepatic circulation. Once in the blood stream, 
drugs may be metabolised, ionised or bound to plasma pro­
teins. Upon reaching the CNS, the drug must dissociate 
from plasma proteins, transverse the capillary endothelium 
and tight junctions of the blood-brain barrier, and enter 
the extracellular space of the brain. The agent must then 
cross the tumour cell membrane, enter the cytoplasmic 
water and finally reach its site of action. These physical 
and pharmacological barriers mean that to achieve an 
adequate concentration of the drug at the tumour site for 
an adequate time even the most therapeutically effective 
drug, if administered systemically, must be given at a con­
centration such that systemic side effects become inevitable. 
Furthermore, as tumours grow the distance between capillaries 
and cell increases, cells furthest from the capillaries
will become starved of oxygen and nutrients, become hypoxic,
42enter the G0 state and eventually die . The centre of a 
larger tumour thus becomes poorly perfused, and although 
it will be composed mainly of hypometabolic and necrotic 
cells, it will nevertheless contain a small number of 
viable cells possessing the potential for further growth.
This may conceivable be as many as 10® to 10^ cells. It 
has been calculated that to achieve a sufficient concen­
tration of drug within that low density tumour centre at a 
depth of 1-3cm from the perfused rim of a 6cm diameter glio-
33
blastoma multiforme, a plasma drug level would have to be
maintained at therapeutic concentration for as long as 
4310-24 hours . This is difficult to achieve with many of 
the agents in use at present, resulting in suboptimal 
delivery of drug leading to possible increased drug resist­
ance by the neoplastic cells. This may be manifested as 
impaired intracellular transport of the drug, enhanced 
intracellular detoxification or increased repair of sub- 
lethal drug-induced damage.
A further practical difficulty encountered in assess­
ing the therapeutic effectiveness of a particular drug is 
the difficulty in assessing the tumour cell burden before 
and after chemotherapy. Clinically this is very difficult 
as the patients neurological state may be affected by such 
factors as infection and fever, radiation therapy and 
changes in dosage or responsiveness to the glucocorticoid 
drugs used to relieve the symptoms of raised intracranial 
pressure. No specific biochemical marker of tumour cell 
burden is yet available, although it has been suggested 
that measurement of the serum levels of the acute phase
18proteins may be useful in assessing the response to therapy 
In the meantime the difficulties have been eased somewhat 
by the advent of the CT scanner which is sufficiently 
sensitive to measure tumour cell volume.
Despite all these difficulties a number of drugs have 
been used in an attempt to assess their effectiveness against 
cerebral gliomas, of which the most commonly encountered
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are the nitrosoureas,vincristine and vinblastine, bleo­
mycin, methotrexate, 5 1-fluro-uracil and procarbazine.
These are almost universally used as part of a combined 
therapy involving surgery and radiotherapy. Numerous 
studies have taken place and it has been shown in a number 
of cases that the addition of various forms of chemotherapy 
to the other forms of treatment result in a slight though 
significant increase in survival. Addition of bischloro- 
ethylnitrosourea (BCNU) to a programme of surgery followed 
by radiation therapy, for example, has been shown to in­
crease survival in patients with glioblastoma multiforme
from a median of 37 weeks without chemotherapy to 40 weeks
44with chemotherapy . Although this difference was not
statistically significant, 18% of the BCNU-treated patients
survived 18 months compared with only 9% receiving surgery
and radiotherapy alone. More recently, a combined therapy
involving the drug carmustine has been shown to produce a
survival rate of 78% at six months, 51% at one year and
457% at five years in patients with malignant glioma 
However, various subgroups fared significantly better or 
worse than this, with poorest survival being found in 
patients experiencing paresis or paralysis, or impaired 
mental symptoms, those with markedly anaplastic tumours 
or who were elderly. In particular, patients under the 
age of 40 years fared significantly better, with a 40% 
survival at five years in the 13 patients studied. Because 
of the barriers to effective radiotherapy and chemotherapy
35
arising from the hypoxia and poor perfusion at the centre 
of the tumour, these workers favoured a policy of maximal 
surgery consistent with maintenance of neurological function.
Combined treatment regimens involving two or more
different drugs are being increasingly employed. These
may take the form of an intensive initial therapy involving
radiation and chemotherapy followed by a short rest to
allow removal of dead cells and to give a respite from
the toxicity of the treatment. This is followed by a
further intensive course of chemotherapy employing a
different drug or combination of drugs in order to avoid
the emergence of clonogenic cells resistant to the original
drug. Many of these schedules do show a significant
disease arrest initially, although the period of palli-
43ation is short-lived
In view of the difficulties encountered in the systemic
administration of these drugs, in particular the difficulty
of maintaining adequate drug concentrations across the
blood-brain barrier, attempts have been made at other
approaches. Intrathecal administration of bleomycin has
been used in several small-scale trials, and has been
shown to have a temporary therapeutic effect in several
46cases of disseminated pinealoma and ependymoma , but not
47m  metastatic meningeal carcinoma . Although high levels 
of the drug were achieved in the CSF, no detectable drug 
could be found in the serum.
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Direct intracystic administration of bleomycin into
47cystic tumours (craniopharyngiomas) has been attempted ,
resulting in high concentrations of the drug in the en­
cysted fluid, which would be expected to penetrate the 
solid tumour tissue. The potential advantage of local
injection of antimitotic drugs over systemic administration
48has been suggested by the experience of Vats et al , who 
demonstrated that bleomycin, when given intracerebrally 
into rats, had a significant antitumour effect on gliomas, 
with prolonged survival compared with control animals 
receiving no drug or intravenous drug. However, the vas­
cularity of the tumour bed is such that adequate concen­
trations of the drug cannot be sustained for any length 
of time, resulting in a need to give high initial concen­
trations of the drug. This suggests that an inert depot 
preparation of antimitotic drug injected locally into the 
tumour mass, with subsequent sustained release of the drug, 
might be more effective than a similar dose given systemic- 
ally and would enable a higher dose to be given without 
systemic toxicity.
Liposomes have recently been explored as a possible
vehicle for giving cancer chemotherapy in an attempt to
direct cytotoxicity specifically to diseased areas of the 
49body . When given intravenously, liposomes accumulate
predominantly in the liver with little or no selective
50uptake into malignant tissue . However, the difficulties 
arising from systemic toxicity and non-selective uptake of
37
liposomes when injected intravenously may be overcome by
local injection into the tumour mass of antimitotic drugs
51entrapped within liposomes. Adams et al demonstrated 
in the mouse that liposomes of defined composition may be 
safely used as carriers of therapeutic agents into the 
central nervous system. The potential advantages of such 
an approach will be considered further.
38..
1.2 LIPOSOMES
The concept of the liposome as a means of investigat­
ing membrane structures and as a carrier of biologically
active molecules has developed largely from the pioneering
52 53 54work of Bangham and others in the 1960's ' ' . They
were able to demonstrate that a wide range of phospholipids,
when suspended in aqueous media, spontaneously aggregated
to form not micelles but multilamellar membrane-like
structures. Of particular importance, they were able
to show that these structures consisted of concentric bi-
55layers of lipid separated by aqueous compartments 
These membranes were permeable to water and anions but 
much less so to cations. Of the many phospholipids studied, 
the most widely used has been various forms of phosphatidy- 
choline, frequently in the form of mixed preparations con­
taining varying molar concentrations of cholesterol plus 
either anionic (e.g. phosphatidic acid) or cationic lipids 
(e.g. stearylamine). The latter confer a net overall 
charge to the liposome structure.
These structures were originally used as a means of 
furthering fundamental research on the structure and func­
tion of membranes. For example, studied on these structures 
helped support Mitchell's chemiosmotic theories of energy 
transfer"^. More recently, however, there have been ex­
tensive investigations to determine their potential as 
carriers of therapeutic and other molecules in biological 
systems.
39
Liposomes have been shown to be capable of en­
trapping a wide range of polar and non-polar molecules 
and electrolytes within their structure. Polar molecules 
and small solutes are held in solution in the aqueous 
phases between the bipolar lipid layers, whereas non­
polar molecules may be intercalated between the bilayer. 
Large molecules, and in particular protein molecules, may 
be entrapped within the aqueous compartments or may be 
bound to the surface of the liposomes. In the latter case 
the binding is mainly electrostatic in nature, positively-
charged proteins being bound to the surface of negatively-
57charged liposomes and vice versa
1.2.1 Factors affecting incorporation into and subsequent 
release of molecules from liposomes
Numerous factors have been shown to affect the
efficiency of incorporation of drugs and other molecules
into liposomes and their subsequent release, in particular
the composition and concentrations of lipids used and
the nature of the aqueous phase.
Increasing the degree of saturation or the length of 
the phospholipid fatty acyl chains have been shown to pro­
duce a decrease in the permeability of the bilayers to 
solutes, principally by producing an increase in the trans­
ition temperature of the lipid, resulting in a decrease 
5 8in fluidity . Dipalmitoyl phosphatidyl choline (DPPC), 
one of the most widely used of the phospholipids, undergoes
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a phase transition between 32° and 42°C and will not 
readily produce liposomes below 4 2°C. DPPC liposomes 
produced at temperatures higher than this can be shown 
to exhibit a reduction in liquidity on cooling through 
this critical temperature range. Further changes in mem­
brane volume and thickness, protein NMR line width and
59
light scattering have also been demonstrated
Cholesterol is frequently added to phospholipid up to 
a maximum molar ratio of 1:1. This again has the effect of 
decreasing permeability by decreasing the fluidity of the 
bilayer structure.
Positively (e.g. stearylamine) and negatively (e.g. 
phosphatidic acid) charged lipids are also frequently in­
corporated into liposomes in order to influence the rate 
of incorporation and subsequent release of electrolytes 
and other charged species. Hence positively-charged lipo­
somes are impermeable to cations whilst negatively-charged 
liposomes are freely permeable to cations. On the other 
hand, anions generally diffuse through the liposomes re­
gardless of their charge whereas the permeability of all 
liposome membranes to protons is low.
The permeability of the liposome membrane may also 
be altered by the incorporation of a number of specific 
compounds into the liposome structure. Hence permeability 
to ions may be selectively increased by the addition of 
ionophores such as valinomycin, as well as certain anti­
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biotics and cyclic peptides^. The addition of lysozyme^,
62 63myelin basic protein , immunoglobulins and certain other
proteins to a liposome suspension has been shown to increase
the leakage of anions and glucose from the lipsome, whereas
the addition of general anaesthetics such as ether and
64chloroform produce an increase in cation permeability .
65The addition of calcium ions , however, has been shown to 
result in the formation of giant liposomes composed of 
cylindrical aggregates of individual liposomes.
Since the liposome membrane is relatively impermeable
to protons it is possible to maintain substantial pH gradi-
57ents across the liposomes for considerable lengths of time 
Thus it has been shown that by altering the pH of the 
aqueous phase in order to ionise available functional 
groups and hence increase solubility, the rates of entrap­
ment of certain drugs etc. can be greatly enhanced. The 
amount of solute incorporated may also be increased by 
increasing the volume of the aqueous phase within the
liposome. This may be achieved either by reducing the
66ionic strength of the aqueous phase or by the adoption 
of techniques for synthesis of liposomes which give a high 
aqueous phase volume.
1.2.2 Preparation of liposomes
A number of methods for the preparation of liposomes 
have been described. The original technique, and still
6 Vthe one most frequently used, is that described by Bangham
P
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68and extensively used by Gregordiadis and other workers 
in this field. This involves the rotary evaporation 
under reduced pressure of the lipid solutions dissolved 
in chloroform in order to produce a thin lipid layer 
coating the walls of the vessel used. A small volume of 
the aqueous medium containing the compound to be entrapped 
is then added and the flask gently shaken. The lipid 
layer swells and disperses into the aqueous solution to 
form large multilamellar vesicles (MLV) about 1 |im in dia­
meter. These can subsequently be reduced in size by 
sonication under controlled conditions to yield unilamellar 
vesicles (SUV).
However, both MLV and SUV can entrap only relatively 
small amounts of solute and have a restricted ability to 
encapsulate large macromolecules. For MLV this is due 
to most of the lipid participating in the internal lamellae, 
resulting in a close apposition of adjacent bilayers and 
hence a limited internal aqueous volume. For SUV the 
ratio of surface area to encapsulated volume is so large 
that only a relatively small aqueous volume per mole of 
lipid can be achieved. A number of alternative tech­
niques have been developed which seek to overcome this 
problem as well as producing liposomes with other charac­
teristics more suited to particular applications.
Several techniques have been developed based on 
the injection of phospholipid dissolved in organic sol­
vent through a fine hypodermic needle into an aqueous
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69phase. Batzri and Korn used an ethanolic solution to
produce very small liposomes of 25nm diameter whereas 
70other workers have injected ethereal solutions of lipid 
into aqueous phase held at a constant 60°C to produce 
large unilamellar liposomes with high aqueous phase en­
trapment. Although having 10-20 times the entrapment 
capacity of other techniques described above, the tech­
nique is limited to the use of non-heat labile solutes 
and phospholipids.
71Barenholzt et al have overcome this particular 
problem by forcing aqueous dispersions of multilamellar 
liposomes through the fine orifice of a hydraulic press 
under pressures of 20,000 psi. This produced small uni­
lamellar vesicles of much higher membrane stability than 
sonicated unilamellar vesicles.
Another approach has been the use of detergent to 
produce an aqueous suspension of lipid in a medium con­
taining the solute to be entrapped, followed by dialysis
to remove the detergent. Although this technique has been
72applied to the study of membrane properties / i t  is not
generally suitable for in vivo studies because of the
difficulties of removing all residual traces of deter-
73gent. More recently, Rhoden and Goldin have used the 
natural bile salt sodium cholate, followed by rapid 
hollow-fibre dialysis to produce primarily unilamellar 
vesicles, the size of which can potentially be controlled
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by varying the mole fraction of cholesterol and the pH 
of the dialysate used.
Many of the limitations described have been overcome 
by the method described by Szoka and Papahadjopoulos 
Lipids in a suitable organic solvent are added to an aqueous 
phase containing the solute to be entrapped, and the two- 
phase system is then sonicated briefly under nitrogen until 
a stable homogeneous opalescent dispersion is formed. The 
mixture is then placed in a rotary evaporator and the organic 
phase removed under reduced pressure. The temperature at 
which this is carried out depends on the type of lipid used, 
being 45°C for DPPC but only 20-25°C for most other lipids. 
During evaporation the system froths as organic solvent is 
removed, to leave a viscous gel which subsequently forms an 
aqueous suspension on prolonged evaporation. This suspension 
contains large (200-500nm) uni- or oligolamellar vesicles 
with a high capture efficiency for a wide variety of com­
pounds. The stability of protein molecules in the presence 
of the organic phase does, however, need to be assessed.
Having produced liposomes by any of the techniques 
described above, the majority of applications demand that 
the entrapped material is separated from the remaining free 
material prior to use. This is generally accomplished by 
dialysis, Sepharose 4B or 6B column chromatography, or by 
centrifugation, the technique chosen depending to some 
extent on the characteristics of the substance being trapped. 
Dialysis has a number of disadvantages, in particular the
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length of time required (during which there will inevitably 
be some release of entrapped material), limitation on
molecular size and uncertainty as to completeness of
74 75separation. The chromatographic and centrifugation
techniques may be refined further in order to separate the 
liposomes produced according to size. Thus liposomes that 
have been subjected to prolonged sonication produce two 
peaks following separation on Sepharose 4B: a void peak 
containing larger sized liposomes and an included peak con­
taining much smaller liposomes which can be further separ­
ated by ultracentrifugation. These preparations have been 
particularly useful in studying the interactions of lipo­
somes and cells in vitro and in vivo where it has been shown 
that the rate and site of uptake may vary considerably de­
pending on the size of the liposomes used.
1.2.3 Interaction of liposomes with cells in vitro
Liposomes, particularly unilamellar structures, share 
a number of features in common with cell membranes and have 
been used extensively in the study of basic membrane pro­
perties. Since much of the research on liposomes is now 
being directed to a study of their potential as carriers 
of therapeutic drugs and other substances to cells of 
the body, it is important to understand the means by 
which the liposome interacts with the cell membrane.
This interaction may involve any one of a variety of
76different mechanisms, or a combination of these mechanisms :
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1. Fusion of the liposome membrane with the cell 
membrane.
2. Incorporation of intact liposomes into the cell by
endocytosis.
3. Adsorption of liposome, intact or fragment, onto 
the cell membrane surface.
4. Transfer of lipid between liposome membrane and cell
membrane.
Most of the studies on these interactions have been 
carried out in vitro using monolayers of fibroblasts 
and occasionally other cell lines, incubated with lipo­
somes containing markers of both the lipid membrane and 
the aqueous compartment. Radiolabelled lipids have most 
frequently been used together with water-soluble markers 
containing a different radioisotope, or a fluorophor.
Most studies have shown that the encapsulated aqueous 
phase and the radiolabelled lipid are associated with 
the cell to a similar extent, suggesting that the cell- 
associated liposomes are composed of intact vesicles^' .  
The evidence suggests that this may occur by fusion or by 
endocytosis dependent upon the conditions used. Thus it 
has been shown that when inhibitors of endocytosis are 
employed in a system containing DALB/c mouse 373 cells, 
the uptake of negatively-charged SUV’s and MLV’s con­
taining phospholipids in the non-fluid state is markedly 
77
reduced . The effect on SUV’s and MLV’s containing
47
fluid lipids was, however, minimal even though the lipo­
some size and charge was the same, suggesting that a
/t q
different mechanism is in operation. These studies ' 
have further suggested that endocytosis is the dominant 
mechanism for the uptake of neutral lipids composed of 
egg phosphatidyl choline, with very little cell fusion 
occurring with any of these particular structures. Fusion 
of the lipid envelope of Sendai virus with egg phosphatidyl 
choline can apparently occur, however, when phosphatidy-
ethanolamine or phosphatidylserine is incorporated into
.. • n 78,79the vesicle .
A major difficulty has been distinguishing between 
true membrane fusion and electrostatic adsorption of 
charged vesicles onto the surface of the cell membrane.
Both biochemical and electron microscopy techniques have 
been used in an attempt to distinguish between these two 
processes. However many of the results obtained are 
conflicting and contradictory, largely due to lack of 
acceptance of the validity of the particular technique 
used. On balance the evidence now seems to be in favour 
of adsorption onto the cell surface as being the major 
mechanism of action.
A similarly inconsistent picture emerges when one 
examines the evidence supporting the transfer of phospho­
lipid between liposome and cell surface membranes. On 
balance, however, it does appear that transfer of both 
phospholipids and cholesterol can occur as shown by
48
Bouma et al , who were able to demonstrate the transfer 
of lipid between human erythrocytes and SUV's containing 
DPPC but no simultaneous transfer of ^C-sucrose from the 
aqueous phase.
The reverse transfer of components from the cell surf­
ace to the liposome membrane also appears to occur under 
appropriate conditions. Thus transfer of sphingomyelin, 
phosphatidyl choline and cholesterol as well as ^5j_ 
labelled protein has been demonstrated from human erythro­
cytes to dipalmitoyl phosphatidyl choline-containing SUV 
80at 37°C . This transfer of protein did not appear to 
occur with MLV however.
1.2.4 Fate of liposomes following in-vivo administration 
Following intravenous administration of liposomes in 
the rat, liposomal phosphatidyl choline shows a biphasic 
clearance from the blood, with an initial rapid clearance 
over the first 15 minutes followed by a much slower clear­
ance. The actual rate of clearance appears to depend upon 
the size of the liposome, with up to 75% of clearance in 
15 minutes following administration of large unilamellar
liposomes and around 5% in the case of smaller sonicated 
81liposomes . The relationship between liposome charge and 
the rate of clearance appears to vary with the type of 
liposome used and the marker lipid studied.
Labelling experiments have invariably shown that the 
major site of uptake of liposomal lipid has been the liver,
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followed by the spleen, with much smaller uptake by the
8 2bone marrow and other tissues
Liposomal lipid taken up the liver has been shown to
be associated with the lysosomal fraction of the liver 
83 84cells ' , principally of the Kupfer cells and parenchymal 
cells. The initial uptake appears to be principally by 
the Kupfer cells followed by a later extensive uptake by 
the parenchymal cells. It has been suggested that the 
initial uptake by the Kupfer cells reflects a direct up­
take of intact liposomes and that this correlates with the 
initial rapid clearance of the liposomes from the blood. 
There is good evidence that the later association of 
lipid with hepatocytes represents an indirect transfer 
of lipid that has been released from degraded liposomes
and carried to the liver in the plasma as part of the high
81density lipoproteins
There is in fact considerable evidence to show that 
following intravenous administration there is extensive 
interaction between the liposome and components in the 
serum. Interaction of liposomes with albumin in pure 
solution has been shown to occur, resulting in a signifi­
cant increase in the permeability of the liposome bilayers
to solutes such as sucrose and insulin trapped within the 
8 5aqueous phase . These results correlate closely with 
those obtained using whole blood or plasma. The leakage 
of large molecules such as ^25i-aibumin from the aqueous
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phase has also been demonstrated in the presence of blood 
or plasma, suggesting that considerable modification of 
the liposomal membrane structure must have occurred. This 
appears to be brought about by a direct transfer of phos­
phatidyl choline from the liposome to the albumin when 
carried out in pure solution. In the presence of plasma, 
however, much of the phosphatidyl choline appeared to be 
transferred to the high density lipoproteins. There also 
appears to be a transfer of protein occurring from the
high density lipoproteins to the liposomes. Interactions
86 87of liposomes with a 2-macroglobulin and with 3-globulin
have been demonstrated. Furthermore, it is likely that 
other interactions are occurring, e.g. cholesterol transfer, 
enzymatic degradation of lipids, etc. Consequently, exten­
sive changes to the liposome structure most probably occur 
following intravenous administration. This may result in 
changes in solute permeability, surface change or even 
change in the overall size or shape of the liposomes.
These changes can have significant effects on the inter­
action of the liposome with tissue cells and must have a 
bearing on any proposed applications of liposomes where 
the liposome will be in direct contact with plasma or 
plasma components.
1.2.5 Potential applications of liposomes
Various carriers of therapeutic substances have been
88 89investigated in the past. Chang ' studied the effect of
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intraperitoneally-administered enzymes trapped within < 
nylon or colloidon microvesicles, and more recently a 
system has been developed and marketed for the treatment 
of chronic bone infections by use of gentamicin-impregnated 
polymeric beads. The major disadvantage of many of these 
systems lies in the fact that they are based on the use of 
non-natural materials that may accumulate in the body.
The major advantage in favour of the use of liposomes is 
the fact that they can consist of completely natural mater­
ials or closely related compounds that can eventually be 
fully metabolised in the body. Furthermore, liposomes 
are potentially far more versatile in that the size and 
composition of the liposome can be varied extensively to 
suit any particular application.
There are a number of theoretical reasons why a 
particular therapeutic substance might be more beneficial 
when administered bound to a carrier other than as a free 
substance. These may include any or a combination of the 
following factors:
1. To direct therapeutic substances to specific areas
of the body, e.g. antineoplastic drugs to tumours.
2. To carry potentially antigenic material to these
sites in a form in which that antigenicity is not 
fully expressed, e.g. enzymes and other proteins.
3. To carry potentially toxic substances in a form in
which that toxicity is not fully expressed.
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4. To increase the stability of substances that are 
rapidly cleared from the body, rapidly metabolised 
or otherwise subjected to enzymatic degradation, 
e.g. use of oral insulin preparations.
5. To act as potential depot preparations for the 
delayed release of therapeutic substances in order 
to prolong the length of time of their effective 
action, e.g. use of macrophage-activating factor 
to activate tumouricidal macrophages.
6. To increase the rate of clearance of particular sub­
stances from the body by the reticuloendothelial 
system, e.g. use of entrapped double antibody to 
clear antibodies and immune complexes from the body.
Of the many substances investigated, those that do 
appear to possess a potential advantage when entrapped 
within liposomes generally meet one or more of the criteria 
outlined above. The following examples probably best illus­
trate the ways in which various workers have attempted to 
solve particular clinical problems by the use of drugs and 
other substances entrapped within liposomes.
Enzyme replacement therapy
A number of genetic diseases are characterised by 
low or absent levels of specific enzymes frequently re­
sulting in the accumulation of metabolic intermediates 
leading to particular clinical manifestations. Attempts 
at treatment of these inherited genetic deficiencies have
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in the past been directed towards the reduction of these 
metabolic intermediates by dietary or other means. Alter­
native more direct approaches have been attempted by 
correction of the malfunctioning gene responsible for 
transcription of the missing enzyme, or by exogenous re­
placement of the missing enzyme. The latter approach, 
however, demands that the missing enzyme being replaced 
must, after administration, reach and act in the particular 
cells where the enzyme is normally functioning. On reach­
ing these sites, the enzyme may be degraded by blood en­
zymes, be taken up by the reticuloendothelial system, be 
unable to penetrate target tissues and cells, and almost 
certainly would provoke an immunological reaction.
It has been postulated that many of these difficulties 
might be eradicated by the entrapment of the enzyme mole­
cule within a carrier such as a liposome prior to adminis­
tration. In particular, the treatment of enzyme deficiencies 
within the liver, the principal site of uptake of liposomes, 
might conceivably be possible. This would be particularly 
applicable to certain of the storage diseases where de­
ficiency of a specific enzyme leads to the accumulation of the 
substrate in the lysozomes of the affected tissues. The
potential success of this approach has been demonstrated 
90in vitro , where it has been shown that the use of invert- 
ase entrapped within liposomes eliminates sucrose storage 
vacuoles from mouse peritoneal macrophages deficient in 
invertase. It has also been shown that the enzyme activity
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appears to be rendered latent whilst entrapped within
liposomes in the blood following injection into rats and
83it is only restored upon uptake by the liver and spleen
91Such results encouraged Tyrrell et al to attempt 
the enzyme replacement therapy of a child suffering from 
type II glycogen storage disease, a disease characterised 
by an accumulation of glycogen in liver, muscle, and heart 
due to an absence of lysozomal a-glucosidase. This is 
invariably a fatal disease with afflicted infants generally 
dying before the age of one year. Hence a short daily 
course of injections of amyloglucosidase entrapped within 
liposomes was attempted. Over the course of eight days 
treatment no adverse effect directly attributable to the 
liposome administration was noted and a marked decrease 
in liver size was observed. The child unfortunately died 
on the eighth day of treatment but, following post-mortem 
examination, the amount of glycogen accumulated in the 
liver was found to be considerably lower than would 
normally have been anticipated. Levels in heart and 
muscle, however, were extremely high and apparently un­
affected by therapy. This is not altogether unexpected 
and illustrates what is at present one of the major limit­
ations of this technique - the relatively low affinity of 
liposomes for most tissues other than liver and spleen.
Oral administration of liposomes
There are clearly a number of practical advantages
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to the oral administration of a drug as opposed to its 
subcutaneous, intramuscular or intravenous administration, 
particularly when the drug in question needs to be given 
on a long-term basis. In practice, however, this fre­
quently cannot be achieved, either because of its poor 
absorption, denaturation by digestive enzymes or due to 
insufficient bioavailability due to rapid metabolic con­
version by the liver. This is particularly true in the 
case of proteins and polypeptides and most especially in 
the case of administration of insulin to diabetic patients.
There is evidence, however, that proteins much larger 
than this can be absorbed antigenically and biologically 
intact from the gastrointestinal tract under certain con­
ditions . Thus bovine milk xanthine oxidase has been de­
tected in the blood leukocytes of people following con­
sumption of large amounts of homogenised cows milk.
Indeed, it has been postulated that bovine xanthine oxid­
ase may play an important role in the aetiology of human 
atherosclerotic diseases. Little bovine mild xanthine 
oxidase appears to be absorbed following the consumption 
of raw milk, however, and it has now been demonstrated 
that the process of homogenisation results in the form­
ation of natural liposomes than can subsequently be absorbed
92through the gastrointestinal tract
A number of workers have studied the effects of oral 
administration of insulin that has been entrapped arti­
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ficially within liposomes. Most have demonstrated a hypo- 
glycaemic effect attributable to these preparations in
diabetic rats, although studies on normal rats have pro-
93 94 95duced somewhat contradictory results ' . Patel and Ryman
were only able to demonstrate a hypoglycaemic effect in
normal rats treated with indol-3-ylacetic acid, a compound
known to inhibit insulin degradation within the liver,
96whereas Weingarten et al were able to demonstrate hypo- 
glycaemia in normal rats receiving liposome-entrapped 
insulin via the buccal cavity but not when introduced by 
a strictly intragastric route. These latter workers were 
also able to demonstrate a similar effect when liposomes 
devoid of insulin plus free insulin were administered 
simultaneously into the buccal mucosa but not when adminis­
tered individually. The fact that the insulin need not 
necessarily be entrapped within the liposome suggests that 
the lipid may be acting as a transport agent at a molecular 
level for the transport of insulin across membranes, 
although it is possible that the lipid is also providing 
protection against proteolytic activity in the intestines.
The evidence as to whether or not liposomes are
capable of entering the circulation intact is again very
94contradictory. Dapergolas and Gregordiadis suggested
that insulin was absorbed largely in the entrapped form,
although others have been unable to confirm this. It
would appear, however, that although insulin may be pro-
97tected against proteolytic activity in vitro , the presence
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of bile salts largely nullifies this protection in vivo
and less than 1 % of intragastrically-administered insulin
is absorbed intact when administered within liposomes.
98Similar results have been demonstrated by Patel et al 
in normal human volunteers given entrapped insulin intra- 
jejunally. Small increases in immunoreactive insulin were 
demonstrated corresponding to about 1 % of the total adminis­
tered dose, although no significant changes in blood 
glucose levels were observed.
Hence, although this work may prove of value in the 
long term, much investigation is still required into the 
routes of administration, composition of liposomes, dosage 
of insulin, effect of pH and various other factors likely 
to affect the extent of absorption of intact insulin and 
hence degree of hypoglycaemic effect achieved.
Tumour imaging
In recent years a great deal of interest has focused
on the development of techniques for the location and
imaging of tumours by the use of non-invasive methods.
The use of ^ ^ t e c h n e t i u m - l a b e l l e d  liposomes followed by
y camera scanning for this purpose has been investigated
99by several laboratories . Although it has been possible 
to demonstrate some preferential uptake of ^SMsodium per- 
technetate-labelled liposomes into implanted tumours in 
Wistar rats following intravenous injection, attempts to 
demonstrate similar preferential uptake by tumours in man
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have met with little success. Almost invariably the major 
site of uptake of the labelled liposomes has been the 
liver and spleen, although in several cases of primary 
hepatoma studied little tumour localisation could be demon­
strated. Only in one case of polycythemia rubra vera was 
a markedly different pattern of uptake seen, and here high 
levels of uptake by the bone marrow could be demonstrated.
Attempts at lymph node localisation have met with a 
greater measure of success using this technique. Labelled 
liposomes injected into the hind footpad of rats have 
yielded good visualisation of lymph nodes 3-6 hours after 
injection, suggesting the possibility that this might be 
of value for both diagnostic and therapeutic purposes in 
the investigation and treatment of disorders of the lymph­
atic system.
Generally, however, the possibility of using labelled 
liposomes for tumour imaging has been overtaken by more 
sophisticated techniques such as computerised tomography, 
NMR studies and the use of tumour-specific monoclonal 
antibodies. A number of workers have used monoclonal anti­
bodies directed against either tumour cell antigens or so- 
called tumour-specific proteins such as carcinoembryonic 
antigen (CEA) in order to visualise the tumour by y 
camera imaging. The usefulness of the technique is 
limited, however, by the high proportion of administered 
antibody which remains non-specifically in the circulation
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and extravascular space. Administration of a second anti­
body directed against the first should go some way towards 
clearing this non-specifically bound residual activity, 
although this would be dependent upon the concentration 
of both first and second antibody being such that large 
lattice immune complexes can be formed at equivalence. 
However, even if equivalence is reached, it has been 
claimed that this would lead to complement activation
and tissue damage attributable to serum sickness 
101Begent et al claim to have overcome these difficulties 
by the use of second antibody entrapped within liposomes. 
These were shown to produce accelerated clearance of radio­
labelled antibody directed against carcinoembryonic antigen 
from the circulation in four of five patients with gastro­
intestinal cancer, enhancing y camera imaging of the 
tumour in three of them. These results suggest that lipo- 
somally-entrapped second antibody can improve the sensi­
tivity and specificity of tumour inaging with radiolabelled 
antitumour antibody. It is suggested that this strategy 
may also be of value in improving the therapeutic effect 
of drugs and other agents linked to antitumour antibodies.
Liposomally-entrapped chelating agents
The use of liposomally-entrapped second antibody 
clearly illustrates a potential for the use of liposome- 
entrapped agents in order to facilitate the rapid clearance 
of certain substances from the body. This might have a 
valuable clinical potential if it could be applied to the
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clearance of certain heavy metals from the body, either
in the treatment of metal storage diseases or in patients
exposed to toxic levels of heavy metals such as lead,
102mercury or cadmium. Rahman has demonstrated that it 
is possible to entrap a variety of chelating agents within 
liposomes and that they can be administered to mice without 
undue toxicity. Since both heavy metals and liposomes are 
taken up by the lysozomes of reticuloendothelial cells in 
the liver, spleen and bone marrow, it might be anticipated 
that there would be a high degree of interaction between 
the entrapped chelating agent and the heavy metal in such 
patients, possibly resulting in increased clearance of the 
heavy metal from the body. The potential value of this 
approach has been demonstrated by studies in mice which 
have shown that plutonium-239, lead-210, mercury-203 and 
gold-198 can all be cleared from the body with increased 
rapidity and efficiency by the use of various chelating 
agents entrapped within liposomes.
Liposomes as immunological adjuvants
N-Acetyl muramyl-L-alanyl-D-isoglutamine has been 
demonstrated to be the minimal structure of bacterial pep- 
tidoglycans required for adjuvant activity on immune res­
ponses. This compound, commonly referred to as muramyl 
dipeptide (MDP) has been shown to have potent adjuvant 
activity on both humoral and cell-mediated immune responses 
including tumour-suppressive activity in mice and guinea- 
pigs. The effect is limited, however, by its very short
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half-life in vivo (9 0% elimination within two hours in 
mice), and it has therefore been postulated that encapsul­
ation of MDP within liposomes should greatly increase its 
half-life in the body, which in turn might lead to en­
hanced immunological effect. This has been clearly demon-
103strated by Fraser-Smith et al who showed that much lower
doses of MDP were required to protect mice from Candida
albicans infections, when entrapped within liposomes and
administered by the intravenous route, as compared with
administration of free drug. In-vitro activation of the
tumouricidal properties of rat alveolar macrophages by
104liposome-entrapped lymphokines and by liposome-entrapped 
105MDP has also been demonstrated. Since it has been shown
that the intravenous injection of macrophages that have
been activated in vitro leads to a significant reduction
106in the number of experimental pulmonary metastases , there 
is some reason to believe that the administration of lipo- 
somally-entrapped MDP may be potentially effective against 
tumour cells in vivo.
It is of considerable interest to note that liposomes
themselves can act as immunological adjuvants, since much
of the early work on the clinical use of liposomes was
based on the premise that entrapment of proteins (e.g.
enzymes) within the liposome would protect that protein
from immune recognition. That this was far from so was
107first demonstrated by Allison et al , who showed that 
injection of diphtheria toxoid entrapped within liposomes
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into mice elicited a much greater response than when free 
toxoid was given. Furthermore, they demonstrated that the 
extent of the response was related to the composition of 
the liposomes, with the greatest antibody response occur­
ring when diacetyl phosphate was incorporated into the 
liposome structure. These effects have been confirmed by 
other workers studying a wide range of viral and bacterial 
antigens. Liposomes appear to have several advantages
over the majority of other adjuvants in common use; they
108do not result in the formation of granulomas at the in­
jection site, nor do they lead to hypersensitivity re- 
107actions to the entrapped antigen. Hence there is a 
considerable potential value in the use of liposomes as 
immunological adjuvants in animals and in human subjects.
This immunological activity is further enhanced by
the incorporation of other adjuvants such as mycobacterium
108tuberculosis into the liposome . Conceivable, therefore, 
the incorporation of MDP into liposomes of appropriate 
composition together with the required antigen would 
result in a good immune response, but with the major ad­
vantage that agents of defined chemical composition were
being used for this purpose. This has been confirmed in
109initial studies by Siddiqui et al , who demonstrated 
that the incorporation of malarial parasite fragments 
(Plasmodium falciparum) into liposomes containing MDP 
derivatives and injection into owl monkeys conferred pro­
tection to the animal against subsequent exposure to 
malarial parasite.
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The adjuvant effect of liposomes has also been used
to elicit antibody, response against tumour cell surface
antigens following injection of solubilised cell surface
110components entrapped within liposomes , and this could
have important therapeutic applications. There is some
evidence, however, that an immune response can also, under
111certain circumstances , be elicited against the lipid com­
ponents of the liposome which might therefore prevent the 
repeated injection of liposome preparations into the same 
subject.
1.2.6 Liposomes as carriers of drugs in cancer chemo­
therapy
Most, if not all, chemotherapeutic agents in current 
use have a relatively low therapeutic index, and the toxic 
side effects of the drug on normal tissues is often nearly 
as great as on the neoplastic process. This is especially 
so following prolonged use of the drug and in the treatment 
of solid tumours. Various chemical modifications of chemo­
therapeutic agents in current use (e.g. alteration in
partition coefficient or charge density, or attachment
112of immunological ligands) have met with only limited 
success and the majority of research in this field is now 
directed towards the search for agents with greater tumour- 
specificity or alternatively towards means- of altering 
the tissue distribution of present generation drugs in 
such a way that they may be concentrated at the tumour 
site.
The entrapment of chemotherapeutic agents within lipo­
somes is one approach to this problem which has been studied
extensively over the past 15 years. A number of in-vitro
50 94 113 114 115 and in-vivo studies ' ' ' ' have demonstrated some
apparent increased tumour uptake of chemotherapeutic agents
when entrapped within liposomes. However, more rigorous
studies have not always been able to substantiate these
claims and even under the most favourable conditions the
extent of increased tumour uptake has been modest, the
majority of liposomes still being taken up by the fixed
116reticuloendothelial system in the liver and spleen
There have been a number of attempts to modify the 
basic liposome structure in order to increase their prefer­
ential uptake by tumour tissue, or conversely to reduce 
uptake by normal tissues known to be sensitive to the toxic 
side effects of the particular drug being studied. Thus 
it has been demonstrated that reducing the size of the
liposome to small unilamellar vesicles results in an in-
94 117creased tumour uptake of the drug ' , although to what
extent this is due to increased tumour cell selectivity 
for small liposomes rather than the effect of the longer 
half-life of these small liposomes in the blood is not 
entirely clear. One pratical difficulty with this approach 
is the reduced interior aqueous space of these liposomes 
which may limit the amount of drug that may be entrapped.
An alternative approach has been the incorporation of
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glycolipids into the liposomal membrane structure. Thus
liposomes containing an exposed galactose group on their
surface demonstrate an even greater extent of liver uptake
due to the presence of an asialo-galactose receptor in the 
118liver , whereas the incorporation of a sialic acid group
119will reduce this accumulation . The extent of uptake by
the lung can also be considerably influenced by this
, 120,121 approach ' .
The incorporation of tumour-specific monoclonal anti­
body onto the liposome surface has received considerable 
attention in recent years, and a number of in-vitro studies
have demonstrated that this approach can result in increased
122 123 124target specificity ' ' . However, in-vivo studies have
so far met with a number of practical difficulties and 
although some limited preferential uptake by solid tumours 
has been demonstrated, the major site of uptake has re­
mained the liver and spleen.
A rather novel approach to this problem has made use 
of the fact that the rate of release of drug from lipo­
somes of appropriate composition is much greater at tem­
peratures above the transition temperature of the phospho­
lipid used. Thus local heating applied to the vicinity 
of the tumour has been shown to result in an increased 
release of methotrexate at that site from intravenously-
injected liposomes containing phospholipids having a phase
125transition temperature at 42°C
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Despite the difficulties outlined above, a number of 
animal and a limited number of human studies have demon­
strated therapeutic advantages to the use of chemothera­
peutic agents entrapped within liposomes. Thus Sur et 
126al have demonstrated that Cis-platinum diaminodichloride, 
when entrapped within neutral liposomes at doses much lower 
than when given in free form and administered intraperitone- 
ally to mice with Ehrlich ascites carcinoma, has resulted 
in significant tumour regression and increased survival.
Similar effects have been demonstrated for illudin S en­
trapped within liposomes applied to Ehrlich ascites 
127tumours , and this has been attributed mainly to the 
reduction of toxic side effects of the drug when adminis­
tered in this form.
Considerably improved therapeutic activity of adria-
mycin (doxorubicin) has also been demonstrated in murine
128 129 130leukaemias when the drug is entrapped within liposomes ' '
and it appears that this effect is partly due to a reduction
in the immune suppressive activity of the drug but also due
131to the considerable reduction of its cardiotoxic effects 
1-B-D-arabinofuranosylcytosine, on the other hand, has been 
shown to more toxic entrapped within liposomes than a 
similar dose of the free drug. However, the drug is thera­
peutically far more effective at much lower doses when
132entrapped within liposomes . These workers have also 
demonstrated that the free liposomes containing no drug 
can be administered at very high levels (up to 5500mg 
lipid per kg) without any adverse response.
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Liposomes may also be useful in the treatment of
drug-resistant tumours and this has been demonstrated in
vitro using entrapped thaliblastine on resistant Walker
133tumour cell lines and in vivo using entrapped methotrex-
134ate on solid tumours in rats and mice
A further interesting development in the application
of liposomes is for the administration of water-insoluble
compounds that may have chemotherapeutic activity. Thus
both 2— [31(methoxycarbonylamino)-phenyl]-3-phenyl-methoxy-
135carbonylamino-4-(3H)-quinazolone (NSC-251635) and noco- 
136dazole , two very water-insoluble compounds, have been
shown to have therapeutic activity against murine leukaemias
when incorporated into the lipid membrane of liposomes and
administered to mice. Furthermore, it has recently been
demonstrated that large infusions of NSC-251635 entrapped
within liposomes (up to 400ml at a dose of 135mg lipid/kg
137body weight) were well-tolerated in man . Five patients 
with advanced multiresistant neoplasms were studied, when 
the only clinical side effect observed was a transient 
drowsiness which cleared within three hours of the infusion. 
The major site of uptake of the liposomes was the liver.
A more detailed study of the pharmacokinetics and
9 9Morgan distribution of Tc-labelled liposomes in patients
with cancer showed a similar pattern of uptake of the
138radiolabelled liposomes , with 44.5% of the administered 
dose being taken up by the liver, 25.5% by the spleen and
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13914.5% by the lungs. However, Poste and his co-workers 
have recently demonstrated that although SUV can, to a 
limited extent, penetrate liver sinusoids to interact 
with hepatocytes, MLV were unable to penetrate into the 
extravascular compartment of the liver, spleen or lung.
They considered that the inability of liposomes to escape 
from continuous capillaries and their rapid uptake by 
circulating and fixed phagocytic cells called into question 
the feasibility of using liposomes to target drugs to 
cells in extravascular tissue. These results may well 
explain the failure to demonstrate any significant uptake 
of liposomes by tumour cells in vivo following their ad­
ministration by the intravenous route, and suggest that 
a more direct route of application of liposomes to the 
target tissue may be called for.
140Thus McCullough and Juliano have demonstrated that 
liposome-encapsulated 3-cytosine arabinoside, when adminis­
tered to rats by intratracheal instillation, persisted in 
the lung for considerably longer periods than the free 
drug. No adverse side effects could be demonstrated in 
other tissues, thus encouraging the belief that this 
approach may be relevant to the chemotherapy of pulmonary 
metastases.
It is highly likely that the continuous capillaries 
of the kind found in the CNS would also present an impene­
trable mechanical barrier to the penetration of circulating
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liposomes, and this has been demonstrated by the failure
of potent centrally-acting agents encapsulated in liposomes
141to alter brain function following intravenous injection 
51Adams et al have demonstrated that liposomes of approp­
riate composition are of low toxicity when injected intra- 
cerebrally in the rat. This opens up the possibility that 
the direct intratumoural injection of bleomycin or other 
suitable chemotherapeutic agents entrapped within liposomes 
may be of greater therapeutic activity than a more indirect 
approach.
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1.3 THE ROLE OF BLEOMYCIN IN BRAIN TUMOUR THERAPY
Bleomycin was isolated in 1966 from Streptomyces 
142verticullis . It was found to consist of a group of 
closely related complex glycopeptides, most of which are 
soluble in water and methanol but insoluble in other organic 
solvents. Thirteen analogues were originally identified 
sharing a common disaccharide-peptide backbone but differ­
ing in terminal amine moiety which is not essential for 
drug action, and designated and
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Fig.1.2. Structure of bleomycin and its analogs
1.3.1 Mechanism of action of bleomycin
143Studies using tritiated bleomycin and circular 
144dichroism have shown that bleomycin binds to DNA but 
without causing extensive changes in secondary structure. 
Binding is thought to be a partial intercalation in the 
major groove extending over four base pairs, and results
145in excision of free bases leading to single-strand breaks 
Double-strand breaks occur at higher concentrations of 
bleomycin, although this is thought to be due to a number 
of single-strand breaks occurring proximally enough to
146result in complete double-stranded scission of the DNA
It has been proposed that the bleomycin molecule has an
active centre in which the threonine hydroxyl and the
histidine imidazole groups participate in the binding with
DNA. pH optima studies suggest that the a-amino group of
the 3-amino-alanine is involved, and other studies also
143indicate a role for the carboxyamine moiety . It has been 
shown that bleomycin binds copper ions to form complexes, 
with the copper located mainly in the 3-lactaminopyrimidyl- 
3-hydroxyhistidyl part of the molecule. Although the copper 
complex appears to be still capable of binding to DNA, it 
does not cause excision of the strands, possibly due to 
an alteration in the secondary structure of the bleomycin.
Bleomycin has been shown to inhibit the replication
of viruses, bacteria and mammalian cell including a broad
147range of tumours , and m  vitro this has been shown to 
occur both by degradation of preformed DNA and by in-
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hibition of new DNA synthesis. Although there is some 
inhibition of RNA and protein synthesis, this is much 
less marked.
Eukaryotic cells are reported as being most sensitive
148to bleomycin during the G2 and M phases of the cell cycle
Although frequently regarded as a cell cycle-specific drug,
some studies suggest that non-cycling cells are in fact
149more sensitive to the action of bleomycin
1.3.2 Assay of bleomycin
A number of different assays have been developed for 
the measurement of bleomycin in body fluids and tissues, 
of which the most commonly used are microbiological assays, 
radioimmunoassays and high pressure liquid chromatography 
(HPLC). HPLC is the only one of these techniques that can 
be reliably applied to the measurement of the individual 
forms of bleomycin. An alternative assay approach has 
been to incorporate tritiated bleomycin in the initial 
drug dose and subsequently to measure the levels of radio­
activity in the body fluids and individual tissues. A 
major disadvantage of such an approach, however, is the 
uncertainty as to whether one is measuring bleomycin or 
its breakdown products in the samples.
Microbiological assays
Microbiological assays were among the first assays 
developed for the measurement of bleomycin and are based
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on the measurement of the zones of inhibition produced 
around samples and standards containing bleomycin placed 
on a solid agar plate seeded with bacteria known to be 
highly sensitive to the actions of bleomycin. Samples 
are applied either as filter paper discs to the surface 
of the agar or as a known volume into wells cut in the 
agar and the plates incubated for a sufficient time for 
the bacteria to multiply. The bacteria most commonly
150applied have been Mycobacterium phlei, Bacillus subtilis
151and Escherichia coli . These techniques, which measure 
only biologically active bleomycin, have been reported to 
have a maximum sensitivity of 1 00|ig/litre in blood. The 
zone of inhibition produced is to some extent dependent 
on the sample matrix, and clearly the technique is in­
validated by the presence of antibiotics in the sample.
Radioimmunoassays
Several radioimmunoassays have been reported for the
152assay of bleomycin. The method of Broughton employed
a rabbit antiserum developed against a bleomycin-bovine
1 25serum albumin complex and a I-bleomycin label produced 
by the standard chloramine T iodination technique. Phase 
separation was by the use of dextran-coated charcoal. The 
cross-reactivity of the antiserum varied with the type of 
bleomycin, the highest against the sulphate and A2 and B2 
forms of the molecule. Cross-reactivity with all non­
bleomycin drugs tested was less than 1%. Sensitivity was 
claimed to be 250pg, with an antibody avidity of 1.3 x 10^
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153litres/mole. Similar techniques have been developed
125based on the use of a sheep antiserum and a I-label
154produced by the iodogen technique of Salacinski et al
1.3.3 Pharmacology
Plasma clearance of bleomycin following intravenous
administration is rapid with initial and terminal plasma
half-lives of approximately 24 and 24 0 minutes in patients
155with normal renal function , and mean 24 hour urinary
clearance in the region of 50-70% of the total dose.
Even shorter terminal half-lives in the order of 120
156minutes have been reported by other workers who have 
shown that where the urinary creatinine clearance is 
below 35ml/minute there is a marked exponential increase 
in this value.
Absorption is rapid following intramuscular injection, 
with peak plasma levels being in the order of one-third 
to one-half of those obtained by the intravenous adminis­
tration of the same amount of drug. Urinary excretion is
in the order of 32% of the total dose at four hours and
15660% at 24 hours . There is evidence that the systemic 
absorption of the drug is higher following intracavitary 
administration (intraperitoneal and intrapleural adminis­
tration) , with the urinary excretion being significantly 
lower, and it has been suggested that if the drug is
given by these routes the total dosage should be corres-
157pondingly reduced
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Although the principal mechanism of detoxification
of bleomycin is renal excretion, considerable amounts of
a bleomycin hydrolase enzyme are found in certain tissues 
158of the body , and appears to play a significant role in 
the intracellular inactivation of bleomycin. This enzyme 
is an aminopeptidase which has been found to hydrolyse 
the amide group of the $-amino-alanine moiety of bleo­
mycin. It appears to be present in greatest activity in 
the lymph nodes, bone marrow and kidney, and at very low 
levels in the intestines, muscle and skin. Medium activi­
ties have been found in the liver, lung, brain, spleen and 
159pancreas . Bleomycin is one of the few antineoplastic 
drugs which’ does not exhibit bone marrow toxicity or 
immunosuppressive activity, and this may well be due to 
the high levels of the hydrolase activity in bone marrow 
and lymph nodes. In contrast, the toxic side effects in 
skin and lung appear to be related to the relatively lower 
levels of enzyme in these organs. Bleomycin's antineo­
plastic activity also appears to be related inversely to 
the tissue levels of the enzyme, with greatest activity 
being found in squamous cell carcinomas. Bleomycin 
hydrolase is inhibited by various compounds of which the 
most effective is leupeptin (acetyl-L-leucyl-L-leucyl-L- 
DL-arginal), a specific inhibitor of plasmin, trypsin and 
papain.
It has also been shown by Umezawa that certain low 
molecular weight components present in tissue extracts
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also inhibit bleomycin activity. The presence of certain 
metal ions (e.g. Fe2+) are essential to this inactivation 
which is also stimulated by ascorbic acid. The relative 
importance of this form of inactivation in vivo is not 
entirely clear. Highest levels of this low molecular 
weight component have been found in spleen, lymph nodes 
and lung, with low levels in bone marrow and skin.
Although ascorbic acid levels in brain are relatively 
high, the actual levels of bleomycin inactivation is low, 
the reason for this disparity apparently being the low 
concentration of metal ions present.
A number of attempts have been made to determine the 
level of bleomycin in individual organs following adminis­
tration of the drug, but the results obtained vary consider-
160ably according to the technique used. Umezawa et al 
measured the total radioactivity in each organ following 
subcutaneous injection of tritiated bleomycin into mice, 
and compared this with the values obtained by microbio­
logical assay. The highest levels of radioactivity were 
found in kidney and bladder (almost certainly due to urine 
contamination) and in the skin and peritoneum. Concentrations 
as determined by microbiological assay were much lower in 
all cases, the ratio between microbiological assay and radio­
assay being 0.06 or less in all organs other than skin, 
muscle, lung and peritoneum. It is now known that this 
discrepancy is partly due to the presence of the hydro­
lase in high activity in most other organs studied, although
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the low levels of radioactivity found in the brain were
almost certainly due to the presence of very low molecular
weight metabolites that had penetrated the blood-brain
161barrier. Hayakawa et al , using an intravenous adminis- 
14tration of C-labelled bleomycin, found relatively lower 
levels of radioactivity in skin as compared with lung and 
liver. This probably reflects the differences in routes 
of administration and the probability that different meta­
bolites are being measured in this case. They also found 
somewhat higher ratios as determined by microbiological 
assay compared with radioassay than the previous workers, 
although this probably reflects differences in the way the 
organs were handled prior to assay.
1.3.4 Clinical toxicity
The major dose-limiting side effect of bleomycin
administration is pulmonary toxicity, the severity of
162which is related to age and to dose . The development 
of toxicity is typically delayed 4-10 weeks following 
initiation of therapy. Physical findings generally pre- 
ceed radiographic changes and these may progress to signs 
and symptoms of respiratory failure. Histologically the 
lungs show interstitial pneumonitis and fibrosis, the 
lesions being most frequently found in the lower lobes 
and subpleural areas. Although toxicity is associated 
with changes in pulmonary function tests, it is not 
known whether these can be used to predict impending 
toxicity in the susceptible patient. In earlier studies
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the death rate due to pulmonary toxicity has been reported 
as being as high as 6%.
The other major toxicity reported has been of the 
skin, including alopecia, pigmentation, erythema and 
hyperkeratosis, and it would appear that both of these 
m ajor toxic effects can at least in part be attributed 
to the low bleomycin hydrolase activities found in these 
tissues. Conversely, no significant myelosuppression 
or immunosuppression has been reported, and this has been 
related to the high enzyme activities found in bone 
marrow and lymph nodes. A febrile response has also 
been reported in 20-50% of patients.
1.3.5 Antineoplastic activity
Bleomycin is particularly effective against ecto- 
dermally-derived tumours, and this is thought to be due 
to the low levels of tissue hydrolases present in these 
tissues. It has exhibited strong antineoplastic activity 
against all of the following squamous cell carcinomas, 
either alone or in combination with other drugs: head and 
neck; larynx; cervix; vulvo-vaginal; skin; penis; lymphomas; 
mycoses fungiodes; testicular carcinomas.
It is particularly active in combination with vin­
blastine in the treatment of testicular carcinomas, with
16'a significant number of complete remissions being reported 
Its effectiveness can be further enhanced by incorporating 
platinum and adriamycin into these combination regimens.
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Another major area of treatment has been in combin­
ation with the well-known MOPP combination therapy in the 
treatment of Hodgkins disease, when even higher complete 
response rates have been reported when compared with MOPP 
alone.
Since human cerebral gliomas are ectodermally-derived 
neoplasms, bleomycin might be considered to be effective 
in such tumours, and a considerable amount of work has 
therefore gone into the investigation of the therapeutic 
effectiveness of bleomycin in these tumours.
1.3.6 Bleomycin in the treatment of cerebral tumours
Being a water-soluble drug, bleomycin would not
normally be expected to cross the intact blood-brain
barrier, and this has been confirmed experimentally by 
161Hayakawa and others who were unable to detect any active 
bleomycin in normal brain following intravenous injection 
of the drug. They were, however, able to demonstrate 
selective uptake of bleomycin into chemically-induced 
tumours in mice, with two-thirds of the bleomycin remain­
ing in the active form two hours after injection. This 
has been confirmed by Hayakawa et al^^ who measured bleo­
mycin levels in tumour specimens removed from patients 
who had previously been given intravenous bleomycin two 
hours prior to surgery. Using a microbiological assay 
they were able to demonstrate detectable levels of bleo­
mycin in 4 9 out of 53 tumour specimens and 17 out of 18
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specimens of cyst fluid. Highest tissue levels of bleo­
mycin were found'in cases of glioblastomas, microglio­
matosis and, surprisingly, in metastatic tumours. The 
authors did not give the histological findings on these 
metastatic tumours which, unless they were derived from 
squamous cell primaries, might have been expected to con­
tain high levels of bleomycin hydrolase. There was also 
a tendency for the more malignant tumours to have higher 
levels of bleomycin.
The ratio between the tumour and plasma concentrations 
ranged from 0 to 2.63, although in the majority of cases 
it was less than 1. There was again evidence of a high 
statistical correlation between the ratio and the malig­
nancy of the tissue. In 14 cases small amounts of normal 
brain were unintentionally removed along with the tumour 
tissue, and in no case could bleomycin be detected in any 
of these samples. Similarly, in eight cases where CSF was 
collected during surgery, bleomycin could only be detected 
in one sample and then at a very low concentration. In 
three cases bleomycin was administered by the intraven- 
tricular route, and although high levels were recorded in 
the tumour specimens, plasma levels were low or undetect­
able. This might suggest that this route of administration 
would be clinically effective in certain types of brain 
tumour, but with a strong possibility of fewer systemic 
side effects.
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These results clearly illustrate that there is a 
partial breakdown of the blood-brain barrier due to the 
tumour, and this has been confirmed by others. The 
higher levels of bleomycin found in the more malignant 
tumours may be explained partly by the increased meta­
bolic and mitotic activity in these tumour cells and 
partly by the fact that the blood-brain barrier is more 
defective in the higher grades of tumour and less limiting
A /• C
to the entrance of drugs into the tumour tissue . These
5 7findings accord closely with those found using Co­
labelled bleomycin followed by isotope scanning, and do 
not appear to be due to increased vasculature in these 
tumours.
Takeuchi^'^ has carried out a clinical trial of 
bleomycin in 150 cases of brain tumour, including primary 
and metastatic tumours. Bleomycin chemotherapy was found 
to be markedly effective in seven out of 6 7 cases of 
verified gliomas, to have improved neurological findings 
in 32 cases, and to have been ineffective in a further 23 
cases. It thus appeared to be of some clinical value in 
58% of cases. In more than half of the effective cases 
studied, the patients received no other form of chemo­
therapy .
Despite previous findings that the highest bleomycin 
concentrations were found in the more highly malignant 
tumours, therapy was less effective in these high grade 
gliomas and in medulloblastomas. The results were most
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encouraging in patients with gliomas sited near the third 
ventricle, although treatment was much less effective in 
deeply situated supratentorial gliomas.
However, it is known that signs of initial clinical 
improvement do not necessarily correlate either with 
evidence of histological regression or with improved 
patient survival, hence Takeuchi analysed the results 
on 71 cases of histologically confirmed glioblastoma 
multiforme to determine the effect of bleomycin and other 
factors on survival. There appeared to be no significant 
increase in survival of patients receiving bleomycin 
during their first hospitalisation as compared with those 
receiving no chemotherapy. When results are similarly 
analysed for the whole course of hospitalisation there 
then appeared to be some increase in survival of patients 
receiving bleomycin chemotherapy, although this was not 
significant at below the 5% probability level. Six cases 
survived for more than five years after surgery and all 
had received some form of chemotherapy; two cases had 
received a post-operative course of bleomycin five years 
previously and had received no further treatment since 
then.
Histological changes have been reported in glioma 
tumours which have been attributed to the effects of bleo­
mycin administration. These changes include degenerative 
necrosis, proliferation and hypertrophy of vascular endo­
thelium and adventitial cells, necrosis and haemorrhagic 
foci.
Of 14 cases of metastatic tumours reported by 
Takeuchi, only three showed any clinical effect, and 
this was only very temporary. Even cases of squamous 
carcinoma gave poor results. Of 105 cases treated with 
bleomycin, 54 showed some side effects that could be 
attributed to bleomycin administration, with three deaths 
being observed that may have been attributable to bleo­
mycin toxicity. These included one case with pulmonary 
complications and two cases of haemorrhaging from the 
tumour. The major complications reported in this series 
was fever in 22% of cases and cutaneous complications in 
20% of cases. In view of the dose-limiting toxic side 
effects of systemic administration and since tumour infil 
tration may preceed the development of a 'leaky1 blood- 
brain barrier, alternative means of bleomycin adminis­
tration have been sought.
48Vats et al compared the therapeutic effectiveness 
of intracerebral compared with intravenous administration 
of bleomycin in the treatment of rats bearing experimen­
tally-induced gliosarcomas. In all cases therapy was 
initiated on day 7 and continued on a weekly basis there­
after. Rats received either doses of 0.1, 0.5, 1.5, 2.5 
or 3.0mg/kg body weight intracerebrally or 1.5 or 2.5mg/ 
kg body weight intravenously. Animals receiving intra­
venous bleomycin showed an improved initial survival, 
although the long-term survival rate was in fact-slightly 
worse than in a control group receiving no drug therapy.
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In the intracerebral group, animals receiving high doses 
of bleomycin had a significantly decreased initial survival 
which could be attributed to severe toxic side effects. 
Animals receiving 3.0mg/kg bleomycin had a death rate of 
41% and animals receiving 2.5mg/kg had a death rate of 25% 
on day 13 compared with the control group death rate of 
12%. Those receiving 0.5mg/kg, however, had a significantly 
lengthened survival rate (p<0.01), with an initial survival 
rate better than the control group. By day 35 all control 
animals had died although more than 25% of those receiving 
low dose intracerebral therapy were still alive. Some 
toxicity was noted in animals receiving 1,5mg/kg intra- 
cerebrally, as judged by initial survival rates, but by 
day 6 0 10% of these animals were still surviving, as com­
pared to 7% of those receiving 0.5mg/kg bleomycin.
The mechanism of action of bleomycin appears to be
very similar to that of radiation therapy and it might be
expected, therefore, that a combined modality therapy
involving intracerebral bleomycin therapy and radiation
treatment would be more effective than either given in
167isolation. However, Vats et al were unable to demon­
strate any synergistic effect in rats, although they did 
show that toxicity effects did not appear to be increased 
by combined therapy. It is conceivable therefore that by 
giving adjuvent bleomycin therapy the doses of potentially 
harmful radiation therapy could be reduced without com­
promising the therapeutic benefit.
The work of Vats et al gives encouragement to the 
belief that the intracerebral administration of the drug 
to human subjects may be therapeutically more beneficial 
to the patient than intravenous administration of the drug 
However, it is clear that in rats at least high-dose 
cerebral administration carries with it a high risk of 
toxicity-related morbidity and mortality, despite the 
apparently low levels of bleomycin in the systemic adminis­
tration, neveretheless it would appear from the work of 
161 164Hayakawa et al ' that relatively high levels of the 
drug need to be sustained in the tumour tissue in order 
to achieve a significant reduction of tumour growth.
If bleomycin could be entrapped within liposomes in 
such a way that free drug was subsequently only released 
slowly from the preparation, then it is conceivable that 
a very high total dose of the drug could be administered 
intracerebrally without the symptoms of toxicity develop­
ing. It might be anticipated, however, that by allowing 
the drug to be released slowly in the vicinity of the 
tumour tissue, the rate of drug uptake by the cells might 
be greater overall than if the cells were challenged 
with the same total dose of the drug over a much shorter 
period of time.
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1.4 AIMS OF THIS STUDY
The aim of the present work was to investigate the
following:
1. To study the factors affecting the incorporation into, 
and subsequent release of bleomycin from liposomes of 
defined composition, and to study the effects of 
these preparations on a glioma cell line.
2. To inject sterile liposome-entrapped bleomycin of 
defined composition intracerebrally into experimental 
animals and to study the histological and physio­
logical effects of these preparations, and the tissue 
uptake and subsequent urinary clearance of the drug, 
compared with the intracerebral injection of free 
drug into similar animals.
3. To prepare sterile bleomycin-containing liposomes for 
direct intracerebral injection into human subjects 
suffering from gliomas, and to study the appearance
of the drug in blood and urine as compared with intra­
cerebral injection of the same amount of free drug 
and with intravenous injection of the drug.
4. Clearly these initial studies can ethically only be 
carried out in patients who have already received 
surgery together with radiotherapy, and it is 
anticipated that by the time such preparations are 
administered it is unlikely that they will have any 
significant therapeutic effect. Clinical assessment
87
of these patients will largely be confined to a study 
of any adverse effects arising from the administration 
of liposome preparations. However, should the initial 
studies lend encouragement to further work, it is 
anticipated that a small-scale clinical trial will 
be undertaken to assess the therapeutic effects of 
these preparations given over a period of time to a 
group of suitably selected patients at an earlier 
stage in the course of their treatment.
CHAPTER 2
STUDIES ON THE FACTORS AFFECTING THE ENTRAPMENT 
OF BLEOMYCIN WITHIN LIPOSOMES AND OF THEIR 
SUBSEQUENT ACTION ON A HUMAN GLIOMA CELL LINE
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2.1 INTRODUCTION
Few detailed studies have been published on the 
factors that might affect the extent of entrapment of 
drugs and other substances within liposomes or their sub­
sequent rate of release. The reports that are available 
have demonstrated the effect of lipid charge and composition 
on the rate of entrapment and of liposome size on the sub­
sequent rate of uptake by various animal tissues. However, 
a number of other factors, particularly the ionic strength 
and pH of the aqueous buffers used, may have a significant 
effect on the rate of entrapment of water-soluble-com­
pounds within liposomes. It is also likely that a number 
of other factors such as the concentration of lipid and 
of the compound to be entrapped, and the volumes of 
organic and aqueous phases used, might also be of import­
ance .
For the purposes of this study it seemed desirable 
that the highest possible degree of entrapment should be 
attained, as long as the conditions used did not con­
tribute to any adverse toxic side effects associated with 
the in-vivo administration of the liposomes. Clearly 
it was of equal importance to study the effects that these 
factors might have on the subsequent rate of release of 
the drug in vivo, since it would seem desirable that this 
should occur over a relatively sustained period of time.
In order to carry out this study it is necessary to
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measure the level of bleomycin entrapped within liposomes 
as well as the level of non-entrapped bleomycin. Although 
this could be carried out by standard analytical tech­
niques such as radioimmunoassay (RIA) or high pressure 
liquid chromatography (HPLC), this approach would be im­
practical in view of the large number of assays that would 
need to be carried out as well as the need to have the 
results available within a relatively short period of time. 
The most suitable alternative approach is the use of a 
marker of bleomycin activity. Such a marker must behave 
in the system used in a manner which is as closely analo­
gous as possible to the cold unlabelled bleomycin present 
in the system. Possible markers that could be used are 
^^indium-labelled bleomycin, ^^ I - i o d i n a t e d  bleomycin, 
or tritium-labelled bleomycin.
111The entrapment of indium-labelled bleomycin has 
been studied in some detail, but there are several dis­
advantages to this approach. The indium is chelated 
rather than covalently bound to the bleomycin, it has a 
half-life of only 2.8 days, and there is evidence that 
the complex binds more strongly with the phosphatidic 
acid component of the liposome than does the cold un­
labelled bleomycin. The use of tritiated bleomycin would 
have one major advantage in that it would be expected to 
be the most faithful marker of cold bleomycin activity, 
since it is structurally the most similar. However, this 
material is not commercially available, and to have
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commissioned a custom synthesis of tritiated bleomycin 
would have been prohibitively expensive. Bleomycin can 
be readily iodinated, however, without the need for 
derivatisation using standard iodination techniques.
Once iodinated, the purified material could be used to 
monitor the liposome incorporation studies as well as 
being used in subsequent RIA techniques to monitor blood 
and urine levels of the drug following its in-vivo adminis­
tration .
There are a number of reports in the literature of 
the effects of serum and other body fluid constituents on 
the structure and stability of the liposome. Thus once 
a suitable liposome preparation had been produced it would 
be necessary to study its stability in vitro in the pre­
sence of serum and cerebrospinal fluid (CSF) prior to any 
in-vivo investigation.
In-vitro tissue culture studies would also need to 
be carried out in order to assess the effect of bleomycin 
entrapped within liposomes on the growth of a glioma cell 
line, and to compare this with the anti-tumour activity 
on the non-entrapped bleomycin. The nature of any inter­
action between the liposome and the cell will require 
investigation, since there are a number of possible 
mechanisms whereby the drug might be transferred from 
the liposome carrier to the tumour cell.
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2.2 RADIOIODINATION OF BLEOMYCIN
Radioiodination of bleomycin was carried out using 
the lactoperoxidase technique and the iodogen technique 
as described below.
(a) Lactoperoxidase technique
60ng bleomycin in 20|il 0.05M phosphate buffer, pH 7.4,
was added to 25|il 0.2M phosphate buffer, pH 7.4, followed
125by 25|il Bio-Rad ' Enzymobead1 reagent and 1 0jul (1mCi) I- 
sodium iodide. The reaction was initiated by the addition 
of 20^ ,1 of 20g/l 3-D glucose and was allowed to proceed 
for 25 min at room temperature.
(b) Iodogen technique
30|ig bleomycin in 10^1 0.2M phosphate buffer, pH 7.4,
was added to the bottom of a polypropylene vial which had
125previously been coated with 20p,g iodogen. 10|il (1mCi) I- 
sodium iodide was added and the reaction was allowed to 
proceed for 10 min at room temperature, following which 
0.2ml of the 0.2m phosphate buffer, pH 7.4, was added.
125In each case separation of free iodide from I- 
labelled bleomycin was achieved using a Bio-Rad 10cm x 
0.7cm internal diameter column containing Sephadex G-10 
in a 0.05M phosphate buffer (pH 7.4) containing 1g/l 
gelatin and 170mg/l thimerosal. 10-drop fractions were 
collected and 5n,l aliquots of each were subsequently counted 
for 10 s on a Wilj y-counter. Fractions containing sub­
stantial levels of activity were assessed for specific
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binding to bleomycin antisera by adding 200|il of an 
appropriate dilution of each to yield a total count of 
4 00 counts per second (cps) in phosphate buffer to excess 
bleomycin antisera (200^1 of a 1:100 dilution). The 
level of non-specific binding of label in each fraction 
was also assessed by carrying out the assay in the 
absence of antisera. Following an overnight incubation 
at room temperature, phase separation of bound from un­
bound label was achieved by the use of dextran-coated
1 25charcoal. Free (charcoal adsorbed) I-bleomycin activity 
in each tube was measured by counting for 30 s on the Wilj 
y-counter.
In each case a radioactive peak corresponding with 
the void volume was obtained followed by a second retained 
peak between fractions 30 and 40 (Figs.2.1 and 2.2). 
Following iodination using the lactoperoxidase technique 
neither peak could be demonstrated to have specific affinity 
for bleomycin antisera. However, the void volume peak 
obtained following iodination using the iodogen technique 
was shown to bind strongly to specific bleomycin antisera.
Further studies using a 15cmx 0.7cm column together 
with collection of 4-drop fractions following the iodin­
ation of 1 jig bleomycin demonstrated that this peak could 
be resolved into two separate peaks, the first of which 
exhibited the greatest degree of antibody binding and 
lowest non-specific binding activity (Fig.2.3). This
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fraction was used in all subsequent studies.
The stability of the iodinated bleomycin was assessed 
by measuring the maximal level of binding activity over 
a period of eight weeks, when it was demonstrated that 
binding activity was at least 85% of maximum throughout 
this period.
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2.3 PREPARATION OF LIPOSOMES USING THE AQUEOUS SWELLING 
TECHNIQUE
The following solutions were prepared in organic 
solvent and stored under nitrogen at -20°C until required.
DPPC 4mM/l in chloroform:methanol (1:1)
CHOL 4mM/l in chloroform
PTA 2mM/l in chloroform:methanol (1:1)
STEARYLAMINE 2mM/l in chloroform:methanol (1:1)
In separate preparations liposomes were prepared 
using the following combinations of lipid.
Ratio Liposome charge
7:2:1 Negative
1:1 Neutral
7:2:1 Positive
In all cases the total lipid per preparation was 20|imol.
Liposome preparations were carried out using the method 
of Gregoriadis as described below.
20jj.mol of each lipid preparation was evaporated to 
dryness in a 100ml flask on a rotary evaporator to leave 
a thin film of lipid coating the walls of the flask.
Once all traces of chloroform had been removed, several 
glass beads were added to the flask, followed by 1ml
0.05M phosphate buffer (pH 7.4) containing 3mg cold bleo-
125 - .mycin plus approximately 15,000 cps I-labelled bleomycin.
The air in the flask was displaced by nitrogen, the flask
Lipid composition 
DPPC : CHOL : PTA . 
DPPC : CHOL 
DPPC : CHOL : STEAR
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securely stoppered and shaken by hand for 2 min. Following 
a further 4 0 min shaking on a mechanical shaker, the pre­
paration was sonicated for 2.5 min at 4 5°C at an amplitude 
of 8(i on a Fisons Soniprep. The preparation was then 
stored overnight under nitrogen at 4°C in order to allow 
the lipids to coalesce. Liposomes were then separated 
from free bleomycin using a 10cmx1cm internal diameter 
column containing Sepharose 6B, using 0.05M phosphate 
buffer (pH 7.4) as eluting agent. 10-drop fractions were 
collected and counted for 30 s on a.Wilj y-counter. The 
results obtained are shown in Fig.2.4.
In each case two peaks were obtained, a small peak 
of radioactivity corresponding with the void volume followed 
by a retained peak containing non-entrapped label. The 
first peak of radioactivity clearly correlated with the 
liposome peak, as could be seen from visual inspection of 
opalescence in the tubes and by enzymatic estimation of 
total cholesterol, indicating that some labelled bleomycin 
had been entrapped within or associated with the liposomes. 
However, in each case the level of entrapment was un- 
acceptably low, as shown in Table 2.1.
The apparently low levels of entrapped bleomycin might 
have been due to release of labelled drug from the lipo­
somes during the period of overnight storage at 4°C. 
Therefore the experiment was repeated with the exception 
that the Sepharose 6B separation was carried out immediately
Fig.
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TABLE 2.1
Effect of lipid composition on the incorporation of 
labelled bleomycin into liposomes, prepared by the 
aqueous swelling technique
Lipid composition Liposome charge
Percentage
incorporation
DPPC : CHOL : PTA 
7 : 2 : 1
Negative 2.0
DPPC : CHOL 
1 : 1
Neutral 2.7
DPPC : CHOL : STEAR 
7 : 2 : 1
Positive 3.0
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following the sonication stage. No improvement in the 
degree of incorporation of labelled drug into the lipo­
somes could be observed.
2.3.1 Effect of incorporating human serum albumin into 
the liposome preparations
It is known the bleomycin binds to serum albumin, 
and therefore the degree of incorporation of the drug 
within liposomes might be increased by associating the 
bleomycin with human serum albumin prior to incorporation 
within the liposome. The subsequent rate of release of 
the small molecular weight drug from the liposome might 
also be decreased if the drug was bound to albumin within 
the liposome. Incorporation of labelled bleomycin into 
neutral and negatively-charged liposomes was therefore 
repeated as previously described with the addition of 
20mg pure human serum albumin to the buffer containing 
bleomycin prior to shaking with lipid. In neither case 
could any improvement in the degree of entrapment of 
labelled bleomycin into liposomes be demonstrated.
2.3.2 Effect of lipid concentration on incorporation of 
bleomycin into liposomes
Negatively-charged liposomes consisting of DPPC:CHOL: 
PTA (7:2:1) and neutral liposomes consisting of DPPC:CHOL 
(1:1) were prepared under the conditions previously des­
cribed, except that a total of 200|imol of lipid instead of 
20|imol was used in each preparation.
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Following preparation of the neutral liposomes an 
unstable preparation was produced which could not be 
separated on the Sepharose 6B column owing to apparent 
aggregation of the liposomes. A stable liposome prepar­
ation was obtained, however, using negatively-charged 
liposomes, and 13.7% of the labelled bleomycin obtained 
from the column appeared in the liposome fraction (Fig.2.5).
Since 75% of the labelled material added to the 
column was recovered in the eluate, this indicated that 
10.3% of the bleomycin in the original preparation was 
recovered entrapped within liposomes.
2.3.3 Rate of egression of labelled bleomycin from
negatively-charged liposomes at high lipid con­
centration
The liposome fraction obtained in the previous experi­
ment was pooled and placed into quarter inch diameter 
Visking tubing and dialysed against 28ml 0.05M phosphate 
buffer (pH 7.4) at room temperature. At various times 
over a period of four days 0.5ml aliquots of dialysis 
fluid were sampled in duplicate and counted on the Wilj 
y-counter for 1,000 s. After subtraction of background 
count levels and allowance for radioactive decay, the 
percentage retention of bleomycin within the liposomes 
was calculated. After seven days the dialysis bag and 
contents were removed and the total remaining activity 
was counted. The contents of the dialysis bag were then
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separated on a Sepharose 6B column as previously des­
cribed, in order to assess whether or not the remaining 
bleomycin activity was still associated with the liposome 
fraction.
The results obtained are shown in Fig.2.6. The rate 
of release of free drug from liposomes was very slow, 
with only 10% of the total radioactivity being recovered 
in the dialysate after four days. After seven days 80% 
of the total radioactivity was shown to be associated with 
the dialysis bag and contents, and this activity was almost 
entirely associated with the liposome fraction as demon­
strated by Sepharose 6B chromatography. Only minimal 
activity was bound to the dialysis bag itself.
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2.4 PREPARATION OF LIPOSOMES USING THE REVERSE PHASE
TECHNIQUE
In view of the low levels of entrapment of bleomycin 
achieved using the aqueous swelling method, the studies 
were repeated using the reverse phase technique described 
by Szoka and Papahadjopoulos . A total of 66|imol of 
lipid in organic solvent was evaporated to dryness and re­
dissolved in 10ml diethyl ether:chloroform (1:1). 2ml
0.05M phosphate buffer (pH 7.4) containing 3mg bleomycin 
125plus 6,000 cps I-labelled bleomycin was added and the 
mixture was sonicated on ice for 2 min at '1 Ojx • The 
resulting milky suspension was added to a 100ml long-necked 
evaporating flask and warmed to 45°C. The organic solvent 
was removed by careful evaporation under reduced pressure 
to leave a gel. After further evaporation the gel started 
to bubble and form a foam which eventually collapsed to 
form an opalescent aqueous phase. This aqueous phase was 
separated on Sepharose 6B as previously described. Wherever 
possible each stage in the procedure was carried out under 
nitrogen.
2.4.1 The effect of lipid composition on incorporation 
of bleomycin into liposomes and studies on the 
subsequent rate of release
Reverse phase liposomes were prepared as described 
above consisting of DPPC:CHOL:PTA (7:2:1), DPPC:CHOL:PTA 
(4:4:1) and pure DPPC. In each case a total of 66p.mol was 
used. Following separation on Sepharose 6B the liposome
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fraction was dialysed against 0.05M phosphate buffer 
(pH 7.4) and the rate of release of bleomycin assessed 
over a period of several days. The results obtained are 
shown in Table 2.2
The percentage incorporation of bleomycin into lipo­
somes prepared by the reverse phase technique was signifi­
cantly greater than that obtained with the aqueous swelling 
technique. Under the conditions of entrapment used, a 
slightly greater incorporation was achieved using DPPC:CHOL: 
PTA (7:2:1). The rate of release of encapsulated drug 
was relatively low and of a similar order of magnitude 
to that obtained using the aqueous swelling technique.
Loss of drug from liposomes prepared using DPPC as the 
sole lipid was minimal.
2.4.2 Reproducibility of incorporation technique
Experience with the reverse phase technique indicated 
that there was a batch-to-batch variation in the percentage 
incorporation of bleomycin achieved, and that the day-to- 
day variation was greater than the within-day variation. 
Investigations on the factors affecting the rate of in­
corporation of drug were therefore best carried out as a 
single sequential study over the shortest possible period 
of time.
The technique previously described was therefore 
carried out a total of five times and the percentage in-
TABLE 2.2
Effect of lipid composition on the incorporation 
of labelled bleomycin and its subsequent rate of 
release from reverse phase liposomes
Lipid composition
Percentage
incorporation
Percentage 
retention 
following 16h 
dialysis at 20°C
DPPC : CHOL : PTA 24.0 89
7 : 2 : 1
DPPC : CHOL : PTA 18.7 88
4 : 4 : 1
DPPC 21 . 0 98
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corporation of bleomycin in each liposome preparation was 
measured. The mean percentage incorporation of bleomycin 
was 24.9% with a standard deviation (SD) of 1.87% (CV = 
7.5%).
2.4.3 Effect of lipid concentration on the incorporation 
of bleomycin into liposomes
Liposomes were prepared using the conditions of en­
trapment previously described, except that the total con­
centration of lipid in each preparation varied from 16.5 
limol to 66|imol. The ratio of DPPC: CHOL: PTA was kept 
constant at 7:2:1, and the percentage incorporation was 
measured for each preparation.
The results obtained are shown in Fig.2.7. Over the 
range of lipid concentrations investigated there appeared 
to be a linear relationship between the total concentration 
of lipid and the percentage' ’incorporation of bleomycin 
achieved. Since it was desirable to achieve a relatively 
high degree of incorporation of drug within the liposome, 
a total lipid concentration of 66|imol per preparation was 
retained as being the most suitable.
2.4.4 Effect of temperature on the rate of release of 
bleomycin from liposomes
Liposomes were prepared as previously described. The 
fractions from the Sepharose 6B column containing the 
liposome-entrapped bleomycin were pooled and mixed, and
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0.5ml aliquots were placed into three separate quarter
inch diameter Visking dialysis bags. Each was dialysed
against 20ml 0.05M phosphate buffer (pH 7.4), but at
temperatures of 4°C, 19°C and 37°C. Controls consisting
of 0.5ml of buffer containing approximately the same
quantity of cold and radiolabelled free bleomycin in the
125absence of lipid were treated in a similar manner. I
levels in the dialysis buffer were measured at regular 
intervals over a period of three days.
The results are shown in Fig.2.8. The rate of release 
of bleomycin into the dialysis buffer was much slower when 
entrapped within liposomes, and this was slowest at 4°C. 
After three days 87% of the bleomycin remained entrapped 
within or associated with the liposomes at 4°C and 67% 
at 37 °C.
2.4.5 Effect of pH on the incorporation of bleomycin 
into liposomes
Liposomes were prepared as previously described but 
at phosphate buffer pH values ranging from 5.8 to 8.0; 
the ionic strength of buffer was kept constant at 0.05M 
in each case. The percentage incorporation of bleomycin 
into liposomes and its subsequent rate of release were 
then determined as previously described.
The results obtained are shown in Fig.2.9. The highest 
degree of entrapment was shown to occur at the lower pH
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values, although the subsequent rate of release of drug 
was slightly more rapid at pH 5.8.
2.4.6 Effect of ionic strength on the incorporation of 
bleomycin into liposomes
The effect of varying the ionic strength of the 
phosphate buffer at a pH of 5.8 on the entrapment of 
bleomycin and its subsequent release from liposomes was 
studied. The highest degree of entrapment occurred at 
the lower ionic strengths of buffer, the optimum ionic 
strength being in the region 0.01-0.02M (Fig.2.10). A 
0.02M buffer was chosen for all subsequent investigations 
since this gave the greater degree of buffering capacity.
Studies on the effect of pH on entrapment were re­
peated at this ionic strength and this again confirmed 
that the maximum incorporation of bleomycin into liposomes 
occured at pH 5.8.
2.4.7 Effect of aqueous and organic volumes on the in­
corporation of bleomycin into liposomes
The effects of varying the volumes of phosphate buffer 
and of organic solvent used in each preparation on the 
degree of entrapment of bleomycin were studied. The per­
centage incorporation of bleomycin varied considerably 
with the volume of aqueous phase used, ranging from 27% 
entrapment at an aqueous volume of 4ml to a maximum 54% 
incorporation where 1 ml of buffer was used (Fig.2.11).
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Thus a volume of 1ml of buffer was used in all subsequent 
preparations.
The volume of organic phase had only a minimal effect 
on the percentage incorporation of drug, although it was 
slightly greater when only 2ml chloroform : 2ml diethyl 
ether (1:1) was used (Fig.2.12). This was probably due 
to a somewhat greater efficiency of sonication under 
these conditions.
2.4.8 Effect of sonication time on the incorporation of 
bleomycin into liposomes
The effect of varying the period of sonication of each 
preparation was studied over sonication times ranging from 
30 s to 4 min. No variation in percentage incorporation 
of drug into liposomes could be demonstrated (Fig.2.13).
2.4.9 Effect of bleomycin concentration on percentage 
incorporation of the drug within liposomes
Using the previously established conditions for pro­
ducing the maximal incorporation of bleomycin within lipo­
somes, the effect of varying the initial concentration of 
drug used in the preparation over a range from 1 to 15mg 
was studied. The results obtained are given in Table 2.3. 
No significant difference in the percentage entrapment of 
the drug was observed over the range of bleomycin concen­
trations studied.
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TABLE 2.3
Effect of bleomycin concentration on 
incorporation of the drug into liposomes
Initial bleomycin 
concentration Percentage incorporation
1mg 54 .3
3mg 58.0
7 . 5mg 57.8
1 5mg 56.4
2.4.10 Effect of serum and CSF on the rate of release of 
bleomycin from liposomes
Bleomycin was iodinated at pH 5.8 by the iodogen tech­
nique and subsequently incorporated at a high count level 
into liposomes produced according to the previously des­
cribed conditions. The liposome fractions obtained were 
pooled and 0.2ml of the pool added separately to 1ml of 
pooled human CSF, pooled human serum or 0.05M phosphate 
buffer (pH 7.4). 1ml of each was then placed in a 
dialysis bag and dialysed against 20ml of CSF, serum or
buffer at 37°C. 0.1ml samples of the dialysate were counted
125for I activity at intervals, and the rate of release of
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the drug from liposomes subsequently calculated. Controls
1 25consisting of 0.2ml of similar amounts of cold and I- 
labelled bleomycin in the absence of liposomes were treated 
in a similar manner.
The results obtained are shown in Fig.2.14. Free 
drug was rapidly lost from the dialysis bag when not en­
trapped within liposomes (50% loss in 3h). Bleomycin was 
only slowly released from liposomes and the rate of release 
was similar whether in the presence of CSF, serum or buffer. 
Between 80.9% and 86.6% of the radioiodinated bleomycin 
activity remained associated with the liposomes at 49h 
compared with less than 15% in the case of the free drug 
control.
2.4.11 Use of radioimmunoassay technique for the measure­
ment of bleomycin incorporation within liposomes
125I-labelled bleomycin has been used as a marker of 
cold bleomycin in these studies. In order to ensure that 
radiolabelled bleomycin was behaving in a similar manner 
to cold bleomycin, 3mg of bleomycin was entrapped within 
liposomes using the previously optimised conditions, but 
in the absence of radiolabel. Following separation on 
Sepharose 6B, each fraction obtained was diluted 1:400 in 
ethanol to lyse the liposomes and each dilution was sub­
sequently assayed for bleomycin activity using the RIA 
technique to be described later.
The elution profile obtained from this study (Fig.2.15)
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was very similar to that obtained for the incorporation 
of radiolabelled bleomycin under optimised conditions 
(Fig.2.16). Furthermore, the percentage incorporation 
achieved in this study (61.4%) was of the same order of 
magnitude as that previously achieved with radiolabel. 
Subsequent studies using a direct RIA technique have also 
demonstrated that the rate of release of cold bleomycin 
from liposomes is similar to that of radiolabelled bleo­
mycin.
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2.5 CELL FUSION AND ENDOCYTOSIS STUDIES ON REVERSE PHASE
LIPOSOMES AND A HUMAN GLIOMA CELL LINE
(a) Liposomes were prepared by the reverse phase tech­
nique, incorporating the cell fusion marker PS-DPPE, 
suspended in tissue culture medium containing 10% foetal 
calf serum, and incubated with the glioma cell line 
U-251-MG. A Johnson Foundation compensated fluorimeter 
was used to measure the fluorescence of the cultures at 
415 and 550nm after excitation at 366nm.
(b) Liposomes containing carboxyfluorescein were suspended 
in tissue culture medium with 10% CSF and incubated with 
either human glioma cell line U-251-MG or a mouse macro­
phage cell line (J774-1) for three days, and separately 
for 4h using 100% tissue culture medium. In both series
of experiments control studies were performed using cyto- 
chalasin B (2|ig/ml in DMSO) to inhibit endocytosis.
Further controls included cells incubated with liposomes 
and DMSO alone and cells incubated with free carboxy- 
fluorescein. All cells were washed three times with 2ml 
phosphate-buffered saline followed by extraction of car­
boxyf luorescein by two washes of the cells with 0.75ml 
ethanol. Fluorescence in the extract was measured with 
a Perkins-Elmer Fluorimeter (excitation maximum 500nm, 
emission maximum 522nm, slit width 5nm).
No fusion could be demonstrated between liposomes 
and the cell line U-251-MG using the PS-DPPE fusion probe
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over 90 min incubation. However, it was demonstrated by 
use of fluorescent microscopy that a proportion of the 
liposomes had adsorbed onto the surface of the cells after 
gently washing with phosphate-buffered saline. No accumul­
ation of carboxyfluorescein could be demonstrated in 
U-251-MG cells following 4h and 3 days incubation with 
liposomes containing carboxyfluorescein. Accumulation 
of carboxyfluorescein was however demonstrated in the mouse 
macrophage control cell line.
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2.6 DOSE-RESPONSE STUDIES OF A HUMAN GLIOMA CELL LINE 
TO BLEOMYCIN
Liposomes were prepared incorporating cold bleomycin 
125and I-labelled bleomycin, and suitable dilutions were
prepared in tissue culture medium containing 10% CSF.
Free drug in the absence of liposomes was treated in a
similar manner. The human glioma cell line U-251-MG was
6plated onto 6cm petri dishes at a density of 0.25x 10 
cells per dish. After 24h incubation the medium was 
replaced with 2ml per dish of free or liposome-entrapped 
drug at varying dilutions. Following a further 24h in­
cubation the medium was removed and 1ml of tissue culture
14medium containing C-thymidine was added and incubated
for 1h. The dishes were then washed with phosphate-
buffered saline three times, and then 1ml ice-cold 5%
trichloroacetic acid (TCA) was added for 10 min. The
cells were removed from the plate, washed three times in
cold 5% TCA and the pellet dissolved in 1M sodium hydroxide.
An aliquot was neutralised with 1M hydrochloric acid and 
14C-thymidine activity was counted using an LKB Ultrabeta 
scintillation counter.
The results obtained are shown in Fig.2.17. The dose-
response curve demonstrated that there was a significant
anti-tumour effect of bleomycin on the human glioma cell
line U-251-MG. Furthermore, no significant difference in 
1 4C-thymidine uptake could be demonstrated whether in res­
ponse to free drug or drug entrapped within reverse phase 
liposomes.
Dose Response of U25I MG Cell Line to Bleomycin, Free 
and Entrapped Within Liposomes
•  Free Drug
LO_. = 6.6 x IO'6M 50
o Liposomes + Drug
L 0 „  =4.5 x I0‘5M 50
 I-------------- 1--------------1--
10-13 IQ” 9 I0”s
Bleomycin Concentration (M)
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2.7 DISCUSSION
125Bleomycin iodinated with I by the iodogen tech­
nique has been shown to retain its antigenic activity for 
a period of at least eight weeks. RIA of the free and 
liposome-entrapped fractions obtained following Sepharose 
chromatography, and of the rate of release of bleomycin 
from the liposomes with time have indicated that this label 
can be used as a faithful marker of cold bleomycin activity 
in these studies. Using the radiolabel it has been demon­
strated that the degree of entrapment of bleomycin within 
liposomes is greatly dependent upon the technique used 
for the production of the liposomes, the quantity of lipid, 
and the volume, pH and ionic strength of the aqueous buffer.
The level of entrapment achieved using the aqueous 
swelling technique was very low, as might be anticipated 
from the low internal aqueous space within liposomes 
produced by this technique (less than 0.5|il per umol lipid) . 
Although the percentage entrapment could be increased by 
increasing the amount of lipid used relative to the volume 
of aqueous phase, the amount of lipid required to be in­
jected in subsequent in-vivo studies would have been high 
relative to the dose of bleomycin administered. This 
approach would have been extremely uneconomical and would 
also have increased the risk of any potentially toxic re­
action to the lipid components administered.
In contrast, liposomes produced by the reverse phase
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technique had a high encapsulation efficiency, in keeping 
with their internal aqueous volume which has been estimated 
at greater than 10jul per umol lipid. Under the optimal 
conditions of entrapment described, a mean percentage in­
corporation of 58.2% was achieved with a batch-to-batch 
variation ±1 SD of 2.8% (CV 4.8%). The size of the uni­
lamellar liposomes produced by this technique was relat­
ively large, being in the range 0.7 to 3.6tm as demonstrated 
by electron microscopy (Figs.2.18 and 2.19), and this 
might be anticipated to affect their subsequent behaviour 
in in-vitro and in-vivo studies. Virtually all of the lipo­
somes were shown to be associated with the void volume peak 
following Sepharose 6B chromatography, and this was con­
firmed by estimation of the cholesterol content (BCL Kit 
No. 290319) of each fraction following separation (Fig.2.20).
However, although the efficiency of entrapment of 
water-soluble compounds is, to a considerable extent, 
determined by the internal aqueous volume of the liposome, 
the entrapment of charged molecules is also dependent upon 
the charge of the molecule and the surface charge of the 
lipid. Hence alteration in pH of the aqueous buffer has 
been shown to affect the efficiency of entrapment, and 
reduction of the ionic strength of the medium, by a lower­
ing of the charge-quenching of the drug and/or lipid, 
has resulted in an increased efficiency of incorporation 
of bleomycin into the liposome. Although it appeared from 
these studies that a greater degree of incorporation of
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Fig.2 .18
Electron microscopy of reverse phase liposome preparation 
(x 2800). Phosphotungstic acid staining.
i— sast---,
Fig.2.19
Electron microscopy of a single large unilamellar liposome 
produced by the reverse phase technique (x 60,000). Phos­
photungstic acid staining.
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bleomycin into liposomes might be obtained at a pH below 
5.8, it was considered that the increasingly unphysio- 
logical conditions, if used in brain tumour investigations, 
and the requirement for an alternative buffer precluded 
the use of these conditions.
The percentage entrapment of bleomycin within lipo­
somes increased in a linear manner with increases in the 
molar concentration of lipid used. This implies that vari­
ations in the amount of lipid used in the preparations 
resulted in a change in the total number of liposomes 
produced rather than any significant change in liposome 
size.
The subsequent rate of release of bleomycin from the 
liposomes has been shown to be dependent upon the pH and 
ionic strength of the aqueous compartment buffer and on 
temperature. In all cases the dialysis buffer used was 
a 0.05M, pH 7.4 phosphate buffer, hence it would appear 
from the results obtained that the greater the charge or 
osmotic gradient across the lipid membrane the greater 
the loss of the drug. Nevertheless, although the rate of 
loss of bleomycin was somewhat greater at pH 5.8, because 
the initial entrapment of the drug was that much greater 
the actual amount of drug remaining entrapped within the 
liposomes at the end of the study period (16h ) was still 
higher at pH 5.8 than at the other pH values studied.
These studies have demonstrated that bleomycin
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remains entrapped within the liposome for considerable 
periods of time in vitro. The dialysis technique used 
in these investigations is temperature-dependent as has 
been clearly demonstrated from the control studies, and 
this effect must be separated from the effect of tempera­
ture on the rate of loss of bleomycin across the lipid 
membrane. Nevertheless, from the results obtained it is 
apparent that the rate of egression of bleomycin from the 
liposome is temperature-dependent and is slowest at 4°C. 
Although a number of interactions between liposomes and
blood serum are known to occur in vivo, it has been
demonstrated that in vitro at least, the rate of release 
of the drug from the liposome is only marginally affected 
by the presence of human serum or CSF.
As a result of these investigations the conditions 
for entrapment of bleomycin have been standardised in 
order to yield the maximum degree of entrapment within 
the liposomes. These are summarised below.
Reverse phase technique for production of bleomycin- 
entrapped liposomes - final conditions
Lipids 66|imol DPPC : CHOL : PTA (7:2:1)
Organic phase 2ml diethyl ether:chloroform (1:1)
Aqueous phase 1ml 0.02M, pH 5.8 phosphate buffer
Sonication time 2 min at 10p- amplitude
In parallel with these studies similar investigations 
have been carried out using the drug vincristine, an
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anti-tumour agent obtained from the periwinkle plant
168Catharanthus roseus . The degree of entrapment of 
vincristine was similarly affected by variations in the 
conditions used. However, although the percentage in­
corporation of vincristine was less markedly affected by 
changes in pH and ionic strength of the aqueous buffer, 
these factors had a much greater effect on the subsequent 
rate of release of the drug, and it was this more than 
the degree of entrapment of drug which primarily determined 
the optimal conditions for use. The dose-response curve 
of vincristine against the glioma cell line U-251-MG was 
similar to that obtained with bleomycin, in as much that 
liposome-entrapped vincristine was very similar to free 
vincristine in its anti-tumour activity. However, in­
hibition of cell growth occurred at much lower molar con­
centrations of vincristine compared with bleomycin.
Considerable caution is required in extrapolating 
the results of in-vitro measurements of tumour cell sensi­
tivity to various chemotherapeutic agents to in-vivo studies. 
However, these results are sufficiently encouraging to 
suggest that drugs when entrapped within liposomes and 
administered locally as a single injection into a tumour 
bed should be as effective as the same amount of free drug 
given by repeated injections over a prolonged period of 
time intracerebrally.
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The studies suggest that liposomes prepared by the 
reverse phase technique did not fuse with and were not 
endocytosed by the tumour cell line but were, to a certain 
extent, adsorbed onto the surface of the cell. If these 
in-vitro results apply in vivo, then local injection of 
high concentrations of bleomycin within liposomes should 
act as a depot preparation of the drug, although the 
possibility remains of adsorption of the liposome to the 
tumour cell, reducing the diffusion distances involved.
CHAPTER 3
STUDIES ON THE INTRACEREBRAL INJECTION 
OF BLEOMYCIN, FREE AND ENTRAPPED WITHIN 
LIPOSOMES, IN THE RAT
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3.1 INTRODUCTION
In-vitro studies have demonstrated that liposomes can 
act as a depot preparation of bleomycin with sustained 
release of the drug occurring over a significant period 
of time. Before it is possible to entertain the use of 
these preparations in human patients, it is necessary to 
carry out animal studies in order to investigate the poten­
tial toxicity of these preparations and to determine the ■ 
rates of clearance of the drug from the brain, and to 
measure the degree of uptake of bleomycin by other tissues 
and organs.
Although radiolabelled bleomycin can be used as a
marker of liposome incorporation of drug in these studies,
it cannot be used directly in vivo to measure blood and
urinary clearances or tissue uptake since it cannot be
assumed that the radiolabelled drug has remained in an
intact non-metabolised form. The rate of clearance of
bleomycin from the brain would therefore be monitored by
use of a RIA technique for the measurement of blood, urine
125and tissue levels of bleomycin using a I bleomycin label 
and specific bleomycin antisera. RIA methods for the 
estimation of blood and urinary levels of bleomycin are 
fairly well established, but it is necessary to establish 
the validity of the method for the assay of tissue levels 
of the drug, and for the assay of bleomycin levels when 
entrapped within liposomes.
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3.2 DEVELOPMENT OF THE RADIOIMMUNOASSAY TECHNIQUE
The basic RIA was set up as follows:
20^1 or 50|il sample
200m,1 125j bleomycin (24 ,000 cpm)
200|il diluted bleomycin antisera.
After an overnight incubation at room temperature, 
the phase-separating agent was added followed by incub­
ation for an appropriate time at the appropriate tempera­
ture and counting of free or bound label on a Wilj y- 
counter.
The following factors likely to affect the efficiency 
of the assay were assessed.
(i) Choice of assay buffer
An antiserum dilution curve was carried out using 
either 0.05M barbitone buffer (pH 8.6) containing 1.0g/l 
bovine serum albumin or 0.05M phosphate buffer (pH 7.4) 
containing 1.0g/l gelatine and 0.17g/l thiomerosal. 
Following phase separation using dextran-coated charcoal 
the degree of antiserum binding to label was assessed.
(ii) Choice of phase-separating agent
The maximum binding by bleomycin antisera added in 
excess and the extent of non-specific binding of label was 
measured using either dextran-coated charcoal or donkey 
anti-sheep serum/polyethylene glycol (PEG; 30g/l final 
concentration) as phase-separating agents. The results
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indicated that the use of donkey anti-sheep serum/PEG 
as phase-separating agent was preferable, and all further 
investigations were carried out using this system.
(iii) Antiserum displacement curves
Bleomycin antiserum dilution curves were set up in 
the presence of buffer only, bleomycin-free serum, and 
serum containing 10ng/ml bleomycin. Following an over­
night incubation, phase separation was carried out using 
donkey anti-sheep serum/PEG, and the antibody-bound 
fraction was counted on a Wilj y-counter for 30s.
(iv) Optimisation of donkey anti-sheep serum titre
Following an overnight incubation of label with the
optimum titre of bleomycin antiserum, 200jil of varying 
dilutions of donkey anti-sheep serum was added in duplicate 
to the appropriate tube followed by 200|il of 120g/l PEG. 
After 3 0 min incubation at room temperature all tubes were 
centrifuged for 10 min at 2000g, and then antibody-bound 
fraction counted for 30s.
(v) Effect of time on donkey anti-sheep serum binding
Assay tubes were set up as previously described using
the optimum titres of bleomycin antisera and donkey anti­
sheep serum. Following the addition of the phase-separating 
agents the tubes were centrifuged after varying periods of 
incubation at room temperature ranging from 5-30 min, and 
the antibody-bound fraction then counted.
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(vi) Effect of polyethylene glycol concentration
The effect of adding various concentrations of PEG
to the assay under optimised conditions of bleomycin and 
donkey anti-sheep serum titres and phase separation time 
was studied using initial PEG concentrations ranging 
from 80 to 200g/l.
(vii) Effect of disequilibrium assay on method 
sensitivity
Bleomycin was added to bleomycin-free serum and sub­
sequently diluted to give a range of standards from 3.1ng/ml 
to 200ng/ml. A RIA standard curve was set up using the 
method described. In addition, 20p,l of each standard was 
diluted with 200(j.l bleomycin antiserum and mixed. Follow­
ing a 2h incubation 200p,l labelled bleomycin was added 
and the tubes incubated for a further 2h. Phase separation 
was then carried out as normal.
These studies demonstrated that a much higher maximum 
binding activity by antisera was achieved when the assay 
was carried out in the presence of the phosphate buffer 
(pH 7.4) rather than the barbitone buffer (pH 8.6), 
although little difference in the level of non-specific 
binding activity was demonstrated (Fig.3.1). Phosphate 
buffer (hereafter referred to as the assay buffer) was 
used in all subsequent studies.
Although the choice of phase-separating agent had 
little effect on the level of maximum binding activity,
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a much lower non-specific binding was observed with the 
use of donkey anti-sheep/PEG, and this was used in all 
subsequent assays.
The most suitable initial titre of bleomycin anti­
serum to give the maximal sensitivity of assay was shown 
to be 1 in 800 (Fig.3.2). This corresponds to a final 
antiserum titre of 1 in 6720, since antiserum was supplied 
at an initial dilution of 1:4. Lower levels of antibody 
binding at zero bleomycin concentration were observed in 
the absence of serum, indicating that there was a matrix 
effect which would need to be taken into account when 
subsequently assaying bleomycin in the presence of 
different types of media and body fluids.
The most suitable initial dilution of donkey anti­
sheep serum for use at the optimum anti-bleomycin titre 
was shown to be 1:40 (Table 3.1), with an optimum in­
cubation period of 30 min at room temperature (Table 3.3).
Within the range of PEG concentrations studied there 
appeared to be very little effect on either the percentage 
binding obtained or on the non-specific binding of the 
label, hence the 120g/l concentration of PEG was retained 
(Table 3.2).
No increase in sensitivity of the assay could be 
demonstrated, under the conditions used, for a two-stage 
disequilibrium assay as opposed to the normal equilibrium
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TABLE 3.1
Effect of donkey anti-sheep (DAS) serum 
titre on phase separation technique
Initial DAS titre
Percentage binding 
of label
1 in 10 59.0
1 in 20 57.5
1 in 30 54.2
1 in 40 53.0
1 in 50 51.2
1 in 60 46.7
TABLE 3.2
Effect of polyethylene glycol (PEG) 
concentration on phase separation technique
Initial Final
PEG PEG Percentage binding
cone. cone. of label
80g/l 19.5g/l 55.3
120g/l 29.3g/l 56.7
16 0g/l 39.0g/l 54.6
200g/l 48.8g/l 53.8
Effect 
on phase
TABLE 3.3
of incubation time 
separation technique
Incubation time Percentage binding
(minutes) of label
5 37 .0
10 44 .0
15 47.1
20 48.8
25 50 .4
30 50.9
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assay and the RIA was therefore carried out using the 
simpler one-stage assay.
As a result of these studies the final technique 
used was as follows:
20|il serum or standards in bleomycin-free serum 
200(il bleomycin (24 ,000 cpm)
200|il bleomycin antiserum diluted 1 :800 in assay buffer 
Incubate at room temperature for a minimum or 4h, or over­
night.
200|il donkey anti-sheep serum (1:40)
200jil PEG (120g/l)
Incubate at room temperature for 3 0 min.
Centrifuge at 2000g for 10 min.
125Aspirate and count bound I activity for 3 0s.
Where necessary to achieve maximal sensitivity, the 
volume of serum and of standard used could be increased to 
0.1ml without encountering any loss of specificity.
3.2.1 Effect of liposomes on the RIA of bleomycin
The effect of reverse phase liposomes, free and con­
taining entrapped bleomycin, on the RIA of bleomycin in 
serum was studied, directly and following treatment with 
methanol, chloroform, diethyl ether or tween 80. The 
direct effects of these potential liposome-disrupting 
agents on the assay were also assessed as follows.
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Liposomes, free and containing known amounts of en­
trapped bleomycin, were diluted in bleomycin-free human 
serum, a range of serial dilutions being made in each 
case. These were assayed against bleomycin standards in 
serum by the RIA technique previously described. In 
addition, all samples and standards were treated with an 
equal volume of chloroform or methanol, and following 
centrifugation the aqueous layer was assayed for bleomycin. 
Furthermore, separate assays were also carried out in the 
presence of buffer containing 0.5% Tween 80, since it has 
been reported that this will disrupt the liposomes and 
release the entrapped aqueous phase.
Liposomes prepared by the reverse phase technique 
had no observable effect on the level of antibody binding 
of labelled bleomycin or on assay sensitivity, except at 
liposome concentrations vastly in excess of any that would 
be encountered following their intravenous administration 
in either human or animal subjects (Tables 3.4 and 3.5).
When liposomally entrapped bleomycin preparations 
were assayed at various intervals of time following their 
preparation, the results obtained correlated well with 
the values obtained by previously described techniques 
for the level of non-entrapped bleomycin in the prepar­
ations . These results indicate that the direct RIA tech­
nique used was capable of detecting bleomycin when it was 
free in solution but not when entrapped within liposomes.
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TABLE 3.4
The effect of liposomes in serum on the 
binding of bleomycin antisera to label
Liposomal lipid 
concentration 
in serum 
(limol/1)
Percentage binding 
of label by 
bleomycin antisera 
(%)
0 45.9
0.63 43 .6
1.25 45.1
2.5 45.1
oLO 43 .9
10.0 46 .3
100.0 41.5
TABLE 3.5
The effect of high serum liposome concentration 
on the RIA of bleomycin in serum
Bleomycin 
concentration 
in serum
(M-g/1)
Percentage
Liposome-free
serum
binding of label
100|imol/l liposomal 
lipid in serum
0 45.9 41.5
31.3 26.1 23 .1
62.5 20.7 18.8
125 13.5 13.2
250 9.2 8.3
500 5.2 4.7
1000 2.8 3.0
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It was therefore necessary to use a releasing agent 
which would release the entrapped bleomycin leaving it 
in a form which could be fully measured by the RIA tech­
nique. Various detergents have been reported as being 
suitable for this purpose, and in addition certain organic 
solvents such as chloroform are known to disrupt the 
liposomal membrane, allowing free outflow of their con­
tents. Methanol and diethyl ether can also be shown to 
clarify aqueous suspensions of liposomes.
Tween 80 at a final concentration in buffer of 0.5% 
v/v was found to decrease the antibody binding levels to 
approximately 80% of that found in the absence of the 
detergent at any given bleomycin concentration. The 
results obtained for serum containing bleomycin entrapped 
within liposomes, however, were essentially identical to 
those obtained in the absence of detergent, indicating 
that the use of tween 80 was unsuitable for the release 
of entrapped bleomycin from liposomes.
The effects of methanol on the RIA were minimal, with 
only a small reduction of about 5% in the level of anti­
body binding at zero bleomycin concentration (when 40|il 
of the specimen was used), although there was some re­
duction in assay sensitivity (Table 3.6). However, the 
results obtained for the measurement of bleomycin in 
serum containing bleomycin entrapped within liposomes 
correlated well with the estimate of total bleomycin con­
tent estimated by more direct means.
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TABLE 3.6
Effect of methanol extraction on the 
radioimmunoassay of bleomycin in serum, 
free and entrapped within liposomes
Direct assay
Methanol
extraction
Specimen
o*6
binding
Blearycin
(ng/ml)
o.*o
binding
Bleomycin
(ng/ml)
BLEOMYCIN STANDARDS
In serum: Ong/ml 45.0 42.6
15.6ng/ml 35.4 34.7
31.3 " 30.2 28.4
62.5 " 20.7 20.1
125 " 15.3 13.9
250 " 9.0 9.1
500 " 5.1 5.8
LIPOSOME-ENTRAPPED BLEOMYCIN
Diluted in serum: 
1:1000 25.7 44.6 10.2 210
1:2000 32.3 23.3 14.9 110
1:4000 37.6 11.6 23.3 48
1:8000 41.0 5.8 28.4' 31
Mean liposomal bleomycin concentration by 
radioimmunoassay - 218|ig/ml
Mean liposomal bleomycin concentration by 
radioimmunoassay following initial lysis 
of liposome suspension in methanol and sub­
sequent dilution in assay buffer =
Liposomal bleomycin concentration estimated 
from Sepharose 6B column eluate
counts/s in 1ml eluatex initial bleomycin conc.(ng) 
counts/s of 1 2 5 added to reaction mixture 
110 x 3000
220|ig/ml
1274
|ig/ml 
= 259p-g/ml
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Chloroform reduced the antibody binding at zero 
bleomycin concentration by approximately 20% (Fig.3.3). 
However, following chloroform extraction of serum con­
taining liposomally entrapped bleomycin, the results 
obtained again correlated well with the results obtained 
following methanol extraction and with the values ob­
tained by other means for the estimation of total bleo­
mycin content.
Diethyl ether was unsuitable for use, the amount of 
organic solvent remaining in the aqueous phase following 
extraction being sufficient to cause a considerable re­
duction in assay precision, accuracy and sensitivity.
These results indicate that the direct RIA of serum 
containing bleomycin entrapped within liposomes gives a 
measure of the amount of free, non-entrapped bleomycin 
in the sample, whereas RIA following chloroform or methanol 
extraction measures the total bleomycin content of the 
specimen.
3.2.2 The effect of human and animal body fluids and 
tissue extracts on the RIA of bleomycin
Preliminary studies demonstrated that the RIA was 
susceptible to matrix effects in the presence of different 
body fluids and tissue extracts. This was investigated 
further by comparing standard curves of bleomycin diluted 
in human and rat serum and urine and by measuring the 
degree of antibody binding of label in the presence of
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Fig 3.3
EFFECT OF CHLOROFORM EXTRACTION ON THE SUBSEQUENT 
RADIOIMMUNOASSAY OF BLEOMYCIN IN SERUM.
• ----•  DIRECT ASSAY
O— O CHLOROFORM EXTRACTION
5 10 20 50 100 200
SERUM BLEOMYCIN C O N C E N T R A T IO N  (n g /m l )  -  (20pl  sample)
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human and rat brain extracts free of bleomycin, and of 
rat tissue extracts containing no bleomycin. The effects 
of methanol and chloroform extraction on the extent of 
binding were also investigated.
Bleomycin standard curves carried out in the presence 
of human and rat serum and urine are shown in Figs.3.4 and 
3.5. Standard curves carried out in the presence of human 
or rat urine showed a considerable reduction in antibody 
binding as compared with the respective serum. Urine 
diluted 1:100 in assay buffer showed higher levels of 
binding than undiluted urine and correlated closely with 
standard curves carried out in the presence of buffer 
alone. However, the percentage binding of antibody in 
the presence of bleomycin-free human serum or urine 
(diluted or 20|il of undiluted specimen) varied to only 
a small degree from one patient specimen to another. 
Similar observations were made for bleomycin-free serum 
and urine from different rats, indicating that bleomycin 
levels could be measured in any of these speciments 
provided that a standard curve was carried out in the 
presence of the appropriate fluid.
Bleomycin-free tissue extracts from both humans and 
rats were shown to influence the degree of antibody bind­
ing of label and this effect was dependent both on the 
concentration of the extracting buffer and on the type 
of tissue involved. Most extracts, when added to the RIA
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Fig 3.4
EFFECT OF HUMAN SERUM AND URINE ON THE RADIOIMMUNOASSAY 
OF BLEOMYCIN.
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Fig 3 .5
EFFECT OF RAT SERUM AND URINE ON THE RADIOIMMUNOASSAY 
OF BLEOMYCIN.
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system, resulted in a level of antibody binding similar 
to or slightly less than the degree of binding in the 
presence of the appropriate serum, and the binding re­
duced as the amount of extract added was increased. In 
the case of rat brain tissue this effect could be minimised 
by making up the standard solutions in an extract of normal 
rat brain. However, this clearly was impractical in the 
case of many other rat tissues studied or for human brain 
extracts. In these cases the errors caused by this 
variable matrix effect could best be minimised by carry­
ing out a chloroform or chloroform/methanol extraction 
of the extracts or standards in appropriate serum, 
followed by the addition of 20|il of normal serum to all 
immunoassay tubes in addition to the extract. , Results 
obtained using this technique were repeatable and showed 
parallelism with the standard curve within certain limits. 
However, in view of the many variables involved, the 
results, at least in the case of rat tissue extracts, 
should with the exception of brain tissue extracts be 
regarded only as semi-quantitative using this technique.
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3.3 CEREBRAL TOXICITY STUDIES IN THE RAT
Liposomes prepared by the reverse phase technique
were prepared containing 66|imol of lipid incorporating
either 0.02M (pH 5.8) sodium phosphate buffer or 7.5mg
1 25bleomycin together with I bleomycin marker in the 
same buffer. Suitable dilutions were made and 5|il ali­
quots were injected intracerebrally in each investigation.
Male Wistar rats weighing approximately 250g were 
anaesthetised using an air/nitrous oxide/halothane 
mixture. A 1mm hole was drilled through the skull 2.7mm 
anterior to the bregma point and 1.5mm laterally over the 
left hemisphere using a stereotactic manipulator. Suit­
able dilutions in a total buffer volume of 5p-l of free 
liposome, free bleomycin or liposome-entrapped bleomycin 
were injected to a depth of 2mm into the cerebral hemi­
sphere cortex using a Hamilton syringe and stereotactic 
manipulator.
Two animals were studied at each concentration of 
lipid and of bleomycin free or entrapped within liposomes 
together with two buffer only controls. The rats were 
allowed to recover in metabolic cages where food con­
sumption, urine and faeces production and general be­
haviour were observed for seven days. The animals were 
then sacrificed and the brain removed after it had been 
perfused with heparinised saline followed by buffered 
formol saline. The brains were stored in buffered formol
158
saline at 4°C until processed for histology. Serial 
sections were cut and stained with haematoxylin and 
eosin. The serial sections were coded and the degree 
of cerebral damage was assessed by two observers (GBF 
and ROM) with light microscopy. The observers had no 
knowledge of the code. The degree of histological damage 
was graded on a three-point scale.
No alteration in behaviour, food consumption, urine 
or faeces production was detected in any of the animals 
after intracerebral injection of reverse phase liposomes 
containing either buffer or bleomycin over a period of 
seven days1 observation, except in the case of one animal 
which was subsequently shown to have developed a cerebral 
abscess.
The cerebral histological changes observed after 
intracerebral injection of free bleomycin or reverse phase 
liposomes containing either buffer or bleomycin are shown 
in Table 3.7. No histological change was observed in the 
cerebral hemispheres after injection of different amounts 
of free bleomycin or reverse phase liposomes containing 
buffer. A mild local inflammatory response was recorded 
when bleomycin was entrapped within liposomes, tending to 
be more marked at the higher concentrations.
159
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3.4 PRELIMINARY OBSERVATIONS ON THE CLEARANCE OF BLEO­
MYCIN FOLLOWING HIGH-DOSE INTRACEREBRAL INJECTION
OF FREE BLEOMYCIN IN THE RAT
A 250g male Wistar rat was anaesthetised as previously 
described. 750|ig bleomycin in 5|il 0.02M (pH 5.8) sodium 
phosphate buffer was then injected into the front left 
forebrain using a stereotactic manipulator. Blood and 
urine samples were collected via catheters at regular 
intervals for 60 min. At 6 0 min the animal was sacri­
ficed and lung, spleen, muscle, kidney, liver, small 
intestine and brain were removed. The brain was sectioned 
into left and right rear, mid and front brain and all 
specimens were homogenised in 0.1M (pH 6.8) phosphate 
buffer using a M.S.E. homogeniser. All extracts were 
then centrifuged at 2000g for 3 0 min at 4°C. Blood and 
urine samples were centrifuged at 2000g for 10 min.
Tissue extracts and sera were assayed directly against 
bleomycin standards in normal rat serum using the pre­
viously described RIA technique. Brain extracts were 
also assayed at dilutions of 1:10 and 1:100 in assay 
buffer. In addition, serum samples were diluted.1:11 
and urine samples diluted 1:21 and 1:101 in assay buffer 
and measured against bleomycin standards in assay buffer. 
The results obtained are shown in Fig.3.6 and Table 3.8.
The results from this initial study led to some of 
the preliminary observations being made regarding matrix 
effects on the binding of label by antisera in the RIA.
1 6 1
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TABLE 3.8
Tissue bleomycin levels in a rat 1 hour after 
intracerebral injection of 750|ig free bleomycin
Bleomycin concentration
Weight of l-ig'/g
tissue Total wet weight
Organ (g) (jug) tissue
Brain
- Right rear 0.25 0.447 1 .78
- Left rear 0.23 0.265 1.15
- Right midbrain 0.35 2 .564 7.37
- Left midbrain 0.37 3.548 9.69
- Right front 0.33 6.62 20.35
- Left front 0.36 283.00 795.80
Lung 1 .71 1 .40 0.82
Spleen 1 .53 1 .85 1 .21
Muscle 1 .32 <0.20 <0.12
Kidneys 2.33 3.37 1.44
Liver 14.31 8 .30 0.58
Small intestine 7.55 5.40 0.72
Urine (1 hour - 48.00 —
collection)
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However, because of the relatively massive dose of 
drug given in this first trial, the extent of antibody 
displacement by the bleomycin in the tissue extracts 
was in most cases considerably greater than any differ­
ences due to matrix effects alone. Hence, although there 
may be some degree of inaccuracy in the actual values 
obtained, the overall conclusions remain valid. The 
results obtained from serum, urine and brain extracts 
at the different dilutions used all showed good agree­
ment.
Following the intracerebral administration of free 
bleomycin, considerable levels of antigenically intact 
drug could be detected in blood and in urine within 
6 min of injection. Peak concentrations of drug occurred 
in the blood at approximately 12 min following injection 
followed by a relatively fast clearance with an initial 
half-life of about 24 min, over the limited period of 
time studied. Peak excretion in the urine occurred at 
approximately 30 min with about 65% of the administered 
dose being excreted in the first hour.
After 1h 40% of the injected dose could be detected 
as antigenically active bleomycin in the brain, with 85% 
of this residual drug remaining localised to the frontal 
lobe of the injected hemisphere. Concentrations of 
bleomycin in the tissues examined were generally of the 
same order of magnitude as the levels in the blood,
164
although slightly higher levels were found in the kidney 
and spleen, and much lower levels in muscle tissue.
3.4.1 Studies on the clearance of bleomycin after intra­
cerebral injection free and entrapped within lipo­
somes
Male Wistar rats, anaesthetised with pentobarbitone, 
were injected intracerebrally with either free or lipo­
some-entrapped bleomycin using the technique described 
above. Repeated blood and urine samples were obtained 
over a period of 4h and assayed for bleomycin. The 
animals were sacrificed at 4h and tissue samples were 
taken and stored at -20°C until assayed for bleomycin.
In addition, similar long-term experiments were also 
performed following the intracerebral injection of bleo­
mycin free and entrapped within liposomes in rats anaes­
thetised with an air/nitrous oxide/halothane mixture. 
These animals were sacrificed at 24h and 72h and seven 
days, with blood, urine and tissue samples obtained at 
those times.
All studies were carried out in duplicate or tripli­
cate at each concentration of drug, free or entrapped, 
that was used. In all cases the concentration of the 
drug injected was confirmed by carrying out a RIA on 
suitable dilutions of an aliquot of the sample at the 
same time as assaying the blood and urine samples.
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Blood and urine levels of bleomycin in the short 
and longer term experiments obtained after intracerebral 
injection of free or liposome-entrapped bleomycin are 
shown in Tables 3.9 and 3.10 and Figs.3.7 and 3.8. 
Following the intracerebral injection of free drug, 
antigenically active bleomycin appeared in the blood and 
urine within 5 min, with peak levels occurring at 
10 min in the blood. Between 44% and 68% of the total 
dose of drug injected was excreted in the urine within 
4h. Following the intracerebral injection of a similar 
amount of bleomycin entrapped within liposomes, however, 
the blood levels of the drug remained near or below the 
detection limit of the RIA method used, with the urinary 
excretion reduced to well below 10% of the injected dose 
in 4h.
Measurement of the amount of bleomycin in the brain 
demonstrated that most of the drug remained localised 
to the injected hemisphere at 4h, after both free and 
liposome-entrapped bleomycin had been injected, and 
also at one, three and seven days in those experiments 
where sufficient drug remained to be estimated. 4h after 
injection approximately two to three times the amount of 
bleomycin could be detected in the brain of rats given 
bleomycin entrapped within liposomes compared with those 
given the same amount of free drug. At one, three and 
seven days, 12%, 2.5% and 0.25% of the total dose of 
bleomycin given entrapped within liposomes remained
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Urinary Clearance of Bleomycin Following 
Intracerebral Injection of Free Bleomycin and 
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within the brain whereas minimal levels could be detected 
in animals given free drug.
Under the conditions of the experiment, bleomycin 
could not be detected in extracts of any of the tissues 
studied (lung, spleen, liver, kidney, small intestine, 
bladder and muscle) after 4h, one, three or seven days 
following intracerebral injection of free or liposome- 
entrapped bleomycin.
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3.5 DISCUSSION
In view of the wide range of specimens being 
measured for bleomycin levels using the RIA, the assay 
has been specifically designed to measure levels over 
as wide a range as possible. Under these conditions 
the assay has been shown to have an interassay coefficient 
of variation of 3.5%, and an intra-assay coefficient of 
variation of 7.5% at a level of 50ng/ml and a detection . 
limit of 40pg per tube. The technique, like many RIAs, 
is susceptible to matrix effect, but this can be overcome 
in the case of blood or urine samples by the incorporation 
of bleomycin-free serum or urine into the standard curve.
It is more difficult to eliminate completely matrix 
effects when assaying tissue extracts; however, these 
effects can be minimised by extraction of the specimen 
with chloroform and/or methanol. This also has the effect 
of disrupting any liposomes in the specimen, so releasing 
the entrapped bleomycin in a form in which it can be 
measured. Although chloroform was used for the extraction 
of tissue extracts and for the extraction of serum follow­
ing liposome administration in these animal studies, it 
was subsequently shown that the precision of the assay 
was improved by the use of methanol rather than chloroform. 
This improvement in precision was in part due to the 
relatively minor effect of methanol on the percentage 
binding of label, but it was also due to the difficulties 
encountered in the accurate pipetting of chloroform-
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extracted samples using air displacement pipettes. Meth­
anol extraction was therefore used in all subsequent in­
vestigations.
These studies have demonstrated that the single-dose 
intracerebral injection of large unilamellar liposomes of 
defined composition (DPPC:CHOL:PTA) produces no demon­
strable side effects in the rat. When injected intra- 
cerebrally either as the free drug or entrapped within 
liposomes, bleomycin is of low toxicity to normal rat 
cerebral cortex even at relatively high concentrations.
It is of interest to contrast these findings with parallel 
studies carried out using the drug vincristine. When 
injected intracerebrally at doses as low as 1 . 25p,g, vin­
cristine was shown to result in a marked local inflam­
mation and necrosis at the injection site, and this re­
action was even more marked when a similar dose of drug
168was injected entrapped within liposomes . Remarkably, 
however, minimal behavioural changes were observed even 
at considerably higher doses. These results do not 
necessarily preclude the clinical use of vincristine 
entrapped within liposomes since in-vitro dose-response 
studies against cultured glioma cell lines have shown that 
vincristine is active at much lower molar concentrations 
than bleomycin, although of course considerable caution 
is necessary in extrapolating such in-vitro results to the 
in-vivo situation.
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Following the intracerebral injection of free 
bleomycin, the drug is quickly cleared from the injection 
site with rapid appearance in the blood and urine. When 
injected within liposomes, however, blood levels remain 
below the limit of detection of the method on most 
occasions (2ng/ml), with markedly lower levels of ex­
cretion in the urine. 4h after injection the levels in 
the brain remain at a level two to three times that found 
following injection of the free drug. It is highly un­
likely that the drug has passed into the bloodstream still 
entrapped within liposomes and thus escaped detection by 
direct RIA. However, to rule out this possibility, assays 
were repeated following chloroform extraction, when 
identical results were obtained. Any liposomes passing 
into the bloodstream would undergo the complex series of 
interactions with serum that have already been described, 
and it is therefore conceivable that in this altered 
form they may be less susceptible to the disrupting effect 
of chloroform than liposomes added to serum in vitro.
It is also possible that the large unilamellar liposomes 
would be rapidly taken up by the cells of the reticulo­
endothelial system, thus escaping detection in the blood. 
Neither of these possibilities has been completely ruled 
out by the studies described here. Nevertheless such a 
sequence of effects remains rather unlikely.
With the exception of the very high dose preliminary 
investigation, bleomycin could not be detected in any
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tissues following intracerebral injection either free or 
entrapped within liposomes. This differs from previous 
studies in which tritium-labelled bleomycin has been 
given systemically and tissue levels of radioactivity 
measured. This difference may be due partly to matrix 
effects masking low levels of bleomycin in the extract 
but may also be due to the presence of a tissue hydrolase 
that is present in all tissues other than those that are 
ectodermally-derived. Thus when tritiated bleomycin is 
administered, both the free drug and its metabolites will 
be measured whereas with RIA only antigenically intact 
bleomycin will be measured.
These studies have demonstrated that bleomycin, when 
entrapped within liposomes and injected intracerebrally 
in the rat, is cleared from the injection site more slowly 
than when administered as free drug, with much lower levels 
appearing in the systemic circulation. If these observ­
ations hold true in human subjects suffering from cerebral 
gliomas, the likelihood remains that bleomycin when adminis­
tered intracerebrally entrapped within liposomes may be 
more therapeutically effective than present chemotherapeutic 
regimens, with the possible added advantage that systemic 
toxicity may be less likely to arise as a result of 
administering the drug in this form.
I!
CHAPTER 4
STUDIES ON THE CLEARANCE OF BLEOMYCIN FOLLOWING 
ADMINISTRATION OF THE DRUG, FREE OR ENTRAPPED WITHIN 
LIPOSOMES, -IN HUMAN SUBJECTS WITH GRADE IV GLIOMAS
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4.1 INTRODUCTION
Bleomycin, when administered systemically in normal
animals, is only poorly adsorbed across the intact blood-
brain barrier. Following subcutaneous injection of tri-
tiated bleomycin in normal mice, only 0.1% of the total \
dose could be detected in the brain one hour after ad- 
160ministration . The growth of a malignant glioma,
• however, results in some local variable breakdown in the 
integrity of the blood-brain barrier and it has been de­
monstrated that in mice bearing experimentally-induced
14malignant gliomas there is some preferential uptake of C-
t
bleomycin into the tumour within two hours of administration 
161of the drug . Levels of drug were three times higher in 
the glioma than in the surrounding normal brain tissue, 
and furthermore much of this drug appeared to be present 
in a biologically active form in the glioma, as measured 
by a bioassay technique, although no biologically active
J
bleomycin could be detected in the normal brain tissue.
This high ratio of bioactivity to total activity in the
f
tumour appears to be due to the low levels of bleomycin 
hydrolase in this and in other ectodermally-derived 
tissues, and is said to be indicative of a likely response 
to bleomycin therapy.
Studies of brain bleomycin levels in human subjects 
receiving the drug have been variable, with many earlier 
studies being unable to detect bleomycin activity in brain 
tumour tissue following intravenous administration of the
176
drug. A more recent study has demonstrated some drug
uptake by most glioma tumours studied, with the most
malignant tumours having the greatest concentrations of 
164bleomycin . These conflicting results might be attrib­
utable to a number of factors, although it is probable 
that they are most likely to be due to differences in dose 
and route of administration and in the assay techniques 
used.
i
I
The main conclusion to be drawn from these studies 
is that the amount of drug taken up by the tumour is 
highly variable, ranging from negligible amounts to £t 
best levels of up to three times the concentration of bleo­
mycin .in the blood. The major factors contributing to this 
variability appear to be the metabolic and mitotic activity 
of the tumour tissue, the extent of damage to the blood- 
brain barrier, and possibly the degree of vascularity of 
the tumour bed. Unfortunately all these factors work to­
gether in such a way that those tumours likely to be the 
most amenable to chemotherapy may exhibit' a much smaller 
degree of bleomycin uptake than the more highly malignant 
tumours that are less likely to show a favourable response 
to chemotherapy.
. The amount of bleomycin reaching the tumour bed can 
be more closely controlled by direct intracerebral in­
jection of the free drug. However, the animal studies 
reported here and elsewhere have demonstrated that the
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drug is rapidly cleared from the injection site with more 
than 50% of the injected dose appearing in the systemic 
circulation and in urine within four hours. The results 
obtained in this study, following the direct intracerebral 
injection of bleomycin entrapped within liposomes in the 
rat, have suggested that these preparations have a potential 
as depot preparations of the drug, and have been sufficiently 
encouraging to justify a limited initial study of the applic­
ation of this technique in patients suffering from grade IV 
gliomas.
4.2 STUDIES ON THE UPTAKE OF BLEOMYCIN BY HUMAN CEREBRAL
GLIOMAS
Bleomycin (10mg) was administered by intravenous in­
jection to eight patients (seven with grade IV astrocytomas 
and one with a cerebral secondary) during the course of 
craniotomy operations for the surgical excision of the 
tumours. Blood samples and tumour tissue samples taken 
at different depths of the tumour were obtained 15 and 30 
minutes following bleomycin administrations. Blood samples 
were assayed for bleomycin as previously described. The 
tumour tissue samples were stored at -20°C until assayed. 
Specimens were homogenised in ice-cold 0.05M (pH 7.4) 
phosphate buffer using a glass hand-held homogeniser, 
shaken with an equal volume of chloroform and then centri­
fuged at 2000 g-for 30 minutes at 4°C. The clear aqueous 
supernatant was then assayed for bleomycin activity and
• . - I  I
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. • ■
the concentration calculated in terms of weight of bleo- : 
mycin per mg of wet tumour tissue. In three patients^the 
amount of tissue specimen obtained was inadequate to allow
. v  *  •  ■
for accurate estimation of bleomycin content.
In the remaining five patients the concentration of 
bleomycin at different depths in the tumour after intra­
venous injection of 1Omg bleomycin 15 and 30 minutes before 
sampling are shown in Table, 4.1. The lowest levels of 
bleomycin were found in the patient with a cerebral secoild-
I . '
ary (patient A). In four cases there was no great differ­
ence in the amount of bleomycin, which had1 penetrated the
f
tumour tissue at 30, minutes as compared with 15 minutes.
* ’
However, in the three patiehts where adequate specimens 
were obtained, higher concentrations of the drug were 
.found in the tumour mantle as compared with the periphery 
and centre of the tumour.
4.3 STUDIES ON THE ADMINISTRATION OF BLEOMYCIN, FREE AND 
ENTRAPPED WITHIN LIPOSOMES, IN PATIENTS WITH CEREBRAL 
GLIOMAS
All the patients studied were suffering from grade IV 
malignant cerebral gliomas, and at the time of the initial 
investigation were being treated as inpatients at the 
Atkinson Morley's Hospital, Wimbledon. Ethical approval 
for these studies had been granted by the St. George's 
Hospital District Ethical Committee. A total of four 
patients were studied during the initial investigations.
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4.3.1 Studies following intravenous administration of 
bleomycin
Fr§e bleomycin (5, 10 and 15mg) was administered in-
fr
travenously to patient 1, and blood levels and urinary 
clearance were monitored over a period of four hours. In 
patient 2, 2mg of free bleomycin was administered intra-
i
venously., In addition, 2mg of bleomycin entrapped within 
liposomes was prepared using the optimised technique as 
previously described, and administered intravenbusly on a 
separate occasion. Standard sterile techniques were adopted 
throughout the procedure. Radioiodinated bleomycin, used' 
to monitor percentage incorporation of the drug, was pre­
pared using the iodogen technique, bijit elution of5 the radio- 
labelled' drug was achieved using a 0.05M (pH 5.8) phosphate 
buffer containing 30mg/litre unlabelled bleomycin. This 
prevented the non-specific binding of radiolabelled bleo­
mycin which would otherwise have occurred since gelatin 
could not be incorporated into the buffer for subsequent 
human use'. The preparation was sterilised by filtration 
prior to incorporation into liposomes. *
Samples from each liposome preparation were sent for 
microbiological examination and cultured for 48 hours prior 
to human administration, during which time the liposomes 
were stored at 4°C to reduce the rate of release of free 
drug. At the time of administration the amount of free 
drug in the preparation was assessed by separation of an 
aliquot on Sepharose 6B. Following administration, blood
181
specimens were collected over a period of six hours, and 
urine specimens for up to 24 hours. Serum samples were 
assayed for bleomycin by direct RIA and following methanol 
extraction in order to release any bleomycin remaining 
entrapped within liposomes.
The blood and urine concentrations of bleomycin 
achieved following intravenous administration of 5, 10 
and 15mg bleomycin are shown in Figure 4.1 and Tables'4.2 
and 4.3. Clearance of drug from the blood was biphasic; 
with initial phase half-life ranging from 11 to 19 minutes 
and terminal phase half-life from 110 to 116 minutes. No 
significant difference in the rate of clearance of the drug 
could be demonstrated at the different doses of drug ad­
ministered. In each case at least 60% of the administered 
dose was excreted in the urine within four hours. No 
changes in serum levels of y-glutamyl transpeptidase, 
alkaline phosphatase, aspartate aminotransferase or urea 
could be detected at any time following administration of 
the drug.
Following intravenous administration of bleomycin en­
trapped within liposomes, the blood concentrations of the 
drug were considerably lower than when a similar dose of 
free drug was given (Fig.4.2), and the urinary clearance 
was less than half that obtained with free drug (40% com­
pared with 90% at 24 hours) (Table 4.3). Following meth­
anol extraction of serum there was a 25% increase in the
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Fig. 4-1
Bleomycin clearance from  blood following intra-venous
adm inistration in a human subject.2000 - i
1000 -
500 -
200 -
100 -
15 mg 
10 mg
50 -
*  5 mg20 -
2 3 4 5 6
Time (hours)
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TABLE 4.2-
• Peak serum bleomycin levels achieved following 
injection of bleomycin, free and entrapped 
within liposomes
\
Dose of 
bleomycin 
injected 
(nig) •
Serum bleomycin (ng/ml)
Intravenous* Intracerebral
Free Entrapped Free Entrapped
0.1 2 .63 <1 .O1
r ■
0.45 4 .63 1.13
2.0 1082
‘ 41 .53 
2 2  . 5 1*
3.63/4.0* 
0 .8 V/ 4 . 0 *
3.3
/
61 72
5.0 5001
6.0
66.03 
40.5** 9 .4 ^
10.0 1 2001
f
15.0 2 0 3 41
1 = Patient 1
2 = Patient 2
3 = Patient 3 
* = Patient 4
*Levels achieved 5 min after intravenous injection
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TABLE 4.3
4-hour urinary excretion of bleomycin following 
intravenous injection, free and entrapped 
within liposomes
Dose of bleomycin 
injected 
(mg)
4-hour urinary bleomycin 
excretion (% of total)
Free Entrapped
2.0 - 25.52 
(39.5% at 24hr)
3.3 682
(91% at 24hr)
5.0 611 -
10.0 691
15.0 641
1 = Patient 1
2 = Patient 2
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Serum Bleomycin levels following intra-venous injection of
Bleomycin, free  and entrapped w ithin Liposomes.
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value obtained by direct assay at five minutes and an 11% 
increase at 10 minutes following administration of bleo­
mycin entrapped within liposomes. All other results ob­
tained by direct assay following administration of free
\
and entrapped bleomycin were unaltered by methanol extraction. 
No change in serum levels of liver enzymes, urea or creatin­
ine were observed during the period of study. No adverse 
clinical reaction to the drug entrapped within liposomes 
was observed in the patient. \
4.3.2 Studies following intracerebral administration of 
bleomycin
Ommaya reservoirs were inserted into three patients ' 
at craniotomy for the removal of grade IV gliomas. In- 
formed consent was obtained from.each patient prior to the 
study. Patient 1 was injected with a sterile preparation 
of 0.1mg bleomycin entrapped within liposomes in 1ml 
phosphate buffer directly into the tumour bed via the 
Ommaya reservoir. 2ml of normal saline was then injected
f
in order to ensure that all of the entrapped drug was 
flushed from the reservoir. Blood and urine samples were 
collected over a. period of 10 hours for estimation of 
bleomycin concentrations, and the patient was very care­
fully monitored clinically immediately after the injection 
and for a period of four weeks in order to assess any 
adverse fesponse to either the intracerebral injection 
of drug or liposomes.
I187
No adverse clinical response was observed in the 
patient during the period of observation which could be 
ajttjibuted to the effect of injecting negatively-charged 
liposomes into the tumour bed, Consequently two further 
patients (patients 3 and 4) were studied at higher doses 
of bleomycin ranging from 0.4 5 to 6mg, both free and en­
trapped within liposomes. Following each injection, 2ml 
of.sterile normal saline was injected through the reser-
i
voir tcj ensure that virtually all of the liposome prepar­
ation was flushed into the residual tumour bed. Blood 
and urine samples were collected over a period of up to 
48 hours and the patients' clinical condition monitored 
following each injection and for at least four weeks after 
the last administration of drug. Each administration of 
drug, either free or entrapped within liposomes, was 
spaced at least three days apart.
With the exception of a mild transient headache in 
patient 4, no adverse clinical effects were noted which 
could be attributed directly to the negatively-charged 
liposomes. The patients' conscious level, clinical evi­
dence of raised intracranial pressure and focal neuro­
logical deficits remained unaltered, and no drowsiness, 
seizures or raised temperature was noticed.
Blood concentrations and urinary excretion of bleo­
mycin following injection of the free drug are shown in 
Figures 4.3 and.4.5, and levels obtained following in-
188
jection of the drug entrapped within liposomes in 
Figures 4.4 and 4.5. Blood concentrations achieved 
following intracerebral injection of the free drug were 
considerably less than those achieved following intra­
venous injection of similar amounts of the free drug in
\
other patients (Table 4.2), and the apparent half-life 
in the blood was approximately three times longer (six 
hours as compared with two hours). Blood concentrations 
achieved following intracerebral injection of the drug 
entrapped within liposomes were at least -5-10 times 
lower than those following the administration of a similar 
amount of free drug by the same, route in each patient, 
and at an injection dose of 2mg were close to or below 
the detection limit of the method. Consequently it was 
difficult to determine the half-life of the drug in blood 
following its intracerebral injection entrapped within 
liposomes. The urinary clearance of the drug was 
similarly much reduced following administration entrapped 
within liposomes (Table 4.4).
f
No changes in routine blood chemistry results (Urea, 
electrolytes, liver function tests and cardiac enzymes) that 
could be attributed to the effect of liposome therapy were 
observed in any of the patients during the course of these 
preliminary trials.
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Fig. 4 . 3  ■
Serum Bleomycin levels following infracerebral
injection of free Bleomycin.
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Fig. 4 .5
Urinary excretion of Bleomycin following intracerebral injection
of Bleomycin free and entrapped within Liposomes.
80 2 mg Free
70
60 6 mg Free
50
40
30
450 pg 
Free
2 mg
Entrapped 
2 mg
Entrapped
450 pg 
Entrapped
20
 □
10
12 164 8 20 24
Hours
TABLE 4.4
24r-hour urinary excretion of bleomycin following 
intracerebral injection, free and entrapped 
within liposomes
i
Dose of bleomycin 
injected 
• (mg)
24hr urinary bleomycin 
excretion (% of total)
j Free Entrapped
0.1
I
1
’ 1 2 .0 3 ND1
\ 0.45 26.53 11.13 '
2.0 79.53 11 . 23/18 .63
46.0" 1 . 9 V  2 .4 *
6.0 60.03
. -
22.04 3 .9 ^
1 •= Patient 1
3 = Patient 3
* = Patient 4
ND = not detected
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4.3.3 Preliminary longer term biochemical and clinical 
studies
Patient D, a 73-year old male, was admitted to St. 
George's Hospital, Tooting, with a diagnosis of possible 
space-occupying lesion and was found to have a left hemi,- 
paresis with a left hemianopia and upper motor neurone 7th 
nerve palsy. He was subsequently transferred to the 
Atkinson Morley1s Hospital, Wimbledon, as an, emergency 
complaining of gradual increasing left-sided weakness. He 
gave a history of left arm and left leg weakness for one week 
which had been gradually increasing associated with a left-
f
sided facial palsy. There was a two-month history of per­
sonality change with aggression and difficulty finding words, 
and a five to six-year history of frontal headaches accom­
panied by dizziness. '
On examination he had no systemic signs of illness.
The respiratory system appeared clear with expiratory rhonchi. 
The cardiovascular system was normal apart from a soft 
ejection systolic murmur. Hepatomegaly wa$ apparent.
Emergency CT scanning was performed which revealed a 
right temporo-parietal lesion. A right temporal craniotomy 
was performed and the tumour was removed with placement of 
anOmmaya reservoir. Histological examination of the tumour 
confirmed a diagnosis of grade IV astrocytoma. He developed 
post-operative complications highly suggestive of; pulmonary 
emboli; it was nevertheless considered appropriate that he
should enter into a trial of bleomycin therapy, and this 
was accomplished following the full,agreement of the patient 
and his relatives.
it + ■
Following the initial clearance studies detailed above, 
further doses of bleomycin entrapped within liposomes were 
administered with the intention that' this should initially 
be given on a regular weekly basis. Tfie patient's response 
to each administration of drug and general clinical con-
Idition were monitored during this time. 1
i
Blood levels and urinary clearance (of bleomycin follow­
ing administration, free and entrapped.within liposomes, 
are shown in Fig. 4.6. Only minimal quantities of bleomycin 
were detected in blood following administration of liposome- 
entrapped drug, and the urinary excretion was much reduced. 
Total 48h urinary excretion of bleomycin following injection 
of 2mg and 6mg of free drug and 2mg of entrapped drug were 
59, 28 and 3.7% respectively. No changes in blood levels 
of bleomycin were demonstrated following extraction of the 
blood with either methanol or chloroform. '
Following the initial administration of 2mg and,6mg 
bleomycin entrapped within liposomes, the patient experienced 
a mild transient headache but no other apparent ill effect.
A marked temporary improvement in the patient's clinical con­
dition was noted following the second administration of lipo­
somes, with improved mental alertness and ability to walk 
unaided. This was short-lived, however, and the patient
\—
y
1
<
I—
2:
yj
I— 
2
o
LU
CD
D
U
CL
CL
£ <  
h~ X  
2 0  
LU !□
LijO 
2  
o
ui
o
CL
L l
O
z:
Q
5
CL 
I—  
lO
2
o
<
a.
LlJ
Q
<
CL
0
>-
X
oI—
Q
<
cl
U
U
>-
X
O
iL l
_J
(2
a
LU 
Q_ 
G_ 
<  
£L  
I— 
Z  
LlJ
Ll I
X
o
LO
o
CL
ffi
D)
£
C\J
D)
CM
O
r^
<L>in
O
*D
To
o
z
o
>-
X
O
liJ
_]
cq
y~
CL
<z
CL
3
JZ
XT
CM
CM
CM
CD
CO
CD
CM
CM
CD
O
o  o
ro cm(jlu/Bu) NioAiAicGia muss
O
196
subsequently developed a chest infection and pyrexia.
Marked abnormalities developed in liver function tests but 
these were considered to be' due to a toxic reaction to co- 
trimoxazole and subsided on withdrawal of the antibiotic.
It was considered inappropriate to give bleomycin en­
trapped within liposomes during this time, but studies re­
commenced following the return of the liver function tests 
to normal. Following each subsequent administration, marked 
drowsiness was noted lasting for a period of three days.
No other ill effects due to the administration of liposomes 
were noted. The patient continued to have difficulties due 
to bronchopneumonia, which was treated with prolonged anti­
biotics. Nevertheless he continued to deteriorate, and a 
CT scan performed following the last administration of lipo­
somes revealed extensive regrowth of tumour. All further 
therapy was withdrawn and the patient died 98 days after 
the craniotomy. Regrettably no post-mortem examination was 
carried out.
f
4.4 DISCUSSION
These studies demonstrated that bleomycin is t^ken up 
by human glioma tissue following intravenous administration 
of the drug, although at relatively low concentrations.
This is in general agreement with the findings of Hayakawa
164et al , who used a microbiological assay for bleomycin 
following administration of higher concentrations of the 
drug. The number of. observations made is insufficient to
197
enable detailed statistical analysis to be carried out,
although it appears that the levels of bleomycin are higher
in the areas of active tumour growth than in the necrotic
centre of the tumour. The periphery of the tumour y^ould
be expected to consist of some normal brain tissue together
' ■ 
with infiltrations of tumour growth. The amount of tumour
tissue present will vary with each sample taken, but it is
noticeable, that at 15 min three of the five peripheral
samples had undetectable levels of bleomycin and a fourth
had a relatively low concentration of the drug. r\'
The actual levels of drug achieved within the tumour
t
will, be dependent upon a large number of variables including 
the degree of breakdown of the blood-brain barrier, the ; 
metabolic activity of the tumour and the tumour vascularity, 
as well as the blood levels achieved and the rate of clearance 
of drug’ from the blood following administration of a standard 
dose of bleomycin. The results obtained here using a 
RIA technique have confirmed that, following intravenous 
injection of free bleomycin, antigenically intact drug is
f
rapidly cleared from the plasma (terminal tj approximately 
2h) with by far., the major route of excretion being via the 
urine. Following administration of bleomycin entrapped 
within liposomes, the peak level of drug in the blood is 
much lower but there appears to be no change in the terminal 
t^ value. Intact liposomes could only be detected in the 
bloo& for a period of 10 min following injection, and this 
probably reflects their rapid uptake by the liver, spleen
198
and lungs. Large unilamellar liposomes such as have been 
used throughout these studies are known to accumulate in the
* '• V
lungs to some extent. This would clearly be undesirable if
* *'
bleomycin entrapped within liposomes were to be administered 
by intravenous injection on a; regular basis in view of the 
known pulmonary toxicity of the drug.
The 24h urinary clearance of bleomycin following intra­
venous injection of the free drug (up to 91% of the to|:al
Idose) was somewhat higher than that found in other larger 
150 155studies ' in patients with normal renal function. - The
. . I .
urine specimens assayed in this study showed parallelism 
with the standard curve when diluted. , It is, likely that 
this apparent discrepancy in 24h urinary excretion is 
methodological rather than physiological, since many earlier 
assays utilised microbiological inhibition assays which 
measure metabolically active drug as opposed to RIA which 
measures, antigenically intact drug. The values obtained for 
different RIAs may also vary to some extent depending upon 
the specificity of the antisera.
Following intracerebral administration of free bleomycin 
at doses of 2mg and above, the drug appears to be cleared 
from the brain fairly rapidly, as demonstrated by the relat­
ively high excretion of the drug in the urine within 24h.
When the drug is administered intracerebrally entrapped 
within liposomes'the urinary clearance .is considerably re­
duced and blood levels of the. drug are virtually undetectable.*
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This provides indirect evidence that liposomes are acting 
as a depot preparation of bleomycin with sustained release 
of the drug occurring'over a period of time; however, this 
would heed to be confirmed by more direct techniques such 
as gamma camera scanning following administration of radio­
labelled drug.
The patients studied to date have appeared to tolerate 
intracerebral administration of these preparations fairly 
well, the only apparent adverse effects observed so far 
being mild transient headaches and prolonged drowsiness in 
one patient. An insufficient number of preparations have 
been administered to any single patient to determine whether 
these adverse effects may be due to the effect of the bleomycin, 
the lipids or indeed to local oedema and inflammation due to 
tumour cell destruction by the preparations. A marked short­
term improvement in patient D's condition was noticeable 
following the second administration of drug entrapped within 
• liposomes, although of course it cannot be assumed that these 
events are related. Unfortunately the patient later deterior-
i
ated due to pulmonary and hepatic complications, and it 
was not possible to administer liposomes on a regular basis.
■ Nevertheless the results obtained following these preliminary 
clearance studies in patients suffering from grade IV 
gliomas are encouraging and plans are now in hand to carry 
out further clinical studies at both major neurological 
centres in the South West Thames Region.
CHAPTER 5
FINAL DISCUSSION
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Liposomes have been studied extensively over the last 
12-15 years with a view to their application as a means of 
selective drug delivery in human disease. Almost without 
exception the original optimism has not been realised and 
only a very few studies have progressed to the stage of 
preliminary trials in human subjects.
This apparent lack of success may, to a considerable 
extent, be attributed to a lack of detailed knowledge at 
the time of the: fate of liposomes or of their individual
i
structural and chemotherapeutic components following in-vivo 
administration. It is now clear that many earlier studies 
were hopelessly optimistic in their scope, and as a result 
these apparent failures have influenced subsequent workers 
faced with the decision to progress various in-vitro and 
animal studies to the stage of preliminary investigations 
in human subjects.
There is now a considerable body of knowledge available 
on the in-vivo fate of liposomes and, to a lesser extent, 
on the factors subsequently affecting the release of chemo­
therapeutic agents from within the liposome. The studies 
reported here have demonstrated the vital importance of 
optimising the conditions of entrapment of the drug in order 
to achieve maximal incorporation within the liposome. These 
factors also affect the rate of release of drug in vitro, 
although further -studies are required in order to determine 
how these affect the release of drug from liposomes in vivo.
The optimum rate of release of drug in vivo required to
achieve maximum therapeutic benefit also needs to be
studied, as well as the effect of different liposome types
and methods of preparation. Many of these factors have
received scant attention in a number of studies. The work 
139of Poste et al has produced a much clearer understanding 
of the limitations to the use of liposomes as a means of 
targeting chemotherapeutic agents to extravascular compart- 
ments. Furthermore, the techniques available for the pro­
duction of liposomes have been considerably refined and it 
is now a relatively straightforward process to produce ( 
liposomes of consistent quality and with high entrapment' 
efficiencies. One can therefore reasonably predict that 
the work of the next few years will determine whether the 
original high hopes for the application of liposome tech­
nology to clinical medicine will be fulfilled.
The work reported here is one of only a very few docu­
mented investigations that have progressed to the stage of
initial clinical studies in human patients. The relative
*
ease with which this has been achieved is to a considerable 
extent due to the fact that most of the general difficulties 
associated with the attempted targeting of the liposome and 
drug to its intended site of action has been eliminated by 
the use of direct intracerebral administration. Furthermore, 
the presumed isolation of the intact liposome from the systemic 
circulation by the blood-brain barrier has overcome the 
problem of unwanted uptake by the liver, spleen and lung.
20?
In addition, the relatively hopeless prognosis for patients 
with grade IV cerebral gliomas .eases the ethical dilemma 
that generally arises when considering the application of 
npvel but untried therapeutic techniques to the treatment 
of human disease. ,
No alternative approach to the treatment of cerebral
gliomas has yet emerged which appears to offer a better
chance for success in improving the present prognosis in
this condition. Any further improvements in surgical and
radiotherapy techniques are unlikely to make any significant
improvement to the overall survival rate.or to the quality
/
of life. The development of new chemotherapeutic agents
*
with a 'greater therapeutic index towards tumour tissue or 
with greater efficiency in penetrating the blood-brain barrier 
may hold hope for the future, but clearly such developments 
are still a long way from being realised. The use of agents 
which increase the permeability of the blood-brain barrier, 
thus allowing greater uptake of presently available thera­
peutic drugs, may be an alternative approach to this problem.
f
Intracarotid infusions of hypertonic solutions of urea,
lactamide, arabinose or mannitol have been shown to increase
the cerebral uptake of drugs such as methotrexate by up to
70-fold without producing gross functional neurological 
169deficits . However, although this approach results in a 
greatly enhanced cerebral uptake of the drug, its half-life 
within the brain is still relatively short - in the order of 
4$h in the case of methotrexate. It has been estimated that
203
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methotrexate would need to be held at therapeutic concen­
trations for 12£ half lifes under these conditionsf and in 
practical terms this will require the repeated administration
.*r # •
of drug and hypertonic agent over a period of approximately 
6 Oh.
Monoclonal antibody technology 'has developed at an 
extraordinarily rapid pace in recent yfears and a large number 
of studies have taken place using so-called tumour-specific
I |
antisera for the visualisation of tumours and to target!
\
various chemotherapeutic agents to these tumours. However, . 
there is now considerable evidence available to suggest that
‘ t
the application o£ these techniques to "the treatment of solid
1 170tumours may. be very limited . The percentage binding of 
radiolabelled 'tumour-specific1 monoclonal antibody to a 
tumour mass following its systemic administration is generally
never more than a fraction of one per cent of the total dose.
»
Furthermore, very similar levels of binding have been achieved 
following the administration of radiolabelled monoclonal anti­
bodies that have no specificity for that particular tumour
1
type. The low level of antibody binding is in part due to 
the very limited ability of IgG antibodies to move through 
the interstitial space of the tumour, thus restricting access 
of antibody and chemotherapeutic agent to much of the tumour 
mass. This transport limitation may partially be overcome . 
by the use of Fab fragments of the IgG antibody, although 
much of this smaller molecular weight fragment will then be 
cleared by the kidneys if administered systemically.
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Therapeutic administration of antibody-targeted 
radiation and drugs may prove to be more successful in 
the irradiation of cystic tumours and micrometastases 
rather than bulk tumours. This may be particularly true 
where the antibody can be administered directly into a 
single compartment, and some preliminary success has already
been achieved following the direct intrathecal administration
131 171of I-labelled neuroblastoma-specific antisera
Similar difficulties have been encountered following 
the use of other forms of immunotherapy. Thus intratumoural 
transplantation of the patient's previously stimulated lympho­
cytes has met with very limited success, partly due to the 
difficulties of achieving lymphocyte infiltration beyond the 
tumour edg'e^ .
More fundamental research in molecular biology may
offer hope for the development of more specific therapies
in the longer term. Oncogenes have been identified in and
isolated from human tumour cell lines and from tumour, tissues
that have been shown to cause malignant transformations of
cells in tissue culture. These cellular genes are closely
related to the viral genes responsible for a range of tumours
in animals and several have been shown to encode for proteins
very similar to growth factors, a class of proteins able
to over-ride some of the regulatory mechanisms controlling
172cell proliferation . Several studies of brain tumour- 
derived cell lines and of primary brain tumour tissue have 
demonstrated various oncogenes that can encode for platelet-
derived growth factor or epidermal growth factor, or
alternatively for proteins that may act as defective cell .
173 *surface receptors . .Although of great fundamental import­
ance to the understanding of the mechanisms of malignant 
transformation of cells, any major therapeutic benefits
derived from these studies are likely to be some years away.
• ' . 
Some initial success has, however, already been reported
in attempting antibody-guided irradiation of grade IV gliomas
131by arterial infusion of I-radiolabelled monoclonal anti-
174body against epidermal growth factor . It is reasonable
to assume that further progress will be made in this area1,
. .1
perhaps using radiolabelled epidermal growth factor itself.
Thus the general approach oulined in this work appears 
to offer more immediate hope for the future, although there 
are a number of alternative techniques available for the 
depot administration of a drug that should also be considered.
One of the main advantages to the use of liposomes in 
these applications is that the lipids used are similar or 
identical to naturally occurring lipids in,the human body 
and are eventually fully metabolised. This approach can 
be carried one stage further by the use of drugs entrapped 
within resealed erythrocyte ghosts that have been derived 
from the patient's own red blood cells. This has recently 
been used for the entrapment of 6-aminolaevulinate de­
hydratase with a view to the enzyme replacement therapy of
175patients suffering from lead intoxication porphyria
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These loaded ghost erythrocytes have an in-vivo life span 
that is almost as long as that of a normal erythrocyte, thus 
this technique is particularly attractive to the treatment 
of metabolic diseases involving red cell deficiencies.
The use of this system as a depot preparation of drug within 
a bodily compartment or for the targeting of antibody- 
labelled erythrocytes has not as yet received adequate 
study.
An alternative system which is now beginning to be 
studied in some detail is the use of magnetically responsive 
albumin microspheres which consist of denatured human serum 
albumin in which a chemotherapeutic agent, together with 
magnetite (Fe3C>4) , is entrapped. These can be infused into 
an artery supplying, a tumour and then subsequently retained 
within the capillary bed of the tumour by use of an external 
magnet placed over the tumour site. The intra-arterial in­
jection of adriamycin-entrapped albumin microspheres in 
•Yoshida sarcoma-bearing rats followed by magnetic localis­
ation has been shown to lead to regression of tumour size and
176 fa dramatic increase in survival . This technique appears 
to have considerable potential for the treatment of sub­
cutaneous tumours in man, but its application to the treat­
ment of deeper sited tumours is at present severely limited 
due to the difficulties of applying high magnetic field 
gradients at these sites.
A number of other techniques for the controlled delivery 
of a drug are now being studied. These include:
207
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i. the use of biodegradable polymers containing water- 
soluble drugs;
ii. maze systems using a polymer such as ethylene vinyl 
acetate which forms a complex pore system, thus 
physically delaying the diffusion of the drug from 
the polymer; and
iii. osmotic devices consisting of drug bound to a core
. material and surrounded by a semipermeable membrane
' 177through which a single minute hole is drilled by laser
i
Some of these alternative techniques may eventually find 
application to the treatment of particular diseases including 
that of. cerebral gliomas; however, all are relatively recent 
innovations and none has yet reached the same state of' the 
, art as has liposome technology. Thus, although none of 
these or other alternatives should be ruled out as being 
applicable to the treatment of human cerebral tumours, 
further studies on the clinical application of liposome tech­
nology is more than justified.
f
The preliminary human studies reported here have demon­
strated that liposomes can be administered directly into
a.tumour bed without any acute adverse response; furthermore, 
no major chronic toxic response has been observed to date. 
There are a number of immediate practical problems that need 
to be taken into account, however, in the design of these 
clinical studies.
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Bleomycin (or any other drug that may be investigated) 
will be slowly released from liposome preparations during 
storage. It is desirable that at the time'of administration 
the percentage of free drug in the preparation is as low 
as possible to give maximal depot effect and to prevent any 
toxic reaction that might occur in response to the regular 
injection of preparations containing high concentrations 
of the free drug. It is not practically feasible to prepare 
each batch of liposomes immediately prior to administration 
and, furthermore,. sterility testing of the product must be 
carried out with a minimum 48h culture required before 
clearing the product for human administration. If large,r 
numbers of patients are to be studied it is desirable that 
a single large preparation of liposomes is made, suitably 
aliquoted so that liposomes of consistent quality and drug 
concentration are available for administration when required. 
The rate of trelease of bleomycin from liposomes can be 
reduced considerably by storage of the preparation at 4°C 
prior to administration (see Fig.2.8). Furthermore, we have 
now demonstrated that even after 10 weeks1 storage at 4°C,
85% of the drug remains entrapped within the liposomes, with 
minimal changes demonstrable in the preparation on electron 
microscopy.
Thus although all preparations so far administered to 
patients have been less than two weeks old, it may be possible 
that suitably aliquoted preparations can be held for much 
longer periods than this. If a commercial availability of
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liposomes for this or for other applications is to be 
entertained, then a storage life of at least one year is 
highly desirable if not essential. However, storage of , . 
preparations at below ambient temperature may not always
be feasible. It may be possible that these preparations can
\
be freeze-dried and then subsequently reconstituted for use! 
without any substantial loss of entrapped drug. It has been 
reported that the addition of a macromolecular diluent such 
as dextran to a liposomal dispersion containing entrapped, 
insulin prior to lyophilisation produced a free-flowing i 
powder. This powder reconstituted easily in aqueous medium
to yield a preparation containing 70% of the insulin remaining
' 178entrapped within the liposome
All liposome preparations for human administration must
/
obviously be sterile and there are several suitable means 
of achieving this. Incorporation of streptomycin/penicillin 
into the preparation has been used by some investigators;
i  *  '
'however, it has been demonstrated that this results in
clumping of the liposomes and this may affect the rate of
*
release of the drug. Gamma irradiation of individually
135 137aliquoted preparations of liposomes ' is the most 
successful means of ensuring complete sterility without 
any apparent adverse effect on the liposome; however, 
the availability of facilities for this is limited. Lipo­
somes used in this study have been prepared using standard 
aseptic techniques including direct collection of the lipo­
some fraction from the Sephadex column into evacuated
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sterile injection vials, followed by culture of a sample 
for a minimum of 48h.
* * Another far more difficult practical problem has been 
encountered throughout the clinical phase of the studies 
reported here. For ethical purposes these preliminary 
investigations had to be limited to patients suffering 
from grade IV.gliomas. These patients had all undergone 
recent major surgery, and because of their generally deterior-
I
ating Condition liposome therapy had, in many cases, to
i
be postponed, delayed or interrupted for considerable 
periods; this has severely restricted the. number of patients 
available for detailed study during this investigation.
Because of this, and because of the nature of the tumour, 
it will be difficult to carry out any properly controlled 
trials of liposome therapy in these patients. A double-blind 
trial in grade IV or lower grade tumours is difficult to 
justify ethically at this stage, since that would entail 
' injection of liposomes containing no bleomycin into patients 
who had previously agreed to the fitting of an Ommaya reser-
f
voir. Instead, a further six patients will now be studied, 
all of whom will receive injections of liposomes containing 
bleomycin on a twice-weekly basis for 6-weekly periods 
whenever possible. Assessment of any response to therapy 
will be based partly on the results of repeat CT scans 
and ultimately on length of survival, but nevertheless will 
have to be based largely on a subjective clinical judgement 
of the patients* progress. If this initial study shows no
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untoward adverse response to the therapy, then it should 
be possible to carry out a more rigorously controlled trial 
in patients with lower grade gliomas who areVfar more likely 
to show a positive response to therapy.
Based on experiences during the initial trials it should 
be possible to refine the therapy in terms of the frequency 
of administration and the depot dose of bleomycin per in­
jection. The maximum dose that' can be given at a time
should be largely dependent upon the rate of breakdown of
liposome and release of bleomycin in vivo. A number of 
factors may affect this. It has been claimed that although 
the use of hypo-osmolar buffers results in an increased 
initial incorporation of bleomycin within the liposome, 
this results in an. osmotic tension across the liposome mem­
brane following in-vivo administration, resulting in increased
179rate of loss of liposomal, content . This has been demon­
strated to some extent in vitro in this study, but the effects
.I ' ,
’ might be accentuated in vivo. Similar effects might result 
from the use of non-physiological conditions of pH. This
• t
hypothesis has not yet been fully tested in either animal 
or human subjects.
Extensive changes in phosphblipid metabolism of brain
tumour cells has been demonstrated. Total phospholipid
32content of tumours is markedly decreased although the P
turnover is increased, suggesting that there is no decrease
180in phospholipid synthesis . Thus there may well be an 
increase in the liposomal phospholipase levels within the
i
212
tumour tissue. This, together with other marked alter­
ations in lipid metabolism in tumour cells may result in 
» •
an increased interchange of lipid between liposome and 
tumour cell as well as possible degradation of the liposome 
and hence increased rate of loss of entrapped drug.
'Some idea of the rate of cellular uptake of bleomycin 
will b£ obtained by gamma camera scanning of the tumour over 
a period of time following the intracerebral administration 
of *^I-labelled bleomybin, free and entrapped within lipo­
somes. Plans for this study are already well in hand. The 
concentration of bleomycin in glioma tissue has been shown
t
to be much higher than that of corresponding normal tissue,
'
and this study should help to determine whether this is due
to decreased uptake or increased metabolism of bleomycin
by normal tissue. If it was demonstrated that there was
relatively specific uptake of bleomycin by tumour tissue
within the CNS, then this opens up the possibility of using
131’ milliCurie doses of labelled I-labelled bleomycin in 
future studies to improve the efficacy of the bleomycin.
1
The technique of direct intracerebral administration 
of liposomes may be used for the delivery of a number of 
other drugs and antitumour, agents apart from bleomycin, 
and plans are already well advanced to widen the scope of 
this general approach to therapy. The sensitivity of in­
dividual tumour c.ells to chemotherapeutic agents varies 
within the tumour mass and increasingly there will be some 
cells present with a low sensitivity to any single drug.
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Thus, as with other chemotherapeutic regimes, it will
ultimately probably be necessary to incorporate two or
more agents within the liposome in order to achieve maximum
therapeutic potential. These may be' incorporated either
into the aqueous phase or into the lipid membrane. We have
already demonstrated than vincristine can be incorporated
168with high efficiency into liposomes ; however, it is
highly neurotoxic and this has been confirmed by other
181 182studies in animals and in man . It is unlikely,
therefore, to1 be a drug of choice in the treatment of
human cerebral gliomas. Cis platinate has recently been
shown to have some therapeutic activity against gliomas ,
183when given in conjunction with radiotherapy ; however, 
it does have unpleasant side effects that limit the dose 
that can be administered systemically. Cis platinate can 
be successfully incorporated into liposomes and has been 
shown to be effective against Ehrlich Ascites tumours in
126mice at much lower doses than when given ini the free form 
However, a.recent report has shown that cis platinate is 
extremely neurotoxic when administered via,the internal 
carotid artery in dogs. Furthermore, bleomycin as well as 
5-fluorouracil and adriamycin were also shown to be neuro­
toxic when administered intra-arterially following the‘
184osmotic opening of the blood-brain barrier . This casts 
some doubt on the use of these agents for direct intracerebral 
administration entrapped within liposomes. However, there 
is some evidence that the neurotoxicity of certain chemo­
therapeutic agents is several fold greater in the canine 
than in primates or humans; furthermore, entrapment of the 
agent within liposomes may affect its neurot;oxic properties. 
Nevertheless it is possible that some or all of these agents 
may exhibit neurotoxicity symptoms when present in the brain 
at concentrations higher than that achieved following 
standard intravenous administration, and it may be necessary 
to titre the doses administered within liposomes such that
these side effects are. minimised. The same workers have
\
shown that both methotrexate and cyclophosphamide are 
reasonably tolerated when administered following osmotic
/
opening of the blood-brain barrie?r. Hence these agents merit
■ ' !
further study with a'/ view to their administration entrapped 
within liposomes, either singularly or in combination with 
bleomycin or with other drugs. These drugs, and virtually 
all other chemotherapeutic agents that have been incorporated 
into liposomes, have been used in their normal commercially 
'available form. Ideally, however, the encapsulated agent 
should be specifically selected or designed to take maximum
t
advantage of the unique properties of liposomes. Methotrexate-
y-aspartate has been used in this way; in the free form it
' enters cells very poorly, but when entrapped within liposomes
that are capable of being endocytosed by the target cell, the
drug is released into the cell cytoplasm to exert its chemo-
185therapeutic effect
The use of monoclonal and polyclonal antibody-labelled 
liposomes has been extensively studied as a means of targeting
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liposomes to specific areas of the body following systemic 
administration. Although the same problem of targeting 
the drug is not so acute following direct intracerebral . 
injection of liposomes, it may nevertheless be that lipo­
somes containing glioma-specific antibodies on their outer 
surface will become more closely associated with the residual 
tumour tissue, thereby reducing the diffusion distances of 
drug and leading to enhanced tumour cell uptake of drug.
We have produced antisera in rabbits against a human glioma 
cell line; (U-251-MG), but much of the specific antisera 
activity is directed against cytoplasmic proteins and also 
reacts with normal grey and white matter. There is a low 
titre residual antiserum activity with specificity for the 
glioma cell membrane and this has successfully been in­
corporated into the outer membrane of liposomes, although 
so far only into SUV containing low levels of entrapped 
bleomycin. , This will be used as a model system to determine 
whether the incorporation of glioma membrane antisera into 
liposomes has any significant effect upon the dose response 
of glioma cells to entrapped bleomycin in vitro. Any further 
more detailed studies in this field must await the general 
availability of monoclonal antisera with high specificity 
for the glioma cell membrane. However, it may well be that 
the added advantage arising from the incorporation of. anti­
body into the system will be minimal and will only be worth 
exploring in further detail once the basic technique for the 
administration of drugs entrapped within liposomes has been 
more fully refined.
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A further area of therapeutic potential which will be 
explored is the administration of liposomes containing 
macrophage-activating factors, either-singularly or in com­
bination with chemotherapeutic drugs. Lymphokines and MDP
have both been incorporated into liposomes to advantage, as
' ■
has been discussed previously. More recently a muramyl
tripeptide (MTP) has been covalently linked to lipids
(dipalmitoyl.phosphorylethylamide), and when incorporated
into the membrane of liposomes has been shown to render
human blood monocytes tumoricidal whilst leaving nprmal
186cells unaffected . Lipid-bound MTP appears to be superior* 
to entrapped MDP in vivo owing to the leakage of water- , 
soluble MDP from the liposomes following administration; 
hence this now appears to be the most suitable macrophage 
activator for use in animal and human studies.
Although liposomes have generally been used simply as
carriers of. other agents, the lipid components are by no
’ means insert, there being considerable interchange of lipid
between the liposome and its surroundings. Indeed the lipid
1
component may in fact illicit an immune response. It has 
recently been demonstrated that one lipid may also exhibit 
chemotherapeutic potential in its own right. Phosphatidyl 
inositols have recently been shown to be very important 
molecules the metabolism of which, stimulated by a variety 
of hormones and other agents, initiates a signal cascade 
with a series of physiologically important consequences.
These include calcium gating, activation of protein kinase C,
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release of precursors of prostaglandins and stimulation of
187guanylate cyclase . Plant but not animal phosphatidyl
inositol has been shown to have cytotoxic effects on a wide
188range of tumour cells grown in tissue culture , and further­
more this effect appears to be highly selective since no 
adverse effects could be demonstrated in normal cells. The 
mechanism of this action is unclear but is likely to be due 
to the different fatty acid composition of plant phosphatidyl 
inositol compared with animal phosphatidyl inositol. We 
have recently demonstrated that soybean phosphatidyl inositol 
has cytotoxic activity against a glioma cell line (U-251-MG), 
although the concentrations of lipid required to achieve 
100% cell death'were very high and this may possibly limit 1 
its therapeutic potential. However, very extensive studies
will be required before this can be accurately determined.
>
Other plant phosphatidyl inositols or derivatives may 
exhibit greater activity; the activity may even be associ­
ated with a breakdown product or contaminant of the prepar­
ation used.
Thus there is still considerable potential for continuing
studies on the application of liposome technology to the
treatment of human cerebral gliomas. The developments
mentioned above, together with other potential applications
such as the incorporation into liposomes of radiosensitisers
or cell synchronisers as an adjunct to radiotherapy, all
merit further sttidy. The present dire prognosis of this
condition together with the acute distress it causes both 
patient and relatives amply justify the efforts.
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APPENDIX
APPENDIX 1
4.3.2. Studies following intracerebral administration
of bleomycin: Continued
A further four patients have been studied 
following insertion of an Ommaya reservoir at craniotomy.
In two cases ( Patients 7 & 8 ) the patients deteriorated 
rapidly following craniotomy and only incomplete clearance 
studies could be performed following intracerebral injection 
of bleomycin, free or entrapped within liposomes.
The results obtained on all four patients are shown below 
( Table Al ).
PATIENT
NUMBER
BLEOMYCIN PEAK BLOOD LEVELS 24hr URINARY
DOSE
(mg)
1
1
0.5
1
ACHIEVED(ng/ml)
FREE
10.8
22.0
ENTRAPPED
0.6
2.0
*
4.0 
(1.8-6.6)
BLEOMYCIN 
(%of TOTAL DOSE) 
FREE ENTRAPPED
2.4/1.6
N.S.
* *
53.0
3.4/7.9 33.0
23.6
(17-30)
6.9
N.S.= No. specimen received 
* = Mean of 9 studies
** = Mean of 6 studies.
Table Al
Blood and urinary bleomycin levels following 
intracerebral injection of bleomycin free or 
entrapped within liposomes
4.3.3. Preliminary longer term biochemical and clinical 
studies: Continued
Patient 7, a sixteen year old female was readmitted 
to Hurstwood Park Neurological Centre having six months 
previously undergone a right temporal craniotomy for 
the removal of a malignant grade IV temporal lobe 
astrocytoma. Subsequent C.T. scans had shown evidence of 
a recurrence of the tumour and therefore in accordance 
with the wishes of the parents a second operation was 
performed when the tumour was re-evacuated and an 
Ommaya reservoir was installed with the aim of commencing 
bleomycin therapy. Over the following six weeks she was 
treated with 0.5mg of free bleomycin injected intracerebrally 
via the reservoir followed by a total of nine doses of 
0.5mg of liposomes entrapped bleomycin twice weekly.
( Figure Al )
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Apart from some nausea and slight drowsiness no other 
adverse response to the therapy was observed. Unfortunately 
a further scan at this time showed evidence of an additional 
lesion in the region of the anterior corpus callosum.
This continued to increase in size, although the original 
tumour was shown to be increasing at a somewhat slower rate.
In view of this it was decided to refrain from a further 
course of therapy following the initial six week course.
She was discharged home and subsequently died three weeks 
later. Regrettably a post mortem examination was not performed.
1314.3.4. Studies on the clearance of I labelled bleomycin
from the injection site following direct intracerebral 
administration
Patient 8, a fifty-three year old female was admitted 
to Atkinson Morley Hospital complaining of focal and grand 
mal seizures. A C.T. scan with contrast media showed a 
poorly defined lesion within the left frontal lobe that was 
tentatively identified as a low grade glioma. A second scan 
performed exactly one month later showed remarkable changes.
A malignant glioma was clearly identified which appeared 
to be haemorrhagic and infiltrating deeply to the genu of the 
corpus collosum and the left lateral ventricles. Craniotomy 
was carried out four days later when a grade IV astrocytoma 
was partially excised and an Ommaya reservoir installed.
131Iodide labelled bleomycin was produced using the
125technique previously described for use with Iodide and
the preparation sterilised by filtration through a 20u
filter. 0.25 mCi of this preparation together with 1 mg
of unlabelled bleomycin was administered to the patient
via the reservoir and the radioactivity imaged and counted
at regular intervals over a period of twenty four hours using
a Gamma Camera. Blood and urine samples were collected over
131forty-eight hours and assayed directly for Iodide activity
and subsequently for bleomycin using the standard
radioimmunoassay technique. Following this 0.25 mCi of 
131 Iodide labelled bleomycin together with 1 mg of
unlabelled bleomycin, both entrapped within liposomes
produced using previously described sterile techniques
were administered to the patient and Gamma camera
scanning and blood and urine collection carred out
over forty-eight hours.
The Gamma camera scans obtained are shown in
131figures A2 and A3 and blood and urine Iodide and
131bleomycin levels in Tables A2 and A3. All Iodide
levels have been corrected backe to the time of injection.
131.
SAMPLE 131 Iodide BLEOMYCIN 'IODIDE/
ACTIVITY CONCENTRATION BLEOMYCIN RATI
Table A2
Counts/sec/ml ng/ml
1. Serum
^hr post 
Injection
2. Serum
4%hr post 
injection
3. Serum
20hr post 
injection
4. Serum
24hr post
injection
5. Urine
0-24 hrs
9.66
3.48
1.59
< 1.0
126.1
22.0
6.1
2.9
1.4
190.0
0.44
0.57
0.55
0.66
6. Urine
24-48 hrs 10.9 i7.:o 0.64
131Iodide and bleomycin level's in blood and urine
following direct intracerebral injection of free drug
Following Sephadex G-10 chromatography of sample 5 
13184% of the Iodide activity applied to the column
eluted in the void volume. - .
Following Sephadex G-50 chromatography of sample 5 
13196% of the Iodide activity applied to the column
eluted in the void volume.
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SAMPLE 131.'Iodide Activity 
counts/sec/ml
Bleomycin
concentration
ng/ml
131Iodide/bleomycir
Ratio
1. Serum 
%hr post 
injection
1.15 3.4 0.34
2. Serum 
2^hr post 
injection
1.06 3.4 0.31
3. Serum 
3%hr post 
injection
4. Urine 
0-12hrs
< 1.0
37.7
1.7
150.0 0.25
5. Urine 
12-24hrs 11.1 26.0 0.42
6. Urine 
24-48hrs 5.6 17.5 0.32
7. Urine 
48-60hrs
Table A3
3.3 9.5 0.35
131Iodide and bleomycin levels in blood and urine following 
direct intracerebral injection of drug entrapped within liposomes
Figure A2 I Gamma Camera head scans on patient 8,
following direct intracerebral injection 
of free drug
a. 1% hours
£
s:
¥
b. 24 hours
V
Figure A3 ^ ^ 1  Gamma Camera head scans on patient 8
following direct intracerebral injection of
drug entrapped within liposomes
a. 1 hour
O
u r n •_« m m  4.(a
b. 24 hours
i
c. 48 hours
DISCUSSION
These further studies have continued to be limited in 
their scope and depth by the nature of the disease.
Thus patient 5 received a total of five injections over a 
period of three weeks, patient 6 two injections and patient 8 
three injections before their rapidly deteriorating condition 
precluded further studies. Only patient 7 could be studied 
over the full six week period and even then received a course 
of only nine injections of liposomes rather than the intended 
twelve because of the fluctuating course of her disease.
The blood and urinary levels achieved following injection 
of bleomycin, free or entrapped within liposomes are 
generally similar to these obtained in previous studies, 
with the exception of patient 7, who had a somewhat higher 
24 hour urinary excretion of bleomycin following administration 
of liposomes and a rather less clear cut difference in the 
peak blood levels achieved. These results may reflect a more 
rapid breakdown of liposomes within this patient/sLtumour 
with subsequent clearance of free bleomycin, but would have 
required further more direct studies in order to confirm this.
131The Iodide-Bleomycin clearance studies reported here
have been designed to investigate more directly the fate of
the fate of the drug entrapped within liposomes following
administration although the study.on patient 8 is of a very
preliminary nature and will require to be confirmed in at least
two further subjects. The Gamma camera scans suggest that the
drug remained localised to the tumour site despite of the
relatively open nature of the tumour cavity following surgical
evacuation. There is some evidence from the sequential scans
131that the rate of clearance of the Iodide labelled bleomycin 
is slower following its injection entrapped within liposomes, 
however, the sensitivity of the scanner required altering during 
the course of the investigation and this study will need to be 
repeated on further patients.
131The ratio between Iodide and the total bleomycin level
remained relatively constant during the period of investigation
in both the blood and urine of this patient during each
study. Furthermore, following Sephadex G-10 or G-50
chromatography of the patient/S urine, no peak was obtained
corresponding with the elution volume of free iodide, the
majority of the radioactivity being recovered in the void
131volume. These results suggest that the Iodide has most 
likely remained associated with antigenically intact 
bleomycin but would require to be confirmed- by high pressure 
liquid chromatography or other suitable technique.
No patient showed any serious adverse response to 
the attempted therapy apart from some headaches and 
general drowsiness. It was difficult to ascribe these 
symptoms definitely to the liposome therapy rather than 
to the disease process itself, however, in general there 
did appear to be some correlation between the timing of 
the injections and the depth of drowsiness. On the other 
hand, no definite clinical improvement could be ascribed 
to the liposome therapy. However, only patient 7 received 
the therapy over any significant period of time. There was 
definite evidence from C.T. scanning that her original 
tumour was growing at a slower rate than a second tumour 
that was discovered subsequently, despite having previously 
received generalised radiotherapy to the whole brain.
The significance of this finding is unclear. The further 
studies reported here remain somewhat inconclusive, however 
the fact that the technique is reasonably well tolerated, 
the demonstration of localisation of radiolabelled drug within 
the tumour cavity and the possible further potentials of the 
technique should encourage Neurosurgeons to refer patients 
at an earlier stage in the disease process than has hitherto 
been the case.
